<SEC-DOCUMENT>0001144204-14-062771.txt : 20141024
<SEC-HEADER>0001144204-14-062771.hdr.sgml : 20141024
<ACCEPTANCE-DATETIME>20141024144255
ACCESSION NUMBER:		0001144204-14-062771
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20141024
DATE AS OF CHANGE:		20141024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AntriaBio, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-196093
		FILM NUMBER:		141172126

	BUSINESS ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>v391811_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-196093</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B>&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">14,958,633 Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the resale, from time to time by
certain selling stockholders (the &ldquo;<B>selling stockholders</B>&rdquo;), of up to an aggregate 14,958,633 shares of our common
stock consisting of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (1) </TD><TD> 2,186,847 shares of common stock issued to the
                                         selling stockholders pursuant to the conversion of our 8% convertible promissory notes
                                         issued in connection with the Bridge Financing (as defined herein); </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (2) </TD><TD> 225,259 shares of common stock issuable upon the
                                         exercise of outstanding warrants (the &ldquo;<B>Bridge Warrants</B>&rdquo;) issued to
                                         the selling stockholders in connection with the Bridge Financing; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (3) </TD><TD> 5,725,325 shares of common stock issued to the
                                         selling stockholders in connection with the Unit Financing (as defined herein); </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (4) </TD><TD> 5,725,325 shares of common stock issuable upon
                                         the exercise of outstanding warrants (the &ldquo;<B>Unit Warrants</B>&rdquo;) issued
                                         to the selling stockholders in connection with the Unit Financing; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (5) </TD><TD> 562,346 shares of common stock issuable upon the
                                         exercise of outstanding warrants (the &ldquo;<B>Bridge Incentive Warrants</B>&rdquo;)
                                         issued to certain selling stockholders that invested in both the Bridge Financing and
                                         the Unit Financing; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (6) </TD><TD> 67,575 shares of common stock issuable upon the
                                         exercise of outstanding compensation warrants issued to certain selling stockholders
                                         as compensation for services rendered to us in connection with the Bridge Financing;
                                         and </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (7) </TD><TD> 223,286 shares of common stock issuable upon the
                                         exercise of outstanding compensation warrants issued to certain selling stockholders
                                         as compensation for services rendered to us in connection with the Unit Financing. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (8) </TD><TD> 242,670 shares of common stock issued to the selling
                                         stockholder pursuant to the conversion of a convertible promissory note and exercise
                                         of Note warrant in connection with the Note Conversion (as defined herin). </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will not receive any of the proceeds from the resale of
these shares of our common stock by the selling stockholders. However, upon exercise we will receive the cash exercise price of
the Bridge Warrants, the Units Warrants or the Bridge Incentive Warrants. We will not receive proceeds from the cashless exercise
of the compensation warrants issued to certain selling stockholders as compensation for services rendered in connection with the
Bridge and Unit Financings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may sell or otherwise dispose of the
shares covered by this prospectus or interests therein on any stock exchange, market or trading facility on which the shares are
traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale,
at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. Additional
information about the selling stockholders, and the times and manner in which they may offer and sell shares of our common stock
under this prospectus, is provided in the sections entitled &ldquo;<I>Selling Stockholders</I>&rdquo; and &ldquo;<I>Plan of Distribution</I>&rdquo;
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our common stock is presently quoted on the OTCQB under
the symbol &ldquo;ANTB&rdquo;. On October 23, 2014, the closing bid price of our common stock was $1.30 per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We issued an aggregate 14,958,633 of the shares covered by
this prospectus in the Unit Financing and upon the conversion of the convertible promissory notes issued in the Bridge Financing
and Note Conversion. Additional information about the Unit Financing, the Bridge Financing and the Note Conversion is provided
in the section entitled &ldquo;<I>Description of Private Placements</I>&rdquo; of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> You should consider carefully the risks that we have
described in the section entitled &ldquo;Risk Factors&rdquo; beginning on Page 14 of this prospectus before deciding whether to
invest in our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the U.S. Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is
October 23, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 90%"> &nbsp; </td>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"> Page </FONT></td></tr>
<tr>
    <TD STYLE="vertical-align: top"> &nbsp; </td>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#ABOUTTHEPROSPECTUS">ABOUT THE PROSPECTUS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase"> 4 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </td>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#SPECIALNOTEREGARDINGFORWARD-LOOKINGSTATEMENTS">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 4 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#PROSPECTUSSUMMARY">PROSPECTUS SUMMARY</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 5 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DESCRIPTIONOFPRIVATEPLACEMENTS">DESCRIPTION OF PRIVATE PLACEMENTS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 12 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#RISKFACTORS">RISK FACTORS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 14 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#MARKETINDUSTRYANDOTHERDATA">MARKET, INDUSTRY AND OTHER DATA</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 29 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </td>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#USEOFPROCEEDS">USE OF PROCEEDS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 29 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#MARKETREGISTRANTSCOMMONEQUITY">MARKET REGISTRANT&rsquo;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AD ISSUER PURCHASES OF EQUITY SECURITIES</A></FONT><FONT STYLE="font-size: 10pt"> </FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 29 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"> <A HREF="#SELECTEDCONSOLIDATEDFINANCIALDATA">SELECTED CONSOLIDATED
    FINANCIAL DATA</A> </FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right">31 <FONT STYLE="font-size: 10pt">  </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#MANAGEMENTSDISCUSSION">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT><FONT STYLE="font-size: 10pt"> </FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 31 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DESCRIPTIONOFBUSINESS">DESCRIPTION OF BUSINESS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 37 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#CHANGESANDDISAGREEMENTS">CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES </A></FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 44 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DIRECTORSEXECUTIVEOFFICERSANDCORPORATEGOVERNANCE">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">45 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#EXECUTIVECOMPENSATION">EXECUTIVE COMPENSATION</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">48 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> &nbsp; </td>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#CERTAINRELATIONSHIPS">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 52 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#SECURITYOWNERSHIP"><FONT STYLE="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></A><FONT STYLE="font-size: 10pt"> </FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 55 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#DESCRIPTIONOFCAPITALSTOCK">DESCRIPTION OF CAPITAL STOCK</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 57 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#SELLINGSTOCKHOLDERS">SELLING STOCKHOLDERS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 58 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </td>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 64 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#LEGALMATTERS">LEGAL MATTERS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 66 </FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#EXPERTS">EXPERTS</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 66 </FONT></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#ADDITIONALINFORMATION">ADDITIONAL INFORMATION</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"> 66 </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may only rely on the information contained in this
prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus
does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the common stock offered by
this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any common stock in
any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus nor any sale made in
connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs
since the date of this prospectus or that this prospectus is correct as of any time after its date.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="ABOUTTHEPROSPECTUS"></A>ABOUT THE PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In this prospectus, references to &ldquo;the Company,&rdquo;
&ldquo;AntriaBio,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; and similar terms refer to AntriaBio, Inc.
References to our &ldquo;common stock&rdquo; refer to the common stock, par value $0.001 per share, of AntriaBio, Inc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus together with additional information
described under the headings &ldquo;Where You Can Find More Information.&rdquo; If there is any inconsistency between the information
in this prospectus and the documents incorporated by reference herein, you should rely on the information in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information contained in or incorporated
by reference in this prospectus. We have not authorized any other person to provide information different from that contained
in this prospectus and the documents incorporated by reference herein. If anyone provides you with different or inconsistent information,
you should not rely on it. You should assume that the information appearing in this prospectus is accurate as of the dates on
the cover page, regardless of time of delivery of the prospectus or any sale of securities. Our business, financial condition,
results of operation and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="SPECIALNOTEREGARDINGFORWARD-LOOKINGSTATEMENTS"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Information set forth in this prospectus and the information
it incorporates by reference may contain various &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of
the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended,
or the Exchange Act. All information relative to future markets for our products and trends in and anticipated levels of revenue,
gross margins and expenses, as well as other statements containing words such as &ldquo;believe,&rdquo; &ldquo;project,&rdquo;
&ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;target,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect&rdquo; and &ldquo;intend&rdquo; and other similar expressions constitute forward-looking statements. These forward-looking
statements are subject to business, economic and other risks and uncertainties, both known and unknown, and actual results may
differ materially from those contained in the forward-looking statements. Examples of risks and uncertainties that could cause
actual results to differ materially from historical performance and any forward-looking statements include, but are not limited
to, the risks described under the heading &ldquo;Risk Factors&rdquo; beginning on page 14 of this prospectus, in our most recent
Annual Report on Form 10-K, as well as any subsequent filings with the United States Securities and Exchange Commission. Given
these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these
forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made.
You should read carefully this prospectus and any related free writing prospectuses that we have authorized for use in connection
with this offering, together with the information incorporated herein or therein by reference as described under the heading &ldquo;Where
You Can Find More Information,&rdquo; completely and with the understanding that our actual future results may be materially different
from what we expect. We hereby qualify all of our forward-looking statements by these cautionary statements. Except as required
by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could
differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the
future. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid; width: 98%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="PROSPECTUSSUMMARY"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> This summary is not complete and does not contain all
of the information you should consider before investing in the securities offered by this prospectus. You should read this summary
together with the entire prospectus, including our financial statements, the notes to those financial statements, and the other
documents identified under the headings &ldquo;Where You Can Find More Information&rdquo; in this prospectus before making an
investment decision. See the Risk Factors section of this prospectus on page 14 for a discussion of the risks involved in investing
in our securities. Unless otherwise noted, all share and per share data in this prospectus, as well as all exercise price or conversion
price data with respect to our convertible securities gives effect to a 6 for 1 reverse stock split of our common stock effected
on May 1, 2014. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ANTRIABIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are a preclinical stage company that is developing novel,
sustained release therapeutics based on our proprietary formulation and manufacturing platform. Specifically, we apply our microsphere
technology to well-characterized pharmaceuticals in order to improve significantly the existing standard of care. We believe that
utilizing our platform with known and approved pharmaceutical agents increases the probability of technical success while reducing
safety concerns, approval risks and development costs. We also believe that our approach may result in differentiated, patent-protected
products which provide significant benefits to patients. Our objective is to use our platform to create new drug candidates in
multiple therapeutic areas that address large potential markets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Lead Product Candidate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our lead product candidate, AB101, is human recombinant
insulin that has been formulated with a polymer in biodegradable microspheres for use in patients with type 1 and type 2 diabetes
who require basal insulin replacement therapy for the control of hyperglycemia. We believe that AB101 is a unique and differentiated
product when compared to existing commercially available therapies. We expect AB101 to be administered through a once per week
subcutaneous injection which provides a near peak-less, slow and uniform release of human recombinant insulin. In contrast, the
two currently approved basal insulin products in this $10 billion market are administered by subcutaneous injection either daily
or twice a day and unlike AB101, these products are insulin analogues (synthetic insulin). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Diabetes is a chronic, life-threatening disease that is
characterized by elevated levels of blood sugar (glucose). Glucose is vital to the body as a source of energy for cells that constitute
muscles and other tissues. Insulin is a hormone that is secreted by the pancreas and it regulates blood glucose levels by moving
glucose into cells for utilization. The pancreas produces what is known as basal insulin which is a slow, steady release of insulin
between meals and overnight and in response to food that is consumed, the pancreas also produces bolus (meal-time) insulin. Diabetes
is a condition that results from either the inability of the pancreas to produce insulin or the inability of the body to effectively
use the insulin that is produced. Further, a condition known as pre-diabetes is characterized by blood glucose levels which are
higher than normal, but not high enough to be classified as diabetes. Possible long-term complications of diabetes include heart
disease, stroke, kidney failure, blindness and amputation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> According to the International Diabetes Federation (IDF),
approximately 380 million people in the world are currently living with diabetes and that number is expected to increase to nearly
600 million by 2035. In 2013, diabetes resulted in more than $500 billion in health expenditures globally, or 11% of the total
healthcare related spending on adults. In the United States, the Centers for Disease Control (CDC) estimates that 29 million people
&ndash; or roughly one out of every 11 people &ndash; are currently living with diabetes. The CDC also estimates that in the US
over 85 million people &ndash; more than one out of three adults &ndash; have pre-diabetes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid; width: 98%"><P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"> The most prevalent forms of diabetes are referred to as type 1 and type 2 diabetes. In type 1 diabetes,
which accounts for approximately 5% to 10% of all diagnosed cases of diabetes, the precise cause is still unknown, although it
is hypothesized that the onset of the disease is triggered by a combination of genetic and environmental factors such as viruses.
In most cases of type 1 diabetes, the body&rsquo;s immune system mistakenly destroys the beta cells in the pancreas that produce
insulin. Type 1 diabetes can only be treated with insulin replacement therapy, delivered via multiple injections or through an
insulin pump both for basal and bolus needs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Type 2 diabetes, which accounts for approximately 90% of
all diagnosed cases, occurs when the body becomes resistant to insulin or does not make enough insulin to properly regulate blood
glucose levels. Common risk factors for type 2 diabetes include: obesity, high cholesterol, high blood pressure, advanced age,
physical inactivity, gestational diabetes, race/ethnicity and a family history of diabetes. Management of type 2 diabetes requires
a multifaceted approach, beginning with a healthy dietary and exercise regimen. While some individuals with type 2 diabetes are
able to successfully manage their blood glucose levels through diet and exercise alone, many require oral medications to: decrease
glucose production and glucose levels, stimulate insulin production, increase sensitivity to the effects of insulin, and prevent
the kidneys from reabsorbing glucose. Examples of oral medications include metformin, sulfonylureas, meglitinides, thiazolidinediones,
DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors. When oral medications in concert with lifestyle adjustments are
insufficient to regulate blood glucose levels, insulin replacement therapy is required for individuals with type 2 diabetes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> AB101 Formulation and Preclinical
Results </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our goal was to develop a human recombinant insulin formulation
which could be administered in a single, small volume injection to cover approximately one week of basal insulin requirements.
We believe that the use of a solvent based microsphere technology is ideal to achieve this objective, but insulin is a protein
that is not dissolvable in oil-based solvents which presents a fundamental challenge when trying to develop a robust, predicable
therapeutic. Our scientific team was able to overcome this conundrum by using PEGylation chemistry to attach a low molecular weight
PEG on a specific site (PheB1) at the terminus of the insulin B peptide chain. By applying a PEG to the molecule in this fashion,
insulin becomes amphiphilic and can be uniformly dissolved in in either oil or water based solutions, including microsphere formulations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> After the insulin in AB101 is PEGylated it is dissolved
in a solvent along with a polymer (poly-lactic co-glycolic acid, or PLGA). The PLGA is critical for determining the rate at which
the PEGylated insulin is released into the body. The combined ingredients are emulsified (a rinse cycle) to remove the solvent
and then dried to form uniform, monolithic microspheres comprised of insulin and PLGA. Prior to being administered to a patient,
the formulation is reconstituted in an aqueous phase comprised mostly of water. Following injection, the microspheres slowly dissolve
through hydrolysis and release insulin in a controlled, highly predictable fashion over the course of one week. As a result of
this unique formulation and manufacturing process, AB101 does not require any new excipients or alterations to the molecular structure
of insulin and the primary ingredients, PEG and PLGA, have been used in numerous approved pharmaceutical products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have completed most of the critical analytical methods
for AB101 including determining the strength and release profile of the drug as well as other physical and chemical attributes
such as particle size and residual solvents. The company we acquired AB101 from, PRP, conducted in vitro as well as in vivo studies
of AB101 including in various rat models where the following promising observations were made: (1) there was no &ldquo;insulin
burst&rdquo; following injection and in fact less than 1% of the weekly dose of the drug was released after injection followed
by sustained release over the dosing interval; (2) there was not batch variability and there were no site injection site reactions;
(3) there was a repeatable pattern from one injection to the next as the profile of drug release is almost identical; (4) there
was minimal peak-to-trough variation after the second injection which we believe indicates that steady-state basal levels of insulin
are achievable with a single once-a-week injection at a specific dose level for individual patient needs; and (5) there was no
reduction in the integrity or biological activity of insulin; and (6) AB101 properly activates the insulin receptor and signaling
cascade. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> AB101&rsquo;s Market Potential
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe that a once-a-week injection of AB101, if approved,
will result in greater patient compliance and set a new standard in basal insulin therapy. In North America, basal insulin already
commands a 47% share of total insulin usage. In 2013, Sanofi-Aventis sold approximately $8 billion of Lantus, a daily injectable
basal insulin therapy while Novo Nordisk sold approximately $2 billion of Levemir, a twice daily injectable basal insulin. Our
once-a-week injection would provide seven days of basal insulin coverage with the potential to significantly improve the treatment
paradigm. Furthermore, there is an opportunity for AB101 to enter new markets outside of North America where basal insulin has
limited penetration. Basal insulin represents 36% of all insulin use in Europe, 29% of all insulin use in Japan and Korea, 13%
of all insulin use in China, and 26% of all insulin use in rest of world. Further, as a result of AB101&rsquo;s weekly injection
profile, it has the potential to be used in patients with type 2 diabetes who are using oral agents but who require improved glycemic
control through the addition of insulin. According to the CDC, 58% of all individuals with diabetes use oral medications only,
and 16% use no medication at all. As a basal insulin replacement therapy, AB101 supplements the effects of endogenous and exogenous
insulin and complements the effects of orally administered hypoglycemic agents. Endogenous insulin is insulin produced by the
pancreas in the human body. Exogenous insulin is insulin delivered by administration of AB101. It is generally believed that the
reluctance to initiate insulin therapy is a result of resistance to take multiple injections for both regular and current long-acting
insulin as well as the multiple finger sticks needed to monitor blood glucose levels. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> AB101 Development Program </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In first half of calendar 2014, we successfully raised more
than $11 million to fund our operations including hiring and retaining qualified staff, leasing a manufacturing and research facility
and engaging third party advisors to assist in the AB101 development efforts. In May 2014, we leased a facility in Louisville,
Colorado which was previously used by a pharmaceutical company, allowing us to take advantage of existing pharmaceutical specific
infrastructure. Nonetheless, we will still have to make leasehold improvements in our laboratory and construct a current good
manufacturing principals (cGMP) aseptic manufacturing suite and we are currently working with advisors on the technical requirements
and design for those improvements which we estimate will cost at least $2.5 million. We have also hired critical staff in the
areas of formulation chemistry, analytical method development, preclinical development, manufacturing and quality assurance and
quality control. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Following the move into our Louisville, Colorado facility,
we placed into service the manufacturing and analytical equipment which was previously used by PR Pharmaceuticals, Inc. to produce
AB101. We are currently testing and re-commissioning the equipment including carrying out simulated manufacturing to ensure that
the platform is operational. As part of this process, we have discovered that some of the equipment is missing, broken or was
managed by software which is outdated and unsupported. As a result, we anticipate acquiring or leasing additional equipment which
may cost approximately $1 million. We also acquired bulk AB101 material that was manufactured by our predecessor in accordance
with GLP (good laboratory practices) and we have been evaluating the feasibility of using this GLP material to advance our development
program as well as for a potential clinical study outside the US. We have decided to use the material to further our preclinical
activities, but it will not be used for any human clinical study. We are planning to produce fresh GLP AB101 material this year
to support our IND enabling animal studies and following the completion of our manufacturing suite, we plan on producing cGMP
material in the 2<SUP>nd</SUP> half of calendar year 2015 to support our US clinical program. We are also in the process of identifying
sources for raw materials including PEG, insulin, as well as PLGA. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> Additional AB101 Preclinical and
Clinical Plans </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"> In the fourth quarter of calendar 2014, as a precursor to our US clinical studies and in order to
fulfill FDA requirements for GLP toxicity studies in support of our IND, we plan on conducting necessary IND-enabling pre-clinical
studies, including acute and sub-acute toxicity studies in at least two species (which are likely to be rodents and dogs), safety
pharmacology, and mutagenicity/genotoxicity studies. We are also planning to conduct additional in vitro and in vivo pharmacology
in the animal to demonstrate the promise of once weekly dosing of basal insulin. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In our clinical studies our objective is to demonstrate
that AB101 is safe and effective at the intended once weekly subcutaneous dosing frequency and that it is non-inferior to current
standard of care basal insulin therapies in controlling blood glucose without an undue risk of hypoglycemia. After completion
of additional IND-enabling work, we plan on filing an IND with the FDA in 2015, followed by the initiation of a clinical trial
in the second half of 2015. The objectives of the Phase 1 program will be to assess the single and repeat (once weekly) ascending
dose safety, pharmacokinetics (PK), and pharmacodynamics (PD) in the target population with type 1 and type 2 diabetes, including
confirmation of the time action profile for glucose lowering (Phase 2a data). Following successful completion of the Phase 1/2a
program, Phase 2b trials in both populations will be conducted to obtain proof-of-concept for the intended once weekly dosing
regimen, using the accepted biomarker for glucose efficacy (hemoglobin A1c; HbA1c), compared to a standard of care basal insulin
such as Lantus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If proof-of-concept trials are successful, we intend to
expand our clinical program to include Phase 3 registration trials in various jurisdictions including the US and Europe, to obtain
regulatory and marketing approval. The Phase 3 program would include studies in combination with other injectable and oral glucose
lowering therapies, and would be designed to meet regulatory guidelines for the development of therapies for diabetes, while achieving
an expanded label at the time of product launch. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Corporate Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The key elements of our business strategy are described
below: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> Advance AB101 into clinical studies </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our objective is to create value by advancing our lead drug
candidate, AB101 through various stages of clinical development. To support this strategy, we have begun hiring additional scientific
staff as well as engaging third parties that will assist with our preclinical and clinical efforts including contract research
organizations. Given that AB101 is an insulin product, we believe that there is tremendous value in animal studies which may be
more predictive of the likelihood of human results than with other preclinical therapies and in other therapeutic environments.
We also believe that our first clinical study will be highly informative with respect to the potential for AB101 to be an efficacious
therapeutic. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Establish a pipeline of drug candidates
which can advance through internal research efforts and advancement of our preclinical drug candidates into clinical trials </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe it is important to maintain a diverse pipeline
of new drug candidates to continue to build on the value of our business and to demonstrate that our technology is a robust platform
which may be applied to other proteins and peptides. Our scientific team plans on applying our technology platform to molecules
across multiple therapeutic areas. A key component of our development strategy is to potentially reduce the risks and time associated
with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic
targets and drugs directed to those targets. We believe that the improved characteristics of our drug candidates will provide
meaningful benefit to patients compared to the existing therapies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Enter into strategic and high-value partnerships
to bring certain of our drug candidates to market </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We intend to enter into collaborations with leading pharmaceutical
and biotechnology companies to fund further clinical development, manage the global regulatory filing process, and market and
sell drugs in one or more geographies. We intend to decide on a drug candidate-by-drug candidate basis how far to advance the
clinical development of a particular drug candidate before seeking a collaborative relationship. The options for future collaboration
arrangements range from comprehensive licensing and commercialization arrangements to co-promotion and co-development agreements
with the structure of the collaboration depending on factors such as the structure of economic risk sharing, the cost and complexity
of development, marketing and commercialization needs, therapeutic area and geographic capabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Continue to build a leading intellectual
property estate in the field of sustained release therapeutics using microsphere technology </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are committed to continuing to build on our intellectual
property position in the field of specialized microsphere formulation and manufacturing. To that end, we have a comprehensive
patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others,
polymer materials, conjugates, formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks that We Face</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our Business is subject to numerous risks and uncertainties,
including those highlighted in the section entitled &ldquo;Risk Factors&rdquo; beginning on page 14. These risks include, among
others, the following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> We
                                         are a preclinical stage company and we do not have, and may never have, any products
                                         that generate significant revenues. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> We
                                         will need substantial additional capital to fund our operations and if we fail to obtain
                                         additional capital, we may be unable to complete the development and commercialization
                                         of our product candidates or continue our research and development programs. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> We
                                         rely on a single product candidate, and if the market does not develop for that candidate
                                         it could adversely impact our operating results. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> Adverse
                                         events in our clinical trials may force us to stop development of our product candidate
                                         or prevent regulatory approval of our product candidates. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> As
                                         our product candidates advance through clinical trials, they may not have favorable results
                                         or receive regulatory approval. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our principal executive offices are located at 890 Santa
Cruz Avenue, Menlo Park, CA 94025, and our telephone number is (303) 222-2128. Our internet address is http://www.antriabio.com.
The information on our website is not incorporated by reference into this prospectus, and you should not consider it part of this
prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> The Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt"> Common stock offered by selling stockholders </FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> 14,958,633 shares of common stock
                           consisting of: </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (1)&nbsp;&nbsp;2,186,847
        shares of common stock issued to the selling stockholders pursuant to the conversion of our 8% convertible promissory
        notes issued in connection with the Bridge Financing; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (2)&nbsp;&nbsp;225,259
        shares of common stock issuable upon the exercise of the Bridge Warrants issued to the selling stockholders in connection
        with the Bridge Financing; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (3)&nbsp;&nbsp;5,725,325
        shares of common stock issued to the selling stockholders in connection with the Unit Financing; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (4)&nbsp;&nbsp;5,725,325
        shares of common stock issuable upon the exercise of the Unit Warrants issued to the selling stockholders in connection
        with the Unit Financing; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (5)&nbsp;&nbsp;562,346
        shares of common stock issuable upon the exercise the Bridge Incentive Warrants issued to certain selling stockholders
        that invested in both the Bridge Financing and the Unit Financing; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (6)&nbsp;&nbsp;67,575
        shares of common stock issuable upon the exercise of compensation warrants issued to certain selling stockholders as compensation
        for services rendered to us in connection with the Bridge Financing; and </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (7)&nbsp;&nbsp;223,286
        shares of common stock issuable upon the exercise of compensation warrants issued to certain selling stockholders as compensation
        for services rendered to us in connection with the Unit Financing. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (8)&nbsp;&nbsp;242,670
        shares of common stock issued to the selling stockholder pursuant to the conversion of a convertible promissory note and
        exercise of warrant in connection with the Note Conversion. </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"> Common stock offered by us </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"> None. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"> Common stock outstanding after this offering (assuming full exercise
    of the Bridge Warrants, the Unit Warrants, the Bridge Incentive Warrants and the Compensation Warrants (as defined below)) </FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"> 25,021,584 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> Use of Proceeds </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"> We will not receive any of the proceeds from the resale or other disposition of the shares
    of our common stock covered by this prospectus by the selling stockholders.&nbsp;&nbsp;However, we will receive the cash exercise
    price upon the exercise of the common stock purchase warrants other than the compensation warrants, the underlying shares
    of which are offered by this prospectus. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> OTCQB symbol for our Common Stock </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"> &ldquo;ANTB&rdquo; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> Risk Factors </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"> Investing in our common stock involves a high degree of risk. See the &ldquo;Risk Factors&rdquo;
    section of this prospectus on page 14 for a discussion of factors you should consider carefully before deciding to invest
    in our securities. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="DESCRIPTIONOFPRIVATEPLACEMENTS"></A>DESCRIPTION OF PRIVATE
PLACEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the first fiscal quarter of 2014, our management and
board of directors (the &ldquo;<B>Board</B>&rdquo;) entered into discussions with respect to potential equity and debt financing
opportunities to raise up to $10,000,000 to address the Company&rsquo;s working capital needs. As a result of these discussions,
on December 13, 2013, we entered into a placement agent agreement (the &ldquo;<B>Placement Agent Agreement</B>&rdquo;) with Paulson
Investment Company, Inc. (&ldquo;<B>Paulson</B>&rdquo; or the &ldquo;<B>Placement Agent</B>&rdquo;), a registered FINRA broker-dealer,
whereby Paulson agreed to act as our exclusive placement agent for a period of eighteen (18) months from the date of the Placement
Agent Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Bridge Financing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 15, 2014, we closed a private placement financing
transaction (the &ldquo;<B>Bridge Financing</B>&rdquo;) with approximately twenty (20) accredited investors. Pursuant to a subscription
agreement and other Bridge Financing transaction documents, we issued 8% unsecured convertible promissory notes with an aggregate
principal amount of $2,703,000 (each a &ldquo;<B>Note</B>&rdquo; and collectively, the &ldquo;<B>Notes</B>&rdquo;) with attached
Bridge Warrants to purchase shares of our common stock equal to one-half of the principal amount of each Note. We received gross
cash proceeds of $2,703,000, excluding Placement Agent compensation, transaction costs, fees and expenses in the Bridge Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Notes bore interest at a rate of 8% per annum and were
payable in a single cash payment on the date that was six (6) months from the date of issuance. Pursuant to the terms of the Notes,
in the event we issued equity securities in a transaction or series of related transactions (the &ldquo;<B>Qualified Financing</B>&rdquo;)
resulting in aggregate gross proceeds to us of at least $3,000,000, the Notes and any accrued but unpaid interest thereon would
automatically convert into equity securities issued pursuant to the Qualified Financing at a conversion price equal to $1.26 per
share of our common stock (the &ldquo;<B>Conversion Price</B>&rdquo;). The close of the Unit Financing qualified as a Qualified
Financing under the terms of the Notes and as a result, the principal and interest due on the Notes were converted into 2,186,847
shares of our common stock. This prospectus covers the shares of our common stock issued upon the conversion of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Bridge Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Bridge Warrants permit the holders thereof to purchase
shares of our common stock at an exercise price of $1.89 per share of common stock for a period of three (3) years from the date
of issuance. The exercise price and the number of shares of our common stock issuable upon the exercise of the Bridge Warrants
is subject to adjustment upon certain events, such as stock splits, combinations, dividends, distributions, reclassifications,
mergers or other corporate change and dilutive issuances. This prospectus covers the shares of our common stock issuable upon
the exercise of the Bridge Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Unit Financing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 17, 2014, we closed a private placement transaction
(the &ldquo;<B>Unit Financing</B>&rdquo;) with approximately 109 accredited investors for 5,725,325 Units at a price per unit
of $1.56 per Unit. In connection with the close of the Unit Financing, we entered into subscription agreements pursuant to which
we issued units of the Company (each a &ldquo;<B>Unit</B>&rdquo; and collectively, the &ldquo;<B>Units</B>&rdquo;) to the investors.
Each Unit consists of one share of our common stock and one transferable Unit Warrant. Each whole Unit Warrant entitles the holder
to purchase one share of our common stock at a price of $2.34 per share of common stock at any time until 5:00 p.m. (Pacific Time)
on the date that is thirty-six (36) months following the close of the Unit Financing. We received gross cash proceeds of approximately
$8.9 million, excluding Placement Agent compensation, transaction costs, fees and expenses in the Unit Financing. This prospectus
covers the shares of our common stock issuable upon the exercise of the Unit Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Bridge Incentive Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the offer and sale of the aforementioned securities
in the Unit Financing, we also issued to investors that invested in both the Unit Financing and the Bridge Financing, an additional
one-half of one Bridge Inventive Warrant for their participation in the Unit Financing for up to 150% of each dollar such investor
invested in the Bridge Financing. The Company issued Bridge Incentive Warrants to purchase 562,346 shares of common stock. Each
whole Bridge Incentive Warrant entitles the holder to purchase one share of our common stock at a price of $2.34 per share of
common stock at any time until 5:00 p.m. (Pacific Time) on the date that is thirty-six (36) months following the close of the
Unit Financing. This prospectus covers, (i) shares of common stock issued as part of the Unit and (ii) the shares of our common
stock issuable upon the exercise of the Bridge Incentive Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Note Conversion</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On June 16, 2014, we entered into a Note Conversion (the
&ldquo;<B>Note Conversion</B>&rdquo;) with an accredited investor in which their 8% unsecured promissory note was converted into
shares of common stock and warrants were issued. The investor on the same day purchased the shares of common stock under the terms
of the warrant using the net issue exercise method as set forth therein. The total number of shares issued to the investor under
the conversion of the conversion of the promissory note and the warrant exercise was 242,670 shares of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Placement Agent Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As compensation for its efforts in the Bridge Financing and
the Unit Financing, we paid Paulson placement agent fees of approximately $1.6 million and we issued them a compensation warrant
in connection with the Bridge Financing to purchase up to 67,575 shares of our common stock for a period of seven (7) years from
the date of issuance with an exercise price of $1.56 per share of common stock. We also issued Paulson a compensation warrant
in connection with the Unit Financing to purchase up to 223,286 shares of our common stock for a period of seven (7) years from
the date of issuance with an exercise price of $1.56 per share of common stock. The compensation warrants issued to Paulson in
connection with the Bridge Financing and the Unit Financing contain cashless exercise rights, and shall be adjusted both as to
the number of shares of common stock and price into which and at which they are exercisable, based on any splits, conversions,
or reorganizations that affect the Company&rsquo;s common stock. The compensation warrants issued to Paulson in connection with
the Bridge and the Unit Financings are collectively referred to herein as the &ldquo;<B>Compensation Warrants.</B>&rdquo; This
prospectus covers the shares of our common stock issuable upon the exercise of the Compensation Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Registration Rights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to our contractual obligations under the Placement
Agent Agreement, the Bridge Financing and the Unit Financing, we are required to file a registration statement (the &ldquo;<B>Registration
Statement</B>&rdquo;) under the United States Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;) within
thirty (30) days following the close of the Unit Financing. The Registration Statement covers: (i) shares of common stock issued
pursuant to the conversion of the Notes; (ii) shares of common stock issuable upon the exercise of the Bridge Warrants; (iii)
shares of common stock issued in connection with the Unit Financing; (iv) shares of common stock issuable upon the exercise of
the Unit Warrants; (v) shares of common stock issuable upon the exercise of the Bridge Incentive Warrants; and (vi) shares of
common stock issuable upon the exercise of the Compensation Warrants issued to Paulson as compensation in connection with the
Bridge Financing and the Unit Financing. We have agreed to take all necessary actions and make all necessary filings to keep the
Registration Statement effective for a period that extends from the first date on which the United States Securities and Exchange
Commission (the &ldquo;<B>SEC</B>&rdquo;) issues an order of effectiveness in relation to the Registration Statement until such
date as our legal counsel issues a legal opinion asserting that the shares of our common stock registered for resale under this
prospectus are available for resale under Rule 144 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="RISKFACTORS"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> An investment in us involves a high degree of risk. You
should consider carefully the following information about these risks before deciding to purchase any of our securities. If any
of the events or developments described below actually occur, our business, results of operations and financial condition would
likely suffer. In these circumstances, you may lose all or part of your investment. In addition, it is also possible that other
risks and uncertainties that affect our business may arise or become material in the future. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need substantial additional capital to fund our
operations and if we fail to obtain additional capital, we may be unable to complete the development and commercialization of
our product candidates or continue our research and development programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our operations will consume substantial amounts of cash.
We expect to spend substantial amounts on research and development, including amounts spent on conducting preclinical activities,
clinical trials for our product candidates, manufacturing, clinical trial materials, and expanding our research and development
program. As of June 30, 2014, we have $5.9 million in cash on hand. It is anticipated that we will need at least an additional
$10 million in capital through calendar year end 2015 to cover operating expenses, clinical testing and leasehold improvements
on a lab facility. We expect that our cash used by operations will continue to increase for the next several years. If we are
unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue
one or more of our drug development or research and development programs. We also may be required to: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> seek
                                         collaborators for our product candidates at an earlier stage than otherwise would be
                                         desirable and on terms that are less favorable than might otherwise be available; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> relinquish,
                                         license or otherwise dispose of rights to technologies, product candidates or products
                                         that we would otherwise seek to develop or commercialize ourselves on terms that are
                                         less favorable than might otherwise be available. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Our independent registered public accounting firms
reports, contained herein, includes an explanatory paragraph that express substantial doubt about our ability to continue as a
going concern. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our financial statements have been prepared on the basis
that we will continue as a going concern. For the period from March 24, 2010 (inception) to June 30, 2014, we have an accumulated
deficit of $17,746,924. As of June 30, 2014, our total stockholder&rsquo;s equity was $6,406,731 and we had working capital of
$5,343,519. We expect to continue to incur losses for the foreseeable future as we develop and commercialize AB101, and we must
raise additional capital from external sources in order to sustain our operations. Primarily as a result of our history of losses
and limited cash balances, our independent registered public accounting firm has included in their audit report an explanatory
paragraphs expressing substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern
is contingent upon, among other factors, our ability to obtain financing to continue to fund our operations. We cannot provide
any assurance that we will be able to raise additional capital. If we are unable to secure additional capital, we may be required
to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash
in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays in our clinical
and regulatory efforts. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are at an early stage of development as a company
and we do not have, and may never have, any products that generate significant revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are at an early stage of development as a proprietary product
specialty pharmaceutical company and we do not have any commercial products. Our existing product candidates will require extensive
additional clinical evaluation, regulatory review, significant marketing efforts and substantial investment before they could
provide us with any revenues. Our efforts may not lead to commercially successful products, for a number of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our
                                         product candidates may not prove to be safe and effective in clinical trials; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> we
                                         may not be able to obtain regulatory approvals for our product candidates or approved
                                         uses may be narrower than we seek; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> we
                                         may not have adequate financial or other resources to complete the development and commercialization
                                         of our product candidates; or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> any
                                         products that are approved may not be accepted or reimbursed in the marketplace. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not expect to be able to market any of our product candidates
for a number of years. If we are unable to develop, receive approval for, or successfully commercialize any of our product candidates,
we will be unable to generate significant revenues. If our development programs are delayed, we may have to raise additional capital
or reduce or cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Initially, we expect to derive all of our revenues, if any,
from AB101. As we cannot currently enter the market with AB101, it is uncertain whether AB101 will achieve and sustain high levels
of demand and market acceptance. Our success will depend to a substantial extent on our ability to successfully commercialize
and market our produces. Failure of consumers to accept AB101 would significantly adversely affect our revenues and profitability. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have never generated any revenues and may never become
profitable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Since inception, we have not generated any revenues and
have incurred an accumulated deficit of $17,746,924 through June 30, 2014. We expect to continue to incur substantial operating
losses for the next several years as we pursue our clinical trials and research and development efforts. To become profitable,
we must successfully develop, manufacture and market our product candidates, either alone or in conjunction with possible collaborators.
We may never have any revenues or become profitable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Our current supply of AB101 may be insufficient in
terms of quality and quantity which would delay preclinical trials </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We acquired a supply of AB101 through the acquisition of
assets from PRP. We have contracted to have this supply filled for use in our preclinical trials. If the supply has expired or
has other quality issues that make it unusable, we could not use it in our preclinical trials. Any inability to use our supply
of AB101 would cause delays and increase costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Our limited operating history makes it difficult to
evaluate our business and prospects </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our operations to date have been limited to organizing and
staffing our company and acquiring product and technology rights. We have not demonstrated an ability to perform preclinical testing,
conduct clinical trials, obtain regulatory approval for or commercialize a product candidate. Consequently, any predictions about
our future performance may not be as accurate as they could be if we had a history of successfully testing, developing and commercializing
pharmaceutical products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Any failure by our third-party manufacturers on which
we rely to produce our preclinical and clinical drug supplies and on which we intend to rely to produce commercial supplies of
any approved product candidates may delay or impair our ability to commercialize our product candidates </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We rely upon a small number of third-party manufacturers
and active pharmaceutical ingredient formulators for the manufacture of certain raw materials which are necessary for formulation
of our material, including AB101, for preclinical and clinical testing purposes and intend to continue to do so in the future.
We also expect to rely upon third parties to produce materials required for the commercial production of our product candidates
if we succeed in obtaining necessary regulatory approvals. If we are unable to arrange for third-party manufacturing sources,
or do so on commercially unreasonable terms, we may not be able to complete development of our product candidates or market them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> There are a small number of suppliers for certain capital
equipment and raw materials that we use to manufacture our drugs. Such suppliers may not sell these raw materials to our manufacturers
at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition
of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of
these raw materials. Although we generally do not begin a clinical study unless we believe we have a sufficient supply of a product
candidate to complete the clinical study, any significant delay in the supply of a product candidate or the raw material components
thereof for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion
of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or
we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial
launch of our product candidates would be delayed or there would be a shortage in supply of such product candidates, which would
impair our ability to generate revenues from the sale of our product candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Reliance on third-party manufacturers entails risks to which
we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory
compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors
beyond our control (including a failure to synthesize and manufacture our product candidates in accordance with our product specifications)
and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at
a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates
be manufactured according to current good manufacturing practices and similar foreign standards. Any failure by our third-party
manufacturers to comply with current good manufacturing practices or failure to scale up manufacturing processes, including any
failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain,
regulatory approval of any of our product candidates. In addition, such failure could be the basis for action by the FDA to withdraw
approvals for product candidates previously granted to us and for other regulatory action, including recall or seizure, total
or partial suspension of production or injunction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Because of the complex nature of our compounds, our manufacturers
may not be able to manufacture our compounds at a cost or in quantities or in a timely manner necessary to make commercially successful
products. If we successfully commercialize any of our drugs, we may be required to establish large-scale commercial manufacturing
capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical study
and commercial manufacturing capacity. We have no experience manufacturing pharmaceutical products on a commercial scale and some
of these suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing, the
satisfaction of which on a timely basis may not be met. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may experience delays in our clinical trials that
could adversely affect our financial position and our commercial prospects</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> For AB101, we are currently planning to begin clinical trials
in the second half of calendar year 2015. Many factors could affect the timing of clinical trials, including lack of material,
slow patient recruitment, the proximity of patients to clinical sites, the eligibility criteria for the trial, competing clinical
trials and new drugs approved for the conditions we are investigating. Other companies may be conducting clinical trials or may
announce plans for future trials that will be seeking patients with the same indications as those we are studying. As a result
of all of these factors, our trials may take longer to enroll patients than we anticipate. Delays in patient enrollment in the
trials may increase our costs and slow down our product development and approval process. Our product development costs will also
increase if we need to perform more or larger clinical trials than planned. Any delays in completing our clinical trials will
delay our ability to generate revenue from product sales, and we may have insufficient capital resources to support our operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adverse events in our clinical trials may force us to
stop development of our product candidates or prevent regulatory approval of our product candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our product candidates may produce serious adverse events.
These adverse events could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA, or
other regulatory authorities requesting additional preclinical data or denying approval of our product candidates for any or all
targeted indications. An institutional review board, independent data safety monitoring board, the FDA, other regulatory authorities
or the Company itself may suspend or terminate clinical trials at any time. We cannot assure you that any of our product candidates
will prove safe for human use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our product candidates do not meet safety or efficacy
endpoints in clinical evaluations, they will not receive regulatory approval and we will be unable to market them</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The regulatory review approval process typically is expensive,
takes many years and the timing of any approval cannot be accurately predicted. If we fail to obtain regulatory approval for our
current or future product candidates, we will be unable to market and sell such products and therefore may never be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the regulatory approval process, we must conduct
preclinical studies and clinical trials for each product candidate to demonstrate safety and efficacy. The number of preclinical
studies and clinical trials that will be required varies depending on the product candidate, the indication being evaluated, the
trial results and regulations applicable to any particular product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results of preclinical studies and initial clinical trials
of our product candidates do not necessarily predict the results of later-stage clinical trials. Product candidates in later stages
of clinical trials may fail to show the desired safety and efficacy despite having progressed through initial clinical trials.
We cannot assure you that the data collected from the preclinical studies and clinical trials of our product candidates will be
sufficient to support FDA or other regulatory approval. In addition, the continuation of a particular study after review by an
independent data safety monitoring board does not necessarily indicate that our product candidate will achieve the clinical endpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA and other regulatory agencies can delay, limit or deny
approval for many reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> a
                                         product candidate may not be safe or effective; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         manufacturing processes or facilities we have selected may not meet the applicable requirements;
                                         and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> changes
                                         in their approval policies or adoption of new regulations may require additional work. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any delay in, or failure to receive or maintain, approval for
any of our products could prevent us from ever generating meaningful revenues or achieving profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our product candidates are prone to the risks of failure inherent
in drug development. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication,
we must demonstrate with substantial evidence gathered in preclinical and well-controlled clinical studies, and, with respect
to approval in the US, to the satisfaction of the FDA and, with respect to approval in other countries, similar regulatory authorities
in those countries, that the product candidate is safe and effective for use for that target indication and that the manufacturing
facilities, processes and controls are adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Despite our efforts, our product candidates may not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> offer
                                         therapeutic or other improvement over existing, comparable therapeutics; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> be
                                         proven safe and effective in clinical studies; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> meet
                                         applicable regulatory standards; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> be
                                         capable of being produced in sufficient quantities at acceptable costs; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> be
                                         successfully commercialized; or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> obtain
                                         favorable reimbursement. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not permitted to market AB101 or any of our other product
candidates in the US until we receive approval of a new drug application, or approval of a biologics license application, from
the FDA, or in any foreign countries until we receive the requisite approval from such countries. We have not submitted a new
drug application or biologics license application or received marketing approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preclinical testing and clinical studies are long, expensive
and uncertain processes. We may spend several years completing our testing for any particular product candidate, and failure can
occur at any stage. Negative or inconclusive results or adverse medical events during a clinical study could also cause the FDA
or us to terminate a clinical study or require that we repeat it or conduct additional clinical studies. Additionally, data obtained
from a clinical study is susceptible to varying interpretations and the FDA or other regulatory authorities may interpret the
results of our clinical studies less favorably than we do. The FDA and equivalent foreign regulatory agencies have substantial
discretion in the approval process and may decide that our data is insufficient to support a marketing application and require
additional preclinical, clinical or other studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Because the results of preclinical testing or earlier
clinical studies are not necessarily predictive of future results none of the product candidates we advance into clinical studies
may have favorable results in later clinical studies or receive regulatory approval </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Success in preclinical testing and early clinical studies
does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational
drug or biologic. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources
and experience, have suffered significant setbacks in Phase 3 clinical studies, even after seeing promising results in earlier
clinical studies. We do not know whether any clinical studies we may conduct will demonstrate adequate efficacy and safety to
result in regulatory approval to market any of our product candidates. If later stage clinical studies do not produce favorable
results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. Even if we believe
that our product candidates have performed satisfactorily in preclinical testing and clinical studies, we may nonetheless fail
to obtain FDA approval for our product candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Due to our reliance on contract research organizations
or other third parties to conduct clinical trials, we are unable to directly control the timing, conduct and expense of our clinical
trials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We plan to rely primarily on third parties to conduct our clinical
trials. As a result, we will have less control over the conduct of the clinical trials, the timing and completion of the trials,
the required reporting of adverse events and the management of data developed through the trial than would be the case if we were
to rely entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes
as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, may undergo changes in priorities
or may become financially distressed, adversely affecting their willingness or ability to conduct our trials. We may experience
unexpected increased costs that are beyond our control. Problems with the timeliness or quality of the work of a contract research
organization may lead us to seek to terminate the relationship and use an alternative service provider. However, making this change
may be costly and may delay our trials, and contractual restrictions may make such a change difficult or impossible. Additionally,
it may be impossible to find a replacement organization that can conduct our trials in an acceptable manner and at an acceptable
cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our competitors may develop and market drugs that are
less expensive, more effective or safer than our product candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The pharmaceutical market is highly competitive. For our
product candidates that use currently approved active ingredients, we will face competition from the existing delivery method
with each product candidate for which we are able to obtain approval. In particular, if we successfully commercialize AB101, our
product candidate would compete directly against Lantus and Levemir, which are in the market as well as Novo Nordisk&rsquo;s Tresiba,
and Eli Lilly&rsquo;s Basil Insulin Peglispro, which are pending FDA approval. Additionally, other pharmaceutical and biotechnology
companies may be developing improved formulations of the same drugs that will compete with products we are developing. While we
are not aware of any products in development for a once-a-week treatment of diabetes using human insulin, we are aware of both
large and small pharmaceutical companies that are attempting to formulate a once a week basal insulin. It is possible that our
competitors will develop and market products that are less expensive, more effective or safer than our future products or that
will render our products obsolete. We expect that competition from pharmaceutical and biotechnology companies, universities and
public and private research institutions will increase. Many of these competitors have substantially greater financial, technical,
research and other resources than we do. We may not have the financial resources, technical and research expertise or marketing,
distribution or support capabilities to compete successfully. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>After the completion of our clinical studies, we cannot
predict whether or when we will obtain regulatory approval to commercialize our product candidates and we cannot, therefore, predict
the timing of any future revenue from these product candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we achieve positive clinical results and file for regulatory
approval, we cannot commercialize any of our product candidates until the appropriate regulatory authorities have reviewed and
approved the applications for such product candidates. We cannot assure you that the regulatory agencies will complete their review
processes in a timely manner or that we will obtain regulatory approval for any product candidate we develop. Satisfaction of
regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires
the expenditure of substantial resources. In addition, we may experience delays or rejections based upon additional government
regulation from future legislation or administrative action or changes in FDA policy during the period of product development,
clinical studies and FDA regulatory review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if our product candidates receive regulatory approval,
they may still face future development and regulatory difficulties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if US regulatory approval is obtained, the FDA may still
impose significant restrictions on a product&rsquo;s indicated uses or marketing or impose ongoing requirements for potentially
costly post-approval studies or post-market surveillance. For example, the label ultimately approved, if any, may include restrictions
on use. Further, the FDA may require that long-term safety data may need to be obtained as a post-market requirement. Our product
candidates will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance,
advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of
drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities
for compliance with current good manufacturing practices and regulations. If we or a regulatory agency discovers previously unknown
problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the
product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including
requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or
the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency
may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> issue
                                         warning letters or untitled letters; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> seek
                                         an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> suspend
                                         or withdraw regulatory approval; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> suspend
                                         any ongoing clinical studies; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> refuse
                                         to approve pending applications or supplements to applications filed by us; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> suspend
                                         or impose restrictions on operations, including costly new manufacturing requirements;
                                         or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> seize
                                         or detain products, refuse to permit the import or export of products, or require us
                                         to initiate a product recall. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The occurrence of any event or penalty described above may
inhibit our ability to commercialize our products and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Asset Purchase Agreement includes contingent payments
that link the amount of consideration paid by us as consideration for the PRP assets to the development of AB101 which could decrease
our working capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We agreed to pay contingent consideration up to a maximum of
$44,000,000 for any of the following events that occur within five years of the Asset Purchase: (i) $2,000,000, if and when we
initiate Phase 2b clinical studies for AB101; (ii) $2,000,000, if we license AB101 to a commercial pharmaceutical company; (iii)
$5,000,000, if and when we initiate Phase 3 clinical studies for AB101; (iv) $10,000,000, if and when the FDA or EMEA approves
the marketing and sale of AB101; and (v) $25,000,000, if and when the cumulative sales of AB101 in a 12 month period exceeds $500,000,000.
These contingent payments could reduce the amount of capital we have available to us to expand our business or develop our other
product lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If any of our product candidates for which we receive
regulatory approval does not achieve broad market acceptance, the revenue that we generate from its sales, if any, will be limited</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The commercial success of our product candidates for which
we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by
the medical community, including physicians, patients and health care payers. The degree of market acceptance of any of our approved
products will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> demonstration
                                         of clinical safety and efficacy compared to other products; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         prevalence and severity of any adverse effects; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> limitations
                                         or warnings contained in a product&rsquo;s FDA-approved labeling; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> availability
                                         of alternative treatments; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> pricing
                                         and cost-effectiveness; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         effectiveness of our or any future collaborators&rsquo; sales and marketing strategies; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our
                                         ability to obtain and maintain sufficient third-party coverage or reimbursement from
                                         government health care programs, including Medicare and Medicaid; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         willingness of patients to pay out-of-pocket in the absence of third-party coverage. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our product candidates are approved, but do not achieve
an adequate level of acceptance by physicians, health care payers and patients, we may not generate sufficient revenue from these
products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party
payers on the benefits of our product candidates may require significant resources and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recently enacted and future legislation or regulatory
reform of the health care system in the US and foreign jurisdictions may affect our ability to sell our products profitably</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to commercialize our future products successfully,
alone or with collaborators, will depend in part on the extent to which reimbursement for the products will be available from
government and health administration authorities, private health insurers and other third-party payers. The continuing efforts
of the US and foreign governments, insurance companies, managed care organizations and other payers of health care services to
contain or reduce health care costs may adversely affect our ability to set prices for our products which we believe are fair,
and our ability to generate revenues and achieve and maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Specifically, in both the US and some foreign jurisdictions,
there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our
ability to sell our products profitably. In March 2010, President Obama signed into law the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Health Care Reform Law, a sweeping
law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against
fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on
the health industry and impose additional health policy reforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will not know the full effects of the Health Care Reform
Law until applicable federal and state agencies issue regulations or guidance under the new law. Although it is too early to determine
the effect of the Health Care Reform Law, the new law appears likely to continue the pressure on pharmaceutical pricing, especially
under the Medicare program, and also may increase our regulatory burdens and operating costs. We expect further federal and state
proposals and health care reforms to continue to be proposed by legislators, which could limit the prices that can be charged
for the products we develop and may limit our commercial opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Also in the US, the Medicare Prescription Drug, Improvement,
and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for
pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement
methodology based on average sales prices for drugs. In addition, this legislation authorized Medicare Part D prescription drug
plans to use formularies where they can limit the number of drugs that will be covered in any therapeutic class. As a result of
this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain
and reduce costs. These cost reduction initiatives and other provisions of this legislation could decrease the coverage and price
that we receive for any approved products and could seriously harm our business. While the MMA applies only to drug benefits for
Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement
rates, and any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private
payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The continuing efforts of government and other third-party
payors to contain or reduce the costs of health care through various means may limit our commercial opportunity. It will be time-consuming
and expensive for us to go through the process of seeking reimbursement from Medicare and private payors. Our products may not
be considered cost-effective, and government and third-party private health insurance coverage and reimbursement may not be available
to patients for any of our future products or sufficient to allow us to sell our products on a competitive and profitable basis.
Our results of operations could be adversely affected by the MMA, the Health Care Reform Law, and additional prescription drug
coverage legislation, by the possible effect of this legislation on amounts that private insurers will pay and by other health
care reforms that may be enacted or adopted in the future. In addition, increasing emphasis on managed care in the US will continue
to put pressure on the pricing of pharmaceutical products. Cost control initiatives could decrease the price that we or any potential
collaborators could receive for any of our future products and could adversely affect our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In some foreign countries, including major markets in the
European Union and Japan, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries,
pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of regulatory marketing
approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical
study that compares the cost effectiveness of our product candidates to other available therapies. Such pharmacoeconomic studies
can be costly and the results uncertain. Our business could be harmed if reimbursement of our products is unavailable or limited
in scope or amount or if pricing is set at unsatisfactory levels. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face potential product liability exposure, and, if
successful claims are brought against us, we may incur substantial liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The use of our product candidates in clinical studies and the
sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability
claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise
coming into contact with our products. If we cannot successfully defend ourselves against product liability claims, we could incur
substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> impairment
                                         of our business reputation; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> withdrawal
                                         of clinical study participants; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> costs
                                         of related litigation; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> distraction
                                         of management&rsquo;s attention from our primary business; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> substantial
                                         monetary awards to patients or other claimants; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         inability to commercialize our product candidates; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> decreased
                                         demand for our product candidates, if approved for commercial sale. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently do not have any product liability insurance coverage
as we have not yet begun our clinical trials on our current product candidate. We plan on obtaining product liability insurance
prior to beginning our clinical trials. Our product liability insurance coverage for our clinical studies may not be sufficient
to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and,
in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against
losses due to liability. If and when we obtain marketing approval for any of our product candidates, we intend to expand our insurance
coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially
reasonable terms. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated
adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline
and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we use hazardous and biological materials in a manner
that causes injury or violates applicable law, we may be liable for damages</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development activities involve the controlled
use of potentially hazardous substances, including toxic chemical and biological materials. We could be held liable for any contamination,
injury or other damages resulting from these hazardous substances. In addition, our operations produce hazardous waste products.
While third parties are responsible for disposal of our hazardous waste, we could be liable under environmental laws for any required
cleanup of sites at which our waste is disposed. Federal, state, foreign and local laws and regulations govern the use, manufacture,
storage, handling and disposal of these hazardous materials. If we fail to comply with these laws and regulations at any time,
or if they change, we may be subject to criminal sanctions and substantial civil liabilities, which may harm our business. Even
if we continue to comply with all applicable laws and regulations regarding hazardous materials, we cannot eliminate the risk
of accidental contamination or discharge and our resultant liability for any injuries or other damages caused by these accidents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to establish sales and marketing capabilities
or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not currently have an organization for the sales, marketing
and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness
of doing so. In order to market any products that may be approved by the FDA, we must build our sales, marketing, managerial and
other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish
adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate
product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded
marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions,
we may be unable to compete successfully against these more established companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Guidelines and recommendations published by various organizations
may adversely affect the use of any products for which we may receive regulatory approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government agencies issue regulations and guidelines directly
applicable to us and to our product candidates. In addition, professional societies, practice management groups, private health
or science foundations and organizations involved in various diseases from time to time publish guidelines or recommendations
to the medical and patient communities. These various sorts of recommendations may relate to such matters as product usage and
use of related or competing therapies. For example, organizations like the American Heart Association have made recommendations
about therapies in the cardiovascular therapeutics market. Changes to these recommendations or other guidelines advocating alternative
therapies could result in decreased use of any products for which we may receive regulatory approval, which may adversely affect
our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to successfully remediate material weaknesses
in our internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected,
which adversely affect investor confidence in us and, as a result, the value of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In connection with the audit of the fiscal 2014 consolidated
financial statements of AntriBio, Inc., our auditors noted material weaknesses in our controls, principally as a result of not
having segregated duties as our chief accounting officer can initiate and complete transactions and not having measures that would
prevent the controller from overriding the internal control system. A material weakness is a deficiency or combination of deficiencies
in internal control over financial reporting that results in more than reasonable possibility that a material misstatement of
annual or interim financial statements will not be prevented or detected on a timely basis. We have also begun evaluating and
implementing additional procedures to improve the segregation of duties. We cannot assure you, however, that these or other measures
will fully remediate the deficiencies or material weakness described above. We also cannot assure you that we have identified
all of our existing significant deficiencies and material weaknesses, or that we will not in the future have additional significant
deficiencies or material weaknesses. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our or our licensors&rsquo; patent positions do not
adequately protect our product candidates or any future products, others could compete with us more directly, which would harm
our business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our commercial success will depend in part on our and our licensors&rsquo;
ability to obtain additional patents and protect our existing patent positions, particularly those patents for which we have secured
exclusive rights, as well as our ability to maintain adequate protection of other intellectual property for our technologies,
product candidates and any future products in the US and other countries. If we or our licensors do not adequately protect our
intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have,
which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize
our product candidates and delay or render impossible our achievement of profitability. The laws of some foreign countries do
not protect our proprietary rights to the same extent as the laws of the US, and we may encounter significant problems in protecting
our proprietary rights in these countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The patent positions of biotechnology and pharmaceutical companies,
including our patent position, involve complex legal and factual questions, and, therefore, validity and enforceability cannot
be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated or circumvented. We and our licensors
will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary
technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained
as trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The degree of future protection for our proprietary rights
is uncertain, and we cannot ensure that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> we
                                         or our licensors were the first to make the inventions covered by each of our pending
                                         patent applications; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> we
                                         or our licensors were the first to file patent applications for these inventions; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> others
                                         will not independently develop similar or alternative technologies or duplicate any of
                                         our technologies; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> any
                                         of our or our licensors&rsquo; pending patent applications will result in issued patents; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> any
                                         of our or our licensors&rsquo; patents will be valid or enforceable; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> any
                                         patents issued to us or our licensors and collaborators will provide a basis for commercially
                                         viable products, will provide us with any competitive advantages or will not be challenged
                                         by third parties; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> we
                                         will develop additional proprietary technologies or product candidates that are patentable;
                                         or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         patents of others will not have an adverse effect on our business. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be unable to adequately prevent disclosure of
trade secrets and other proprietary information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely on trade secrets to protect our proprietary know-how
and technological advances, especially where we do not believe patent protection is appropriate or obtainable. However, trade
secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These
agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event
of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary
information. Costly and time- consuming litigation could be necessary to enforce and determine the scope of our proprietary rights.
Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products
that compete with our products or cause additional, material adverse effects upon our competitive business position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our current patent positions and license portfolio may
not include all patent rights needed for the full development and commercialization of our product candidates. We cannot be sure
that patent rights we may need in the future will be available for license to us on commercially reasonable terms, or at all</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We typically develop our product candidates using compounds
that we have in-licensed, including their original composition of matter patents and patents that claim the activities and methods
for such compounds&rsquo; production and use to the extent known at that time. The Company acquired from PRP a license agreement
with Brookwood Pharmaceuticals (Brookwood) which is owned by Surmodics, Inc. The license agreement allows the Company to use certain
controlled delivery technology owned by Brookwood that may prove useful in the delivery of basal insulin and under certain circumstances
may require royalty payments. For example, royalty payments are to be paid on the commercial sales by the Company with the royalty
rate to be adjusted depending on if the Company also purchases product or supplies from Brookwood. We may also need to license
additional patent rights or other rights on compounds, treatment methods or manufacturing processes because we learn that we need
such rights during the continuing development of our product candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although our patents may prevent others from making, using
or selling similar products, they do not ensure that we will not infringe the patent rights of third parties. We may not be aware
of all patents or patent applications that may impact our ability to make, use or sell any of our product candidates or proposed
product candidates. For example, because we sometimes identify the mechanism of action or molecular target of a given product
candidate after identifying its composition of matter and therapeutic use, we may not be aware until the mechanism or target is
further elucidated that a third party has an issued or pending patent claiming biological activities or targets that may cover
our product candidate. US patent applications filed after November 29, 2000 are confidential in the US Patent and Trademark Office
for the first 18 months after such applications&rsquo; earliest priority date, and patent offices in other countries often publish
patent applications for the first time six months or more after filing. Furthermore, we may not be aware of published or granted
conflicting patent rights. Any conflicts resulting from patent applications and patents of others could significantly reduce the
coverage of our patents and limit our ability to obtain meaningful patent protection. If others obtain patents with conflicting
claims, we may need to obtain licenses to these patents or to develop or obtain alternative technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be able to obtain any licenses or other rights to
patents, technology or know-how from third parties necessary to conduct our business as described in this report and such licenses,
if available at all, may not be available on commercially reasonable terms. Any failure to obtain such licenses could delay or
prevent us from developing or commercializing our drug candidates or proposed product candidates, which would harm our business.
Litigation or patent interference proceedings may be necessarily brought against third parties, as discussed below, to enforce
any of our patents or other proprietary rights or to determine the scope and validity or enforceability of the proprietary rights
of such third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Litigation regarding patents, patent applications and
other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in
bringing product candidates to market and harm our ability to operate</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our commercial success will depend in part on our ability to
manufacture, use, sell and offer to sell our product candidates and proposed product candidates without infringing patents or
other proprietary rights of third parties. Although we are not currently aware of any litigation or other proceedings or third-party
claims of intellectual property infringement related to our product candidates, the pharmaceutical industry is characterized by
extensive litigation regarding patents and other intellectual property rights. Other parties may obtain patents in the future
and allege that the use of our technologies infringes these patent claims or that we are employing their proprietary technology
without authorization. Likewise, third parties may challenge or infringe upon our or our licensors&rsquo; existing or future patents.
Proceedings involving our patents or patent applications or those of others could result in adverse decisions regarding the patentability
of our inventions relating to our product candidates or the enforceability, validity or scope of protection offered by our patents
relating to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we are successful in these proceedings, we may incur
substantial costs and divert management time and attention in pursuing these proceedings. If we are unable to avoid infringing
the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of
the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions
to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend
an infringement action successfully or have our patents declared invalid, we may incur substantial monetary damages; encounter
significant delays in bringing our product candidates to market; or be precluded from participating in the manufacture, use or
sale of our product candidates or methods of treatment requiring licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our patent and other intellectual property protection
is inadequate, our sales and profits could suffer or competitors could force our products completely out of the market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patents which prevent the manufacture or sale of our products
may be issued to others. We may have to license those patents and pay significant fees or royalties to the owners of the patents
in order to keep marketing our products. This would cause profits on sales to suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have been granted patents or licensed patents in the
US, but patent applications that have been, or may in the future be, filed by us may not result in the issuance of additional
patents. For example, in July 2014 we filed a new patent application which significantly improves the injectability of our molecules
using our microsphere platforms, including AB101, which such patent may never issue. The scope of any patent issued may not be
sufficient to protect our technology. The laws of foreign jurisdictions in which we intend to sell our products may not protect
our rights to the same extent as the laws of the US. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to patent protection, we also rely on trade secrets,
proprietary know-how and technology advances. We enter into confidentiality agreements with our employees and others, but these
agreements may not be effective in protecting our proprietary information. Others may independently develop substantially equivalent
proprietary information or obtain access to our know-how. Litigation, which is expensive, may be necessary to enforce or defend
our patents or proprietary rights and may not end favorably for us. We may also choose to initiate litigation against other parties
who we come to believe are infringing these patents. If such litigation is unsuccessful or if the patents are invalidated or canceled,
we may have to write off the related intangible assets and such an event could significantly reduce our earnings. Any of our licenses,
patents or other intellectual property may be challenged, invalidated, canceled, infringed or circumvented and may not provide
any competitive advantage to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Investors may experience dilution if we issue additional
shares of common stock </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In general, stockholders do not have preemptive rights to
any common stock issued by us in the future. Therefore, stockholders may experience dilution of their equity investment if we
issue additional shares of common stock in the future, including shares issuable under equity incentive plans, or if we issue
securities that are convertible into shares of our common stock. Given that we will we require additional capital, we intend to
raise funds in the future by issuing common stock which will cause dilution to our stockholders. The Company also has significant
outstanding warrants to purchase common stock as well as a stock option pool available to employees, which if exercised, would
cause dilution to our stockholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is a limited trading market for our common stock,
which could make it difficult for you to liquidate an investment in our common stock, in a timely manner</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our common stock is currently traded on the OTCQB. Because
there is a limited public market for our common stock, you may not be able to liquidate your investment when you want. We cannot
assure you that an active trading market for our common stock will ever develop. The lack of an active public trading market means
that you may not be able to sell your shares of common stock when you want, thereby increasing your market risk. Until our common
stock is listed on an exchange, we expect that it will continue to be listed on the OTCQB. However, an investor may find it difficult
to obtain accurate quotations regarding the common stock&rsquo;s market value. In addition, if we failed to meet the criteria
set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities to persons
other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending
or selling our common stock, which may further affect its liquidity. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities analysts do not publish research or reports
about our business or if they downgrade us or our sector, the price of our common stock could decline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trading market for our common stock will depend in part
on research and reports that industry or financial analysts publish about us or our business. We do not control these analysts.
Furthermore, if one or more of the analysts who cover us downgrades us or the industry in which we operate or the stock of any
of our competitors, the price of our common stock will probably decline. If one or more of these analysts ceases coverage altogether,
we could lose visibility, which could also lead to a decline in the price of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We cannot assure you that our common stock will become
listed on a securities exchange and the failure to do so may adversely affect your ability to dispose of our common stock in a
timely fashion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We plan to seek listing of our common stock on the NYSE
MKT or a NASDAQ exchange as soon as reasonably practicable. In 2011,the NYSE MKT and the NASDAQ amended their listings to restrict
the ability of companies that have completed reverse mergers to list their securities on such exchanges. In order to become eligible
to list their securities on such exchange, reverse merger companies must have had their securities traded on an over-the-counter
market for at least one year, maintained a certain minimum closing price for not less than 30 of the most recent 60 days prior
to the filing of an initial listing application and prior to listing, and timely filed with the SEC all required reports since
consummation of the reverse merger, including one annual report containing audited financial statements for a full fiscal year
commencing after the date of the filing of the Form 8-K containing the Company&rsquo;s Form 10 information. To date the Company
has not met all of the filing requirements above and may not be able to satisfy the initial listing standards of the NYSE MKT
or NASDAQ exchanges in the foreseeable future or at all. Even if we are able to list our common stock on such exchange, we may
not be able to maintain a listing of the common stock on such stock exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The market price and trading volume of our common stock
may be volatile, which may adversely affect its market price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market price of our common stock could be subject to significant
fluctuations due to factors such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> actual
                                         or anticipated fluctuations in our financial condition or results of operations; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> limited
                                         trading activity; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the
                                         success or failure of our operating strategies and our perceived prospects; realization
                                         of any of the risks described in this section; failure to be covered by securities analysts
                                         or failure to meet the expectations of securities analysts; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> a
                                         decline in the stock prices of peer companies; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> a
                                         discount in the trading multiple of our common stock relative to that of common stock
                                         of certain of our peer companies due to perceived risks associated with our smaller size. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As a result, shares of our common stock may trade at prices
significantly below the price an investor paid to acquire them. Furthermore, declines in the price of our common stock may adversely
affect the Company&rsquo;s ability to conduct future offerings or to recruit and retain key employees. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our common stock may be considered a &ldquo;penny stock&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Trades of our common stock are subject to Rule 15g-9 promulgated
by the SEC under the Exchange Act, which imposes certain requirements on broker/dealers who sell securities subject to the rule
to persons other than established customers and accredited investors. For transactions covered by the rule, broker/dealers must
make a special suitability determination for purchasers of the securities and receive the purchaser&rsquo;s written agreement
to the transaction prior to sale. The SEC also has other rules that regulate broker/dealer practices in connection with transactions
in &ldquo;penny stocks.&rdquo; Penny stocks generally are equity securities with a price of less than $5.00 (other than securities
listed on a national securities exchange, provided that current price and volume information with respect to transactions in that
security is provided by the exchange or system). The penny stock rules require a broker/dealer, prior to a transaction in a penny
stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the SEC that provides
information about penny stocks and the nature and level of risks in the penny stock market. The broker/dealer also must provide
the customer with current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson
in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account.
The bid and offer quotations, and the broker/dealer and salesperson compensation information, must be given to the customer orally
or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer&rsquo;s
confirmation. These disclosure requirements have the effect of reducing the level of trading activity in the secondary market
for our common stock. As a result of the foregoing, investors may find it difficult to sell their shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have no current plan to pay dividends on our common
stock and investors may lose the entire amount of their investment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no current plans to pay dividends on our common stock.
Therefore, investors will not receive any funds absent a sale of their shares. We cannot assure investors of a positive return
on their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="MARKETINDUSTRYANDOTHERDATA"></A><B>MARKET, INDUSTRY AND OTHER DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated, information contained in this prospectus
concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity
and market size, is based on information from various sources, on assumptions that we have made that are based on those data and
other similar sources and on our knowledge of the markets for our services. These data involve a number of assumptions and limitations.
We have not independently verified the accuracy of any third party information. In addition, projections, assumptions and estimates
of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree
of uncertainty and risk due to a variety of factors, including those described in section entitled &ldquo;<I>Risk Factors</I>&rdquo;
of this prospectus and elsewhere in this prospectus. These and other factors could cause results to differ materially from those
expressed in the estimates made by the independent parties and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="USEOFPROCEEDS"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are registering these shares pursuant to the registration
rights granted to the selling stockholders in the Bridge Financing, the Unit Financing and the Note Conversion. We will not receive
any proceeds from the sale or other disposition by the selling stockholders of the shares of our common stock covered by this
prospectus. However, we will receive the cash exercise price of the Bridge Warrants, the Unit Warrants, and the Bridge Incentive
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"> <A NAME="MARKETREGISTRANTSCOMMONEQUITY"></A>MARKET FOR REGISTRANT&rsquo;S COMMON
EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Market Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is currently quoted on the OTCQB tier of the
OTC Markets Group under the trading symbol &ldquo;ANTB.&rdquo; The OTCQB is an inter-dealer quotation and trading system and only
market makers can apply to quote securities on the OTCQB. Trading in our common stock on the OTCQB has been limited and sporadic
and the quotations set forth below are not necessarily indicative of actual market conditions. Further, these prices reflect inter-dealer
prices without retail mark-up, mark-down, or commission, and may not necessarily represent actual transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the high and low last reported
sale price information for our common stock for the fiscal quarters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"> Common Stock (1) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"> High </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"> Low </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"> Third quarter 2013 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 15.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 7.50 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Fourth quarter 2013 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 8.40 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 3.90 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> First quarter 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 5.70 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.85 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Second quarter 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4.56 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.20 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Third quarter 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4.08 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.40 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Fourth quarter 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (1) </TD><TD><FONT STYLE="font-size: 10pt"> The market data table
                                         takes into account our 6 for 1 Reverse Split effective May 1, 2014. The Company acknowledges
                                         that some media sites that report market and trading information reflect our trading
                                         information on a pre-Reverse Split basis and have not updated the share price data prior
                                         to the effectiveness of the Reverse Split to account for the Reverse Split. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to January 1, 2013, there had been limited trades of
our common shares and all had been for a nominal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Holders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As of October 23, 2014 there were of record approximately
214 holders of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Dividends </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never paid cash dividends and intend to employ all
available funds in the development of our business. We have no plans to pay cash dividends in the near future. If we issue in
the future any preferred stock or obtain financing from a bank, the terms of those financings may contain restrictions on our
ability to pay dividends for so long as the preferred stock or bank financing is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Upon our acquisition of Antria Delaware pursuant to the
Reverse Merger, we assumed the option agreements for 1,500,000 shares that had been issued by Antria Delaware (Assumed Options).
The Assumed Options are governed by the terms of their respective option agreements. The Assumed Options generally are nontransferable
and expire no later than five years from the date of grant. Between 50-66.7% of the shares of common stock issuable and/or exercised
under the option agreements vest immediately on the grant date with the remainder to vested ratably monthly until the vesting
date. The Assumed Options have an exercise price of $4.50 per share. The Assumed Options were duly approved by the Antria Delaware
stockholders prior to the closing of the Reverse Merger and were granted to Steve Howe, Hoyoung Huh, Sankaram Mantripragada and
Nevan Elam. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In June 2013, the Company approved the grant of options
to purchase 8,334 shares of common stock to contractors of the Company. The options are governed by the terms of their respective
option agreements and expire no later than five years from the date of the grant. The first 25% of the shares of common stock
issuable and/or exercised under the option agreement vested immediately on the grant date with the remainder vesting in 25% intervals
through October 2015. The options have an exercise price of $4.50 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On March 26, 2014, the board of directors and the holders
of a majority of the Company&rsquo;s issued and outstanding stock, adopted the Company&rsquo;s 2014 Stock and Incentive Plan.
With the effectiveness of the plan by shareholder approval, the board issued to executives, directors and other employees options
to purchase 2,835,000 shares of common stock. The options are governed by the 2014 Stock and Incentive Plan and expire no later
than seven years from the date of the grant. The options vest on a monthly basis over 48 months with some options subject to a
one year cliff and have an exercise price based on the fair value of the common stock on the date of grant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table displays equity compensation plan information
as of June 30, 2014: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"> Number of
    Securities to be </FONT><BR><FONT STYLE="font-size: 8pt"> issued upon exercise of </FONT><BR><FONT STYLE="font-size: 8pt">
    outstanding options, warrants </FONT><BR><FONT STYLE="font-size: 8pt"> and rights </FONT><BR><FONT STYLE="font-size: 8pt">
    (a) </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"> Weighted-average
    exercise </FONT><BR><FONT STYLE="font-size: 8pt"> price of outstanding options, </FONT><BR><FONT STYLE="font-size: 8pt">
    warrants, and rights </FONT><BR><FONT STYLE="font-size: 8pt"> (b) </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"> Number of
    securities </FONT><BR>
    <FONT STYLE="font-size: 8pt"> remaining available for future </FONT><BR><FONT STYLE="font-size: 8pt"> issuance under
    equity </FONT><BR><FONT STYLE="font-size: 8pt"> compansation plans </FONT><BR><FONT STYLE="font-size: 8pt"> (excluding
    securities reflected </FONT><BR><FONT STYLE="font-size: 8pt"> in column (a)) </FONT><BR><FONT STYLE="font-size: 8pt">
    (c) </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-size: 8pt"> Equity compensation plans approved by security holders </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 8pt"> 2,835,000 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 8pt"> 3.14 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 8pt"> 915,000 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> Equity compensation plans not approved by
    security holders </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt"> 1,508,334 </FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt"> $ </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt"> 4.50 </FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt"> - </FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 9pt"><FONT STYLE="font-size: 8pt"> Total </FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt"> 4,343,334 </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt"> $ </FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt"> 3.61 </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt"> 915,000 </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="SELECTEDCONSOLIDATEDFINANCIALDATA"></A>SELECTED CONSOLIDATED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following selected consolidated financial data should be
read in conjunction with &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo;
and our consolidated financial statements and related notes included elsewhere in this prospectus. Our historical results are
not necessarily indicative of the results to be expected in the future, and our interim results are not necessarily indicative
of the results to be expected for the full fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Summary of Operations </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"> Year Ended </TD><TD NOWRAP> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"> Year Ended </TD><TD NOWRAP> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> June 30, 2014 </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> June 30, 2013 </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Revenues </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 74%; text-align: left"> Loss from Operations </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> (5,176,033 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> (6,106,881 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net Loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (9,730,454 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (6,727,457 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Net loss per common share (basic and diluted) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (1.04 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (1.08 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Weighted average common shares outstanding </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,384,662 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,204,568 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Statement of Financial Position </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> June 30, 2014 </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> June 30, 2013 </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"> Cash </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 5,934,534 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 527 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Total Assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 7,404,652 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,103,971 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Convertible Notes Payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 60,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 3,732,500 </TD><TD STYLE="text-align: left"> </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Working Capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 5,343,519 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (4,450,634 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Long Term Debt </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> Stockholder's Equity (Deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 6,406,731 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (4,162,212 </TD><TD STYLE="text-align: left"> ) </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="MANAGEMENTSDISCUSSION"></A>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> The following Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations of contain forward-looking statements which involve risks and uncertainties.
Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors,
including those set forth under &ldquo;Risk Factors&rdquo; and elsewhere in this Annual Report. We assume no obligation to update
forward-looking statements or the risk factors. You should read the following discussion in conjunction with Antria&rsquo;s financial
statements and related notes. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are a preclinical stage company that is developing novel,
sustained release therapeutics based on our proprietary formulation and manufacturing platform. Specifically, we apply our microsphere
technology to well-characterized pharmaceuticals in order to improve significantly the existing standard of care. We believe that
utilizing our platform with known and approved pharmaceutical agents increases the probability of technical success while reducing
safety concerns, approval risks and development costs. We also believe that our approach may result in differentiated, patent-protected
products which provide significant benefits to patients. Our objective is to use our platform to create new drug candidates in
multiple therapeutic areas that address large potential markets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Lead Product Candidate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our lead product candidate, AB101, is human recombinant
insulin that has been formulated with a polymer in biodegradable microspheres for use in patients with type 1 and type 2 diabetes
who require basal insulin replacement therapy for the control of hyperglycemia. We believe that AB101 is a unique and differentiated
product when compared to existing commercially available therapies. We expect AB101 to be administered through a once per week
subcutaneous injection which provides a near peak-less, slow and uniform release of human recombinant insulin. In contrast, the
two currently approved basal insulin products in this $10 billion market are administered by subcutaneous injection either daily
or twice a day and unlike AB101, these products are insulin analogues (synthetic insulin). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe that a once-a-week injection of AB101, if approved,
will result in greater patient compliance and set a new standard in basal insulin therapy. In North America, basal insulin already
commands a 47% share of total insulin usage. In 2013 Sanofi-Aventis sold approximately $8 billion of Lantus, a daily injectable
basal insulin therapy while Novo Nordisk sold approximately $2 billion of Levemir, a twice daily injectable basal insulin. Our
once-a-week injection would provide seven days of basal insulin coverage with the potential to significantly improve the treatment
paradigm. Our objective is to create value by advancing AB101 through various stages of clinical development and to explore potential
partnerships with larger pharmaceutical companies following successful clinical trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Cash Requirements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In first half of calendar 2014 we successfully raised
more than $11 million to fund our operations including hiring and retaining qualified staff, leasing a manufacture and
research facility and engaging third party advisors to assist in the AB101 development efforts. As of June 30, 2014, we had
$5.9 million cash on hand. Our general operating expenses average $350-$500 thousand per month and we anticipate that our
current cash would be sufficient to fund our operations well into 2H of 2015. However, our current cash is not sufficient to
fund the production of cGMP material required for AB101 clinical studies and it is insufficient to pay for our planned
clinical study in 2H 2015. In order to advance our clinical program for AB101, we believe that we require at least an
additional $10 million of cash. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Specifically, in order to produce cGMP material in our facility
we will need to construct a manufacturing suite which we estimate will cost at least $2.5 million and we expect that our first
clinical study in 2H 2015 will cost approximately $4 million. In addition, following the move into our Louisville facility we
discovered that some of the equipment required for the production of microspheres on our platform is missing, broken or was managed
by software which is outdated and unsupported and consequently we anticipate acquiring or leasing additional equipment which may
cost approximately $1 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe that our current cash is sufficient to support
the manufacture of fresh GLP AB101 material as well as to conduct studies in support of our IND, including acute and sub-acute
toxicity studies in at least two species (which are likely to be rodents and dogs), safety pharmacology, and mutagenicity/genotoxicity
studies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are also planning to conduct additional in vitro and
in vivo pharmacology in the animal to demonstrate the promise of once weekly dosing of basal insulin. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In our clinical studies our objective is to demonstrate
that AB101 is safe and effective at the intended once weekly subcutaneous dosing frequency and that it is non-inferior to current
standard of care basal insulin therapies in controlling blood glucose without an undue risk of hypoglycemia. After completion
of additional IND-enabling work, we plan on filing an IND with the FDA in 2015, followed by the initiation of a clinical trial
in the second half of 2015. The objectives of the Phase 1 program will be to assess the single and repeat (once weekly) ascending
dose safety, pharmacokinetics (PK), and pharmacodynamics (PD) in the target population with type 1 and type 2 diabetes, including
confirmation of the time action profile for glucose lowering (Phase 2a data). Following successful completion of the Phase 1/2a
program, Phase 2b trials in both populations will be conducted to obtain proof-of-concept for the intended once weekly dosing
regimen, using the accepted biomarker for glucose efficacy (hemoglobin A1c; HbA1c), compared to a standard of care basal insulin
such as Lantus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If proof-of-concept trials are successful, we would expand
our clinical program to include Phase 3 registration trials in various jurisdictions including the US and Europe, to obtain regulatory
and marketing approval. The Phase 3 program would include studies in combination with other injectable and oral glucose lowering
therapies, and would be designed to meet regulatory guidelines for the development of therapies for diabetes, while achieving
an expanded label at the time of product launch.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Establish a pipeline of drug candidates
which can advance through internal research efforts and advancement of our preclinical drug candidates into clinical trials </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe it is important to maintain a diverse pipeline
of new drug candidates to continue to build on the value of our business and to demonstrate that our technology is a robust platform
which may be applied to other proteins and peptides. Our scientific team plans on applying our technology platform to molecules
across multiple therapeutic areas. A key component of our development strategy is to potentially reduce the risks and time associated
with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic
targets and drugs directed to those targets. We believe that the improved characteristics of our drug candidates will provide
meaningful benefit to patients compared to the existing therapies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Enter into strategic and high-value partnerships
to bring certain of our drug candidates to market </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We decide on a drug candidate-by-drug candidate basis how
far to advance clinical development (e.g. Phase&nbsp;1, 2 or 3) before seeking a partner where our strategy is to enter into collaborations
with leading pharmaceutical and biotechnology companies to fund further clinical development, manage the global regulatory filing
process, and market and sell drugs in one or more geographies. The options for future collaboration arrangements range from comprehensive
licensing and commercialization arrangements to co-promotion and co-development agreements with the structure of the collaboration
depending on factors such as the structure of economic risk sharing, the cost and complexity of development, marketing and commercialization
needs, therapeutic area and geographic capabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Continue to build a leading intellectual
property estate in the field of sustained release therapeutics using microsphere technology </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are committed to continuing to build on our intellectual
property position in the field of specialized microsphere formulation and manufacturing. To that end, we have a comprehensive
patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others,
polymer materials, conjugates, formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Significant Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our consolidated financial statements have been prepared
in accordance with accounting policies generally accepted in the United States of America. The preparation of the consolidated
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going
basis, management evaluates its estimates and judgments, including those related to recoverability of long-lived assets, fair
value of derivative instruments and stock-based compensation, allowances and contingencies. Management bases its estimates and
judgments on historical experience and on various factors that are believed to be reasonable under the circumstance, the results
of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods, estimates,
and judgments used by us in applying these most critical accounting policies have a significant impact on the results we report
in our consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Costs of establishing patents consisting of legal fees paid
to third parties and related costs are currently expensed as incurred. We will continue this practice unless we can demonstrate
that such costs add economic value to our business, in which case we will capitalize such costs as part of intangible assets.
The primary consideration in making this determination is whether or not we can demonstrate that such costs have, in fact, increased
the economic value of our intellectual property. The $13,000 value of the patents acquired in connection with the asset acquisition
from PRP is being amortized over the remaining patent lives of approximately 11 years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred. These
costs consist primarily of expenses for personnel engaged in the design and development of product candidates, the scientific
research necessary to produce commercially viable applications of our proprietary drugs, early stage clinical testing of product
candidates, and development equipment and supplies, facilities costs and other related overhead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We account for stock-based payments by recognizing compensation
expense based upon the estimated fair value of the awards on the date of grant. We determine the estimated grant date fair value
of options using the Black-Scholes option pricing model and recognize compensation costs ratably over the vesting period using
the straight-line method. Common stock issued in exchange for services is recorded at fair value of the common stock at the date
which we became obligated to issue the shares. The value of the shares is expensed over the requisite service period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We account for warrants that are liability classified by
recording the fair value of the warrant derivative liability. The fair value of the warrants is calculated using either the Black-Scholes
or Lattice pricing model. We recorded the derivative expense at the inception of each instrument reflecting the difference between
the fair value and the cash received. Changes in the fair value in subsequent periods were recorded to derivative income or expense
for the warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We use the liability method of accounting for income taxes.
Under this method, we recognize deferred assets and liabilities based on the differences between the tax basis of assets and liabilities
and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. We establish
a valuation allowance for all deferred tax assets for which there is uncertainty regarding realization. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company recorded net losses of $9,730,454 and $6,727,457
for the years ended June 30, 2014 and 2013, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Revenues </I> - We are a preclinical stage company
and have not yet generated any revenues. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Expenses </I> &ndash; Operating expenses for the
years ended June 30, 2014 and 2013, were $5,176,033 and $6,106,881, respectively. The Operating expenses represent expenses for
getting the Company fully operational. The main decrease in operating expenses is for payroll expenses for the year ended June
30, 2014 which included $1,081,792 of stock-based compensation expense compared to $3,687,502 for the year ended June 30, 2013. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Interest expense for the years ended June 30, 2014 and 2013,
were $4,230,112 and $568,859, respectively, which is interest on debt issued and the debt discount related to the beneficial conversion
features recorded. The main increase in interest expense is related to the beneficial conversion feature of $2,922,938 that was
recorded and amortized into interest expense during the year ended June 30, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Factors impacting our Results Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have not generated any revenues since our inception in
March 2010. Since inception, we have engaged in organizational activities, conducted private placements which raised additional
capital, began establishing our management team, entered into an Asset Purchase Agreement to acquire all of PRP&rsquo;s operating
and intellectual property assets, and leased our manufacturing and research facility. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As we have now moved into our facility, hired additional
employees, and placed in service the equipment we have acquired from PRP, we expect our general and administrative expenses as
well as our research and development expenses to increase substantially in the next fiscal year. Among other things, we expect
payroll expenses and research and development expenses to increase as we how have several additional staff hired to begin to manufacture
AB101 and conduct research and development on our pipeline product candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Due to the time required to conduct clinical trials and
obtain regulatory approval for any of our product candidates, we anticipate it will be some time before we generate substantial
revenues, if ever. We expect to generate operating losses for the foreseeable future, therefore we are continuing to evaluate
raising additional capital in the near future to maintain the current operating plan. We cannot assure you that we will secure
such financing, that it will be adequate to execute our business strategy or that it will be on acceptable terms. Even if we obtain
this financing, it may be costly and may require us to agree to covenants or other provisions that will favor new investors over
our existing stockholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Cash Used in Operating Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> During the year ended June 30, 2014 our operating activities
used approximately $3.2 million in cash. The use of cash was $6.1 million lower than the net loss due to non-cash charges for
stock-based compensation, derivative expenses, amortization and depreciation as well as other non-cash activities. Net cash used
in operating activities also included a $134,946 decrease in accounts payable and accrued expenses &ndash; related party and cash
provided by a $271,965 increase in accounts payable and accrued expenses and a $353,091 increase in interest payable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> During the year ended June 30, 2013 our operating activities
used approximately $1.6 million in cash. The use of cash was $4.1 million lower than the net loss due to non-cash charges for
stock-based compensation, derivative expenses and amortization. Net cash used in operating activities also included a $206,609
increase in due from related parties and cash provided by a $804,861 increase in accounts payable and accrued expenses &ndash;
related party and a $270,451 increase in interest payable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Net Cash Used in and Provided by Investing Activities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Net cash used in investing activities during the year ended
June 30, 2014 was $830,185. During the year, the Company paid a security deposit of $750,000, purchased fixed assets of $69,974
and had an increase in interest receivable &ndash; related party of $10,211. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Net cash provided by investing activities during the year
ended June 30, 2013 was $185,114. During the year, the Company paid $500,000 for the acquisition of assets, purchased fixed assets
of $11,717, had a decrease in interest receivable &ndash; related party of $28,206, issued notes receivable &ndash; related party
of $305,603 and received payments on note receivable &ndash; related party of $974,228. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Cash from Financing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Net cash provided by financing activities during the year
ended June 30, 2014 was $9,931,549. During the year, the Company issued convertible notes payable of $2,703,000, repaid convertible
notes payable of $67,500 and paid financing fees of $270,300. The Company also received proceeds from equity financings of $8,931,434
and paid out $1,365,085 in issuance costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Net cash provided by financing activities during the year
ended June 30, 2013 was $1,417,500. During the year, the Company issued convertible notes payable of $1,575,000 and paid financing
fees of $157,500. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As of August 30, 2014, we have approximately $4.9 million
in cash on hand and working capital of approximately $4.7 million. Our operating expenses fluctuate between $350 thousand and
$500 thousand a month. In the 2<SUP>nd</SUP> half of calendar year 2015, as we begin our 1<SUP>st</SUP> clinical study, we estimate
that we will need approximately $4 million for the study. We also estimate that we will need at least $3.5 million for the buildout
of our facility and purchase of equipment. As such, we anticipate that we will need to raise an additional $10 million in funds
to continue our plan above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> During the year ended June 30, 2014, we converted $6.3 million
in convertible notes payable and $722 thousand in interest payable into 5,297,964 shares of common stock and issued warrants to
purchase shares of common stock. During the year ended June 30, 2014, we also closed on an equity transaction in which we issued
5,725,327 units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. The
Company received net proceeds of approximately $7.6 million from the equity transaction. While we do have cash on hand, we anticipate
that we will need an additional $10 million to cover operating and capital expenses through the calendar year end 2015. We are
currently evaluating raising additional capital to fund our current and future operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The continuation of our business is dependent upon obtaining
further financing and achieving a break even or profitable level of operations in our business. The issuance of additional equity
securities by us could result in a significant dilution in the equity interests of our current or future stockholders. Obtaining
commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. There are
no assurances that we will be able to obtain additional financing through private placements and/or bank financing or other means
necessary to support our working capital requirements. To the extent that funds generated from operations and any private placements,
public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be
given that additional financing will be available, or if available, will be on terms acceptable to us. These conditions raise
substantial doubt about our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We had no off-balance sheet transactions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Recently Issued Accounting Pronouncements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In June 2014, the FASB issued Accounting Standards Update
(&ldquo;ASU&rdquo;) 2014-10, <I>Development Stage Entities (Topic 915)</I>. The objective of the amendments in this update is
to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements for
development stage entities. The amendments in this update remove all incremental financial reporting requirements from US generally
accepted accounting principles for development stage entities, thereby improving financial reporting by eliminating the cost and
complexity associated with providing that information. The amendments are effective for annual reporting periods beginning after
December 15, 2014, and interim reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company has
elected to early adopt this guidance, and therefore is no longer presenting the financial statements in accordance with ASU 915,
with inception to date disclosures. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="DESCRIPTIONOFBUSINESS"></A> DESCRIPTION OF
BUSINESS </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> ANTRIABIO, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are a preclinical stage company that is developing novel,
sustained release therapeutics based on our proprietary formulation and manufacturing platform. Specifically, we apply our microsphere
technology to well-characterized pharmaceuticals in order to improve significantly the existing standard of care. We believe that
utilizing our platform with known and approved pharmaceutical agents increases the probability of technical success while reducing
safety concerns, approval risks and development costs. We also believe that our approach may result in differentiated, patent-protected
products which provide significant benefits to patients. Our objective is to use our platform to create new drug candidates in
multiple therapeutic areas that address large potential markets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Lead Product Candidate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our lead product candidate, AB101, is human recombinant
insulin that has been formulated with a polymer in biodegradable microspheres for use in patients with type 1 and type 2 diabetes
who require basal insulin replacement therapy for the control of hyperglycemia. We believe that AB101 is a unique and differentiated
product when compared to existing commercially available therapies. We expect AB101 to be administered through a once per week
subcutaneous injection which provides a near peak-less, slow and uniform release of human recombinant insulin. In contrast, the
two currently approved basal insulin products in this $10 billion market are administered by subcutaneous injection either daily
or twice a day and unlike AB101, these products are insulin analogues (synthetic insulin). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Diabetes is a chronic, life-threatening disease that is
characterized by elevated levels of blood sugar (glucose). Glucose is vital to the body as a source of energy for cells that constitute
muscles and other tissues. Insulin is a hormone that is secreted by the pancreas and it regulates blood glucose levels by moving
glucose into cells for utilization. The pancreas produces what is known as basal insulin which is a slow, steady release of insulin
between meals and overnight and in response to food that is consumed, the pancreas also produces bolus (meal-time) insulin. Diabetes
is a condition that results from either the inability of the pancreas to produce insulin or the inability of the body to effectively
use the insulin that is produced. Further, a condition known as pre-diabetes is characterized by blood glucose levels which are
higher than normal, but not high enough to be classified as diabetes. Possible long-term complications of diabetes include heart
disease, stroke, kidney failure, blindness and amputation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> According to the International Diabetes Federation (IDF),
approximately 380 million people in the world are currently living with diabetes and that number is expected to increase to nearly
600 million by 2035. In 2013, diabetes resulted in more than $500 billion in health expenditures globally, or 11% of the total
healthcare related spending on adults. In the United States, the Centers for Disease Control (CDC) estimates that 29 million people
&ndash; or roughly one out of every 11 people &ndash; are currently living with diabetes. The CDC also estimates that in the US
over 85 million people &ndash; more than one out of three adults &ndash; have pre-diabetes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The most prevalent forms of diabetes are referred to as
type 1 and type 2 diabetes. In type 1 diabetes, which accounts for approximately five to 10% of all diagnosed cases of diabetes,
the precise cause is still unknown, although it is hypothesized that the onset of the disease is triggered by a combination of
genetic and environmental factors such as viruses. In most cases of type 1 diabetes, the body&rsquo;s immune system mistakenly
destroys the beta cells in the pancreas that produce insulin. Type 1 diabetes can only be treated with insulin replacement therapy,
delivered via multiple injections or through an insulin pump both for basal and bolus needs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Type 2 diabetes, which accounts for approximately 90% of
all diagnosed cases, occurs when the body becomes resistant to insulin or does not make enough insulin to properly regulate blood
glucose levels. Common risk factors for type 2 diabetes include: obesity, high cholesterol, high blood pressure, advanced age,
physical inactivity, gestational diabetes, race/ethnicity and a family history of diabetes. Management of type 2 diabetes requires
a multifaceted approach, beginning with a healthy dietary and exercise regimen. While some individuals with type 2 diabetes are
able to successfully manage their blood glucose levels through diet and exercise alone, many require oral medications to: decrease
glucose production and glucose levels, stimulate insulin production, increase sensitivity to the effects of insulin, and prevent
the kidneys from reabsorbing glucose. Examples of oral medications include metformin, sulfonylureas, meglitinides, thiazolidinediones,
DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors. When oral medications in concert with lifestyle adjustments are
insufficient to regulate blood glucose levels, insulin replacement therapy is required for individuals with type 2 diabetes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> AB101 Formulation and Preclinical
Results </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our goal was to develop a human recombinant insulin formulation
which could be administered in a single, small volume injection to cover approximately one week of basal insulin requirements.
We believe that the use of a solvent based microsphere technology is ideal to achieve this objective, but insulin is a protein
that is not dissolvable in oil-based solvents which presents a fundamental challenge when trying to develop a robust, predicable
therapeutic. Our scientific team was able to overcome this conundrum by using PEGylation chemistry to attach a low molecular weight
PEG on a specific site (PheB1) at the terminus of the insulin B peptide chain. By applying a PEG to the molecule in this fashion,
insulin becomes amphiphilic and can be uniformly dissolved in in either oil or water based solutions&mdash;including microsphere
formulations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> After the insulin in AB101 is PEGylated it is dissolved
in a solvent along with a polymer (poly-lactic co-glycolic acid, or PLGA). The PLGA is critical for determining the rate at which
the PEGylated insulin is released into the body. The combined ingredients are emulsified (a rinse cycle) to remove the solvent
and then dried to form uniform, monolithic microspheres comprised of insulin and PLGA. Prior to being administered to a patient,
the formulation is reconstituted in an aqueous phase comprised mostly of water. Following injection, the microspheres slowly dissolve
through hydrolysis and release insulin in a controlled, highly predictable fashion over the course of one week. As a result of
this unique formulation and manufacturing process, AB101 does not require any new excipients or alterations to the molecular structure
of insulin and the primary ingredients, PEG and PLGA, have been used in numerous approved pharmaceutical products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have completed most of the critical analytical methods
for AB101 including determining the strength and release profile of the drug as well as other physical and chemical attributes
such as particle size and residual solvents. The company we acquired AB101 from, PRP, conducted in vitro as well as in vivo studies
of AB101 including in various rat models where the following promising observations were made: (1) there was no &ldquo;insulin
burst&rdquo; following injection and in fact less than 1% of the weekly dose of the drug was released after injection followed
by sustained release over the dosing interval; (2) there was not batch variability and there were no site injection site reactions;
(3) there was a repeatable pattern from one injection to the next as the profile of drug release is almost identical; (4) there
was minimal peak-to-trough variation after the second injection which we believe indicates that steady-state basal levels of insulin
are achievable with a single once-a-week injection at a specific dose level for individual patient needs; and (5) there was no
reduction in the integrity or biological activity of insulin; and (6) AB101 properly activates the insulin receptor and signaling
cascade. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> AB101&rsquo;s Market Potential </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe that a once-a-week injection of AB101, if approved,
will result in greater patient compliance and set a new standard in basal insulin therapy. In North America, basal insulin already
commands a 47% share of total insulin usage. In 2013, Sanofi-Aventis sold approximately $8 billion of Lantus, a daily injectable
basal insulin therapy while Novo Nordisk sold approximately $2 billion of Levemir, a twice daily injectable basal insulin. Our
once-a-week injection would provide seven days of basal insulin coverage with the potential to significantly improve the treatment
paradigm. Furthermore, there is an opportunity for AB101 to enter new markets outside of North America where basal insulin has
limited penetration. Basal insulin represents 36% of all insulin use in Europe, 29% of all insulin use in Japan and Korea, 13%
of all insulin use in China, and 26% of all insulin use in rest of world. Further, as a result of AB101&rsquo;s weekly injection
profile, it has the potential to be used in patients with type 2 diabetes who are using oral agents but who require improved glycemic
control through the addition of insulin. According to the CDC, 58% of all individuals with diabetes use oral medications only,
and 16% use no medication at all. As a basal insulin replacement therapy, AB101 supplements the effects of endogenous and exogenous
insulin and complements the effects of orally administered hypoglycemic agents. Endogenous insulin is insulin produced by the
pancreas in the human body. Exogenous insulin is insulin delivered by administration of AB101. It is generally believed that the
reluctance to initiate insulin therapy is a result of resistance to take multiple injections for both regular and current long-acting
insulin as well as the multiple finger sticks needed to monitor blood glucose levels. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> AB101 Development Program </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In first half of calendar 2014 we successfully raised more
than $11M to fund our operations including hiring and retaining qualified staff, leasing a manufacturing and research facility
and engaging third party advisors to assist in the AB101 development efforts. In May 2014 we leased a facility in Louisville,
Colorado which was previously used by a pharmaceutical company, allowing us to take advantage of existing pharmaceutical specific
infrastructure. Nonetheless, we will still have to make leasehold improvements in our laboratory and construct a current good
manufacturing principals (cGMP) aseptic manufacturing suite and we are currently working with advisors on the technical requirements
and design for those improvements which we estimate will cost at least $2.5 million. We have also hired critical staff in the
areas of formulation chemistry, analytical method development, preclinical development, manufacturing and quality assurance and
quality control. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Following the move into our Louisville facility, we placed
into service the manufacturing and analytical equipment which was previously used by our predecessor to produce AB101. We are
currently testing and re-commissioning the equipment including carrying out simulated manufacturing to ensure that the platform
is operational. As part of this process, we have discovered that some of the equipment is missing, broken or was managed by software
which is outdated and unsupported. As a result, we anticipate acquiring or leasing additional equipment which may cost approximately
$1 million. We also acquired bulk AB101 material that was manufactured by our predecessor in accordance with GLP (good laboratory
practices) and we have been evaluating the feasibility of using this GLP material to advance our development program as well as
for a potential clinical study outside the US. We have decided to use the material to further our preclinical activities, but
it will not be used for any human clinical study. We are planning to produce fresh GLP AB101 material this year to support our
IND enabling animal studies and following the completion of our manufacturing suite, we plan on producing cGMP material in 1H
2015 to support our US clinical program. We are also in the process of identifying sources for raw materials including PEG, insulin,
as well as PLGA. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> Additional AB101 Preclinical and
Clinical Plans </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In the fourth quarter of calendar 2014, as a precursor to
our US clinical studies and in order to fulfill FDA requirements for GLP toxicity studies in support of our IND, we plan on conducting
necessary IND-enabling pre-clinical studies, including acute and sub-acute toxicity studies in at least two species (which are
likely to be rodents and dogs), safety pharmacology, and mutagenicity/genotoxicity studies. We are also planning to conduct additional
in vitro and in vivo pharmacology in the animal to demonstrate the promise of once weekly dosing of basal insulin. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In our clinical studies our objective is to demonstrate
that AB101 is safe and effective at the intended once weekly subcutaneous dosing frequency and that it is non-inferior to current
standard of care basal insulin therapies in controlling blood glucose without an undue risk of hypoglycemia. After completion
of additional IND-enabling work, we plan on filing an IND with the FDA in 2015, followed by the initiation of a clinical trial
in the second half of 2015. The objectives of the Phase 1 program will be to assess the single and repeat (once weekly) ascending
dose safety, pharmacokinetics (PK), and pharmacodynamics (PD) in the target population with type 1 and type 2 diabetes, including
confirmation of the time action profile for glucose lowering (Phase 2a data). Following successful completion of the Phase 1/2a
program, Phase 2b trials in both populations will be conducted to obtain proof-of-concept for the intended once weekly dosing
regimen, using the accepted biomarker for glucose efficacy (hemoglobin A1c; HbA1c), compared to a standard of care basal insulin
such as Lantus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If proof-of-concept trials are successful, we intend to
expand our clinical program to include Phase 3 registration trials in various jurisdictions including the US and Europe, to obtain
regulatory and marketing approval. The Phase 3 program would include studies in combination with other injectable and oral glucose
lowering therapies, and would be designed to meet regulatory guidelines for the development of therapies for diabetes, while achieving
an expanded label at the time of product launch. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Our Corporate Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The key elements of our business strategy are described
below: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I> Advance AB101 into clinical studies </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our objective is to create value by advancing our lead drug
candidate, AB101 through various stages of clinical development. To support this strategy, we have begun hiring additional scientific
staff as well as engaging third parties that will assist with our preclinical and clinical efforts including contract research
organizations. Given that AB101 is an insulin product, we believe that there is tremendous value in animal studies which may be
more predictive of the likelihood of human results than with other preclinical therapies and in other therapeutic environments.
We also believe that our first clinical study will be highly informative with respect to the potential for AB101 to be an efficacious
therapeutic. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt"><B><I> Establish a pipeline of drug candidates
which can advance through internal research efforts and advancement of our preclinical drug candidates into clinical trials </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe it is important to maintain a diverse pipeline
of new drug candidates to continue to build on the value of our business and to demonstrate that our technology is a robust platform
which may be applied to other proteins and peptides. Our scientific team plans on applying our technology platform to molecules
across multiple therapeutic areas. A key component of our development strategy is to potentially reduce the risks and time associated
with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic
targets and drugs directed to those targets. We believe that the improved characteristics of our drug candidates will provide
meaningful benefit to patients compared to the existing therapies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; background-color: white"><B><I> Enter into strategic
and high-value partnerships to bring certain of our drug candidates to market </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> We intend to enter into collaborations
with leading pharmaceutical and biotechnology companies to fund further clinical development, manage the global regulatory filing
process, and market and sell drugs in one or more geographies. We intend to decide on a drug candidate-by-drug candidate basis
how far to advance the clinical development of a particular drug candidate before seeking a collaborative relationship. The options
for future collaboration arrangements range from comprehensive licensing and commercialization arrangements to co-promotion and
co-development agreements with the structure of the collaboration depending on factors such as the structure of economic risk
sharing, the cost and complexity of development, marketing and commercialization needs, therapeutic area and geographic capabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; background-color: white"><B><I> Continue to build
a leading intellectual property estate in the field of sustained release therapeutics using microsphere technology </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are committed to continuing to build on our intellectual
property position in the field of specialized microsphere formulation and manufacturing. To that end, we have a comprehensive
patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others,
polymer materials, conjugates, formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"> We were incorporated under the
name &ldquo;Fits My Style Inc.&rdquo; on July 26, 2010, as a corporation organized under the laws of the State of Nevada. From
inception until the consummation of<FONT STYLE="text-underline-style: double"> a series of transactions entered into on January
31, 2013 by and between the Company, Antria Delaware and the Stockholders of Antria Delaware pursuant to which Antria Delaware
became the wholly-owned operating subsidiary of AntriaBio, Inc.</FONT>, the principal business of the Company was consumer retail
technology.&nbsp; During that time, we had no revenue and our operations were limited to capital formation, website development
and refining of our business plan. As a result of the acquisition of Antria Delaware, on January 31, 2013, we ceased the operations
of &ldquo;Fits My Style&rdquo;. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Antria Delaware was formed as a Delaware corporation in
March 2010 under the name &ldquo;AntriaBio, Inc.&rdquo;&nbsp; Effective January 10, 2013, Antria Delaware changed its name from
&ldquo;AntriaBio, Inc.&rdquo; to &ldquo;AntriaBio Delaware, Inc.&rdquo;&nbsp; Antria Delaware was formed with the express purpose
of acquiring the assets of PRP. PRP was a company that developed proprietary technology to be used with active pharmaceutical
ingredients to create sustained release injectable formulations. On January 31, 2013, we closed an asset purchase, as a result,
PRP&rsquo;s lead product candidate, a potential once-a-week basal insulin injection for the diabetes market, became our lead product
candidate (AB101). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Effective January 10, 2013, we effectuated the following
corporate actions: (i) change our state of incorporation from Nevada to Delaware; (ii) change our name from &ldquo;Fits My Style
Inc.&rdquo; to &ldquo;AntriaBio, Inc.&rdquo;; and (iii) effect a 6 for 1 forward stock split of the outstanding shares of our
common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acquisition of Antria Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On January 31, 2013, we entered into and closed the Share
Exchange and Reorganization Agreement to acquire Antria Delaware through: (i) the purchase of all of Antria Delaware's issued
and outstanding shares of its common stock; and (ii) the assumption of any options, warrants or convertible securities of Antria
Delaware.&nbsp; In the acquisition we issued 5,880,667 shares of our common stock representing approximately 88.2% of our Company&rsquo;s
issued and outstanding capital stock to the stockholders of Antria Delaware. Antria Delaware is now our wholly-owned operating
subsidiary and our business is Antria Delaware&rsquo;s business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Competition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We face competition from pharmaceutical and biotechnology companies,
academic institutions, governmental agencies, and private research organizations in recruiting and retaining highly qualified scientific
personnel and consultants and in the development and acquisition of technologies. In particular, if we successfully commercialize
AB101, our product candidate would compete directly against Lantus, Levemir and Novo Nordisk&rsquo;s Tresiba, which is pending
FDA approval. Each of these drugs is backed by a large pharmaceutical company with substantially greater financial, marketing and
development resources than AntriaBio. Further, the pharmaceutical and biotechnology industries are very competitive and are characterized
by rapid and continuous technological innovation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that there are a number of potential drugs in preclinical
studies and clinical trials to treat diabetes that may result in effective, commercially successful treatments, including drugs
that may be in development by Sanofi, Novo Nordisk and other organizations. Each of these therapies and others may compete with
AB101.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As an innovator in the development of extended release drug
therapies, we are executing a patent strategy to protect technologies and inventions that are essential to our business. As part
of this strategy, we will continue to build on our existing patent portfolio by filing patent applications for additional product
candidates, and novel technologies, through ongoing research and development. Our patent strategy also involves relying upon trade
secrets and know-how &ndash; particularly in formulation and manufacturing &ndash; in order to develop and maintain our competitive
position. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our existing patent involves a single-step method for rapidly
and efficiently preparing conjugates of insulin and its analogs with hydrophilic polymers, specifically polyethylene glycol (PEG).
This method includes reacting a protein and a hydrophilic polymer in the presence of at least one organic solvent and at least
one metal chelator, under near-neutral conditions. More specifically, this invention is directed to the site-specific modification
of the proteins with PEG. It also provides a pharmaceutical formulation for the uniform mixture of the protein-PEG conjugate in
a biodegradable polymer. This patent, which expires in April 2024, is issued in Australia, Japan and Europe, and is pending in
the US, Canada, Brazil, India, China and Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As it relates to this invention, our lead product candidate,
AB101, is comprised of a PEG molecule linked to human recombinant insulin specifically at the phenylalanine amino acid at position
B1 (PheB1). A biodegradable microsphere that is a homogenous solid solution of poly (lactide-co-glycolide) and the insulin-PEG
conjugate is formulated. We plan to apply this method of preparing protein-polymer conjugates, and formulating them with PLGA
to future product candidates as well. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As part of our strategy to enhance our patent portfolio,
in July 2014, we filed a patent application around novel methods and systems used to create biodegradable microparticles with
superior syringability, injectability, flowability, uniformity and purity. When issued, this patent will expire in 2034. The methods
claimed in the patent are directed towards the enhancements to the microsphere manufacturing technology platform that is broadly
applicable to current and future products under development. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We plan on filing additional patent applications over the
next several months that are directed towards both technology enhancements and product candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regulation by governmental authorities in the US and other countries
is a significant factor in the development, manufacture and marketing of pharmaceutical products. All of our potential products,
including AB101, will require regulatory approval by governmental agencies prior to commercialization. In particular, pharmaceutical
therapies are subject to rigorous preclinical testing and clinical trials and other pre-market approval requirements by the FDA
and regulatory authorities in foreign countries. Various federal, state and foreign statutes and regulations also govern or influence
the manufacturing, safety, labeling, storage, record keeping and marketing of such products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A number of steps must be taken before a pharmaceutical agent
may be marketed in the US. First, the pharmaceutical agent must undergo preclinical testing including laboratory evaluation of
product chemistry and animal studies to assess the potential safety and activity of the product candidate and its formulations.
The results of these studies must be submitted to the FDA as part of an IND which must be reviewed by the FDA before a proposed
clinical trial can begin. Typically, clinical trials involve a three-phase process. In Phase 1, clinical trials are conducted with
a small number of healthy volunteers to determine the early safety and tolerability profile and the pattern of drug distribution
and metabolism. In Phase 2, clinical trials are conducted with groups of patients afflicted with a specified disease in order to
determine preliminary efficacy, dosing regimens and expanded evidence of safety and tolerability. In Phase 3, large-scale, multi-center,
adequate and well-controlled comparative clinical trials are typically conducted with patients afflicted with a target disease
in order to provide enough data for the statistical proof of efficacy and safety required by the FDA and others. Some variation
in these typical steps may be expected depending on the therapeutic disease area under investigation. For example, Phase 1 clinical
trials in the area of diabetes may include patients with the target diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results of the preclinical testing and clinical trials for
a pharmaceutical product are then submitted to the FDA in the form of an NDA for approval to commence commercial sales. Once a
drug is approved for marketing in the US, the FDA requires ongoing safety monitoring to ascertain any undiscovered issues since
the expanded patient exposure once a drug is introduced to the marketplace can reveal new risks (as well as new benefits) that
were not detectable during clinical testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Among the conditions for NDA approval is the requirement
that the prospective manufacturer&rsquo;s quality control and manufacturing procedures conform to current good manufacturing principles.
In complying with cGMP, manufacturers must continue to expend time, money and effort in the area of production, quality control,
and quality assurance to ensure full technical compliance. Manufacturing facilities are subject to periodic inspections by the
FDA to ensure compliance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also subject to various federal, state, and local laws,
regulations and recommendations relating to safe working conditions; laboratory and manufacturing practices; the experimental use
of animals; and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious
disease agents, used in connection with our research, development and manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The activities required before a pharmaceutical agent may be
marketed in the European Union are dictated by the International Conference on Harmonization and are generally similar to those
established in the US. Approval of new drugs across the European Union relies on either the centralized authorization procedure
of the European Medicines Agency or national authorization procedures that allow simultaneous approval in several countries via
mutual recognition or decentralization. Under the centralized procedure, the marketing application is referred for review to two
review teams, each representing one of the member countries. Each reviewer then forwards an early assessment to the Committee for
Medicinal Products for Human Use, or CHMP, for discussion and preparation of an initial consolidated assessment report, including
a list of questions requesting clarification as well as additional information. This step initiates a series of dialogues, meetings
and other communications among the CHMP, the two review teams and the applicant, leading in turn to clarification, education and
refinement of the original assessment reports. Ultimately, a decision is reached to either grant marketing authorization or deny
the application if it is determined that the application does not satisfy the regulatory approval criteria. The clinical testing,
manufacture and sale of pharmaceutical products outside of the US and the European Union are subject to regulatory approvals by
other jurisdictions which may be more or less rigorous than those required by the US or the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We did not incur any significant research and development
expenses for the period from July 1, 2013 to June 30, 2014 as most operations were start-up operations and getting the assets
we acquired operational. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Legal </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are not aware of any legal proceedings relating to securities
or other proceedings that could have an adverse impact on the Company in which any director, officer, or any owner of record or
beneficial owner of more than five percent of any class of voting securities of the Company, or any associate of any such director,
officer, affiliate of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material
interest adverse to the Company or any of its subsidiaries. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Employees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As of June 30, 2014, we had five full-time employees as
well as two contract employees, all of whom have experience with pharmaceutical, biotechnology or medical product companies. None
of our employees or contractors are covered by collective bargaining agreements. Since June 30, 2014, we have hired an additional
six full-time employees. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Properties </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our corporate headquarters are located at 890 Santa Cruz
Avenue, Menlo Park, California. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On May 5, 2014, we entered into a lease agreement with SF
Infinite Drive, LLC for a lease of 27,000 square feet of office, lab and clean room space in Louisville, Colorado. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="CHANGESANDDISAGREEMENTS"></A>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Berman &amp; Company</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective on or about February 15, 2013, we terminated the services
of our principal independent auditor, Berman &amp; Company (&ldquo;<B>Berman</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Berman&rsquo;s reports on our financial statements for each
of the past two years, no adverse opinion was issued and no opinion of Berman was modified as to audit scope or accounting principles.
Our principal accountant report on our financial statements for the years-ended June 30, 2012 and 2011, as reported in the our
Form 10-K filed with the SEC on September 22, 2011, and Form 10-K/A filed with the SEC on November 9, 2012, contained a disclaimer
paragraph concerning uncertainty as to our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements did not include any adjustments that
might have resulted from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Spectra Financial Services, LLC</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, effective on February 15, 2013, we terminated the
services of Antria Delaware&rsquo;s independent auditor, Spectra Financial Services, LLC (&ldquo;<B>Spectra</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Spectra&rsquo;s principal accountant reports on Antria Delaware&rsquo;s
financial statements for its fiscal years ended December 31, 2011 and 2010, no adverse opinion was issued and no opinion of Spectra
was modified as to audit scope or accounting principles. Spectra&rsquo;s report on Antria Delaware&rsquo;s financial statements
for the years ended December 31, 2011 and 2010, contained a disclaimer paragraph concerning uncertainty as to Antria Delaware&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each change in auditor was recommended, approved and ratified
by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="DIRECTORSEXECUTIVEOFFICERSANDCORPORATEGOVERNANCE"></A>DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table sets forth certain information with
respect to our current directors, executive officers and key employees. The term for each director expires at our next annual
meeting or until his or her successor is appointed. The ages of the directors, executive officer and key employees are shown as
of October 23, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Name </B></FONT></TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 54%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Position </B></FONT></TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Age </B></FONT></TD>
    <TD STYLE="width: 2%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> Nevan C. Elam </FONT></TD>
    <TD> &nbsp; </TD>
    <TD><FONT STYLE="font-size: 10pt"> Chief Executive Officer and Chairman of the Board </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"> 46 </FONT></TD>
    <TD> (1) </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> Sankaram Mantripragada, Ph.D. </FONT></TD>
    <TD> &nbsp; </TD>
    <TD><FONT STYLE="font-size: 10pt"> Chief Scientific Officer </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"> 55 </FONT></TD>
    <TD> (2) </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> Hoyoung Huh, Ph.D. </FONT></TD>
    <TD> &nbsp; </TD>
    <TD><FONT STYLE="font-size: 10pt"> Director </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"> 45 </FONT></TD>
    <TD> (3) </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"> Barry Sherman, M.D </FONT></TD>
    <TD> &nbsp; </TD>
    <TD><FONT STYLE="font-size: 10pt"> Director </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"> 73 </FONT></TD>
    <TD> (4) </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> Morgan Fields </FONT></TD>
    <TD> &nbsp; </TD>
    <TD><FONT STYLE="font-size: 10pt"> Chief Accounting Officer </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"> 34 </FONT></TD>
    <TD> (5) </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (1) </TD><TD STYLE="text-align: justify"> Effective January 31, 2013, Nevan C. Elam was appointed
as Chief Executive Officer and as a member of the Board for AntriaBio. Effective December 31, 2013, Nevan Elam was appointed as
Chairman of the Board. </TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (2) </TD><TD STYLE="text-align: justify"> Effective January 31, 2013, Sankaram Mantripragada
was appointed as Chief Scientific Officer for AntriaBio. </TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (3) </TD><TD STYLE="text-align: justify"> Effective January 31, 2013, Hoyoung Huh was appointed
as a member of the Board of AntriaBio. </TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (4) </TD><TD STYLE="text-align: justify"> Effective July 18, 2014, Barry Sherman, M.D. was appointed
as a member of the Board of AntriaBio. </TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (5) </TD><TD STYLE="text-align: justify"> Effective July 18, 2014, Morgan Fields was appointed
as Chief Accounting Officer for AntriaBio. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set forth below is biographical information with respect to
each of the aforementioned individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Nevan C. Elam. </B> Mr. Elam serves as our President
and Chief Executive Officer and as the Chairman of our Board. Mr. Elam also currently serves as a Managing Director of Konus Advisory
Group, Inc. Prior to his service with Antria and Konus Advisory Group, Inc., Mr. Elam served as Chief Executive Officer and President
of AeroSurgical Ltd., a medical device company operating out of Ireland. Prior to his service with AeroSurgical Ltd., Mr. Elam
was Head of the Pulmonary Business Unit and Senior Vice President of Nektar Therapeutics from April, 2007 through December 2008
and served as Nektar's Senior Vice President of Corporate Operations and General Counsel from January 2005 through April 2007.
From March 2004 through December 2004, Mr. Elam served as an Advisor to E2open, Inc. From February 2002 through March 2004, Mr.
Elam served as Chief Financial Officer of E2open and from October 2000 to February 2002, he served as Vice President of Business
and Corporate Development of E2open. Prior to E2open, Mr. Elam was a Partner in the corporate practice of the law firm of Wilson
Sonsini Goodrich &amp; Rosati, where he served for eight years. He serves as Director of Savara, Inc., AeroSurgical Ltd. and Aerogen
Ltd. Mr. Elam received his Juris Doctorate from Harvard Law School and a Bachelors of Arts from Howard University. We believe
that Mr. Elam&rsquo;s experience advising pharmaceutical companies of their unique legal and regulatory obligations qualifies
him to serve on the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Sankaram Mantripragada, Ph.D</B>. Dr. Mantripragada
serves as our Chief Scientific Officer. Prior to his service with our Company, Dr. Mantripragada served as the Chief Scientific
Officer of Antria Delaware. Prior to his service with Antria Delaware, Dr. Mantripragada served as VP of Research and Development
of PR Pharmaceuticals from June 2005 until October 2009. From October 2004 until June 2005, Dr. Mantripragada was an advisor to
companies specializing in diabetes, cell-based therapies and cardiovascular diseases. Dr. Mantripragada served as Director, Research
and Development of Guidant Corporation, now part of Abbott Vascular, from September 2003 until October 2004. Prior to that, he
served as Director, Research and Development and Vice President, Scientific Development of SkyePharma from September 1992 until
September 2003. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia, School of Medicine
from January 1989 until September 1994. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute
of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Hoyoung Huh, M.D., Ph.D. </B> Dr. Huh serves as
a member of the Board. Dr. Huh is currently a Managing Director of Konus Advisory Group, Inc. since founding it in January 2012
with Mr. Elam. Prior to founding Konus Advisory Group, Inc., Dr. Huh was Chief Executive Officer of BiPar Sciences, Inc. from </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> February 2008 until December 2010. In addition, Dr. Huh
has been involved in the formation, management and board positions of multiple biotechnology and innovation-based companies. Dr.
Huh currently serves as the Chairman of the Board of Geron Corporation and CytomX Therapeutics as well as on the board of directors
for Addex Therapeutics, ReSurge International and SF Jazz. Dr. Huh holds an M.D. from Cornell University Medical College, a Ph.D.
in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a Bachelor&rsquo;s degree in biochemistry
from Dartmouth College. We believe that Dr. Huh&rsquo;s medical experience and his experience working with pharmaceutical companies
qualifies him to serve on the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Barry Sherman, M.D. </B> Dr. Sherman serves as
a member of the Board. Dr. Sherman was most recently President and CEO of StemPar Sciences, a newly formed company in the emerging
field of cancer metabolism. He has more than 30 years of experience in academic and pharmaceutical biomedical research. Dr. Sherman
was Genentech's first Senior Vice President and Chief Medical Officer, served as President and CEO of Anergen Inc., and was a
founder of Pain Therapeutics and BiPar Sciences. Prior to joining Genentech in 1985, Dr. Sherman was Professor of Medicine and
Endocrinology at the University of Iowa-College of Medicine, where he served as Associate Chairman of the Department of Internal
Medicine and Director of the National Institutes of Health-Sponsored Clinical Research Center. Dr. Sherman is a graduate of the
University of Michigan where he received both his A.B. and M.D. degrees with honors. We believe that Dr. Sherman&rsquo;s medical
experience and his experience working with pharmaceutical companies qualifies him to serve on the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Morgan Fields. </B> Ms. Fields serves as our Chief
Accounting Officer. Ms. Fields, has served as the Controller of Antria Delaware since October 2012. &nbsp; Prior to joining AntriaBio,
Ms. Fields was an Assurance Director with McGladrey LLP and had been with McGladrey LLP since 2003. Ms. Fields is a Certified
Public Accountant and received her Bachelor's degree in accounting as well as her Masters in Accounting from the University of
Northern Iowa. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no family relationships between any of our directors
or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not aware of any material legal
proceedings to which any of our executive officers or any associate of any of our executive officers is a party adverse to us or
any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Other than Mr. Howe, who resigned as
a member of the board on July 18, 2014, we are not aware of any of our executive officers being involved in any legal proceedings
in the past ten years relating to any matters in bankruptcy, insolvency, criminal proceedings (other than traffic and other minor
offenses) or being subject to any of the items set forth under Item 401(f) of Regulation S-K. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2008, PR Pharmaceuticals
Inc. filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code. Mr. Howe served as
the Chief Executive Officer of PR Pharmaceuticals Inc. during the time the bankruptcy petition was filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have adopted a code of business conduct and ethics that is
applicable to all of our employees, officers and directors. The code is available on our web site, <I>www.antriabio.com</I>, under
the &ldquo;Investor Relations&rdquo; tab. We intend to disclose future amendments to, or waivers from, certain provisions of our
code of ethics, if any, on the above website within four business days following the date of such amendment or waiver.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B> Audit Committee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><FONT STYLE="text-underline-style: double; color: Black"> We
do not have a separately designated standing audit committee. Our entire Board acts as our audit committee. We do not have a financial
expert on our Board, however we will consider adding a financial expert as we continue to grow and increase our Board. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B> &nbsp; </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B> Committees of the Board of Directors
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have no standing audit, compensation,
corporate governance or nominating committee due to our small size. Our Board is responsible for developing our approach to corporate
governance issues. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company has established a Scientific Advisory Board
(SAB). Dr. Huh will serve as the Chairman of the SAB. The other members of the board are Fredrick B. Kraemer, M.D., Philip Home,
M.A., D.Phil,., D.M., F.R.C.P., Jerrold Olefsky, M.D., Andrew R. Hoffman, M.D., and C. Ronald Kahn, M.D. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Non-Employee Director Compensation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In consideration for their Antria board of director&rsquo;s
service, Antria compensates its directors in the form of options for each year for their continued service. Antria also reimburses
its directors for reasonable out of pocket expenses incurred in attending Antria&rsquo;s board meetings and in carrying out their
board duties. During the fiscal year ended June 30, 2014, Mr. Howe was granted an option to purchase up to 125,000 shares of common
stock under the 2014 Stock and Incentive Plan. Dr. Huh was granted an option to purchase up to 350,000 shares of common stock
under the 2014 Stock and Incentive Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On July 1, 2012, AntriaBio entered into a consulting agreement
with Dr. Huh whereby Dr. Huh agreed to provide AntriaBio services including, but not limited to, serving on the Board as lead
independent director, assisting AntriaBio in efforts to obtain funding and assisting in business development activities. On March
26, 2013, Dr. Huh and the Company entered into a termination agreement, whereby Dr. Huh and the Company agreed to terminate the
consulting agreement in accordance with the termination agreement. Fees related to this consulting agreement were $54,000 for
the period from July 1, 2013 through June 30, 2014 for the services performed, including serving as a director on the board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="EXECUTIVECOMPENSATION"></A>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Summary Compensation Table </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table shows the particulars of compensation
paid to our current and former executive officers during the years ended June 30, 2014 and 2013. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Name and Principal Position (a) </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Year </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(b)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Salary ($) </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(c)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Bonus ($) </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(d)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Stock Award
    ($) </FONT> <BR><FONT STYLE="font-size: 7pt"> (e)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Option Award
    ($) </FONT> <BR><FONT STYLE="font-size: 7pt"> (f)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Non-Equity </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Incentive Plan</FONT><BR>
    <FONT STYLE="font-size: 7pt">Compensation ($) </FONT><BR><FONT STYLE="font-size: 7pt"> (g)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Change in </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Pension Value</FONT><BR>
    <FONT STYLE="font-size: 7pt">and</FONT><BR>
    <FONT STYLE="font-size: 7pt">Nonqualified</FONT><BR>
    <FONT STYLE="font-size: 7pt">Deferred</FONT><BR>
    <FONT STYLE="font-size: 7pt">Compensation</FONT><BR>
    <FONT STYLE="font-size: 7pt">Earnings ($) </FONT><BR><FONT STYLE="font-size: 7pt"> (h)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> All Other </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Compensation</FONT><BR>
    <FONT STYLE="font-size: 7pt">($) </FONT><BR><FONT STYLE="font-size: 7pt"> (i)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Total ($) </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(j)</FONT> </TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left"><FONT STYLE="font-size: 7pt"> Current Named
    Executive Officers </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 19%"><FONT STYLE="font-size: 7pt"> Nevan Elam (1) </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> 310,252 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> 50,983 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> 557,763 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 7pt"> 918,998 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 7pt"> Chief Executive Officer </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 230,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 1,181,939 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 1,411,939 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Sankaram Mantripragada (2) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 295,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 70,175 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 177,293 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 542,468 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 7pt"> Chief Scientific Officer </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 285,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 337,697 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 622,697 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left"><FONT STYLE="font-size: 7pt"> Former Named
    Executive Officers </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Steve Howe (3) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 125,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 65,625 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 197,676 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 3,283 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 391,584 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 7pt"> Executive Chairman </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 250,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 675,394 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 6,152 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 931,546 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Nickolay Kukekov (4) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 7pt"> Chief Executive Officer<BR>
</FONT> <FONT STYLE="font-size: 7pt">to
    January 31, 2013</FONT> </TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic"></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Nir Bar (5) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 7pt"> President and Treasurer<BR>
</FONT> <FONT STYLE="font-size: 7pt"> to September 15, 2012 </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic"></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Guy Turnowski (5) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; padding-left: 0.125in"><FONT STYLE="font-size: 7pt"> Secretary </FONT> <FONT STYLE="font-size: 7pt"><BR>
to September 15, 2012 </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> (1)&nbsp;&nbsp;&nbsp;&nbsp;Mr.
        Elam was appointed the Chief Executive Officer of Antria Delaware on June 1, 2012 and was appointed the Chief Executive
        Officer of AntriaBio on January 31, 2013. Mr. Elam received a base salary of $230,000 beginning in June 2012 which increased
        to $390,000 on March 26, 2014. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> (2)&nbsp;&nbsp;&nbsp;&nbsp;Dr.
        Mantripragada was appointed the Chief Scientific Officer of Antria Delaware on April 1, 2012 and was appointed the Chief
        Scientific Officer of AntriaBio on January 31, 2013. Dr. Mantripragada is to receive a base salary of $275,000 beginning
        in April 2012 which increased to $295,000 on January 1, 2013. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> (3)&nbsp;&nbsp;&nbsp;&nbsp;Mr.
        Howe was appointed the Executive Chairman of Antria Delaware on April 1, 2012 and was appointed the Executive Chairman
        of AntriaBio on January 31, 2013 and resigned as Executive Chairman on December 18, 2013 and resigned as director on July
        18, 2014. Mr. Howe received a base salary of $250,000 beginning in April 2012, which ended upon his resignation. Also
        included is the cost of a corporate country club membership of which Mr. Howe had exclusive use during the time. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> (4)&nbsp;&nbsp;&nbsp;&nbsp;Dr.
        Kukekov was appointed to these positions on September 4, 2012 and resigned on January 31, 2013. Dr. Kukekov did not receive
        any compensation for his service as our Chief Executive Officer and Director. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> (5)&nbsp;&nbsp;&nbsp;&nbsp;Mr.
        Bar and Mr. Turnowski were appointed to these positions on July 26, 2010 and resigned on September 15, 2012. For the years
        ended June 30, 2014 and 2013 no compensation was paid to either individual. </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table provides a summary of equity awards
outstanding for each of the Named Executive Officers and Directors as of June 30, 2014: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"> Name (a) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Number of<BR>
    Securities<BR>
    Underlying<BR>
    Unexercised<BR>
    Options <BR>
Exerciable (#) <BR> (b) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Number of<BR>
    Securities<BR>
    Underlying<BR>
    Unexercised<BR>
    Options<BR>
    Unexercisable<BR>
 (#) <BR> (c) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Equity Incentive<BR>
    Awards:<BR>
    Number of<BR>
    Securities<BR>
    Underlying<BR>
    Unexercised<BR>
    Unearned<BR>
    Options (#) (d) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Option<BR>
    Exercise<BR>
    Price ($) <BR> (e) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Option<BR>
    Expiration<BR>
    Date <BR> (f) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"> Steve R. Howe (1) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 78,704 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 87,963 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 4.50 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 12%; text-align: center"> 1/30/2018 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 7,813 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> - </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 117,118 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> $ </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> 3.12 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> 3/26/2021 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 86,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 205,081 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Nevan C. Elam </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 429,398 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 153,936 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4.50 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 1/30/2018 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 84,375 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,265,625 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> $ </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> 3.12 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> 3/26/2021 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 513,773 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,419,561 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Sankaram Mantripragada, Ph.D. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,686 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 43,981 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4.50 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 1/30/2018 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 31,250 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 468,750 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> $ </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> 3.12 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> 3/26/2021 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 153,936 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 512,731 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Hoyoung Huh, Ph.D </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 416,667 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4.50 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 1/30/2018 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 105,209 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 328,128 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> $ </TD><TD STYLE="padding-bottom: 1pt; text-align: right"> 3.12 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> 3/26/2021 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 521,876 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 328,128 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.
Howe was originally granted 333,334 options, however, pursuant to a domestic relations order, on April 17, 2013, Mr. Howe transferred
166,667 vested shares to Mrs. Howe. On July 18, 2014, Mr. Howe resigned as a member of the board at which time options to purchase
93,751 shares had vested. The 197,916 options, which were unearned as of July 18, 2014, were forfeited. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table shows the particulars of compensation
paid to our current and former directors during the years ended June 30, 2014 and 2013. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 7pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Name and Principal Position (a) </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Year </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(b)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Fees earned </FONT> <BR>
    <FONT STYLE="font-size: 7pt">or paid</FONT><BR><FONT STYLE="font-size: 7pt"> in Cash ($)</FONT><BR><FONT STYLE="font-size: 7pt">
    (c)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Stock </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Award ($) </FONT><BR><FONT STYLE="font-size: 7pt"> (d)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Option Award ($)
    </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(e)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Non-Equity </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Incentive Plan</FONT><BR><FONT STYLE="font-size: 7pt"> Compensation ($) </FONT><BR><FONT STYLE="font-size: 7pt">
    (f)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Nonqualified </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Deferred</FONT><BR>
    <FONT STYLE="font-size: 7pt">Compensation</FONT><BR><FONT STYLE="font-size: 7pt"> Earnings ($) </FONT><BR><FONT STYLE="font-size: 7pt">
    (g)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> All Other </FONT> <BR>
    <FONT STYLE="font-size: 7pt">Compensation</FONT><BR>
    <FONT STYLE="font-size: 7pt">($) </FONT><BR><FONT STYLE="font-size: 7pt"> (h)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt"> Total ($) </FONT> <BR>
    <FONT STYLE="font-size: 7pt">(i)</FONT> </TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left"><FONT STYLE="font-size: 7pt"> Current Named
    Directors </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Nevan Elam (1) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 20%"><FONT STYLE="font-size: 7pt"> Hoyoung Huh (2) </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> 54,000 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> 54,919 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 7pt"> 108,919 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 108,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 1,482,572 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 1,590,572 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left"><FONT STYLE="font-size: 7pt"><U> Former Named
    Directors </U></FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Steve Howe (3) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 17,260 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 17,260 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Nickolay Kukekov (4) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Nir Bar (5) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> Guy Turnowski (5) </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2014 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> 2013 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> &nbsp; </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (1) </TD><TD> The only compensation received by this individual was
                                         for serving as an officer of the company and included in the executive compensation. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (2)&nbsp;&nbsp;&nbsp;&nbsp;On
July 1, 2012, AntriaBio entered into a consulting agreement with Dr. Huh whereby Dr. Huh agreed to provide AntriaBio services
including, but not limited to, serving on AntriaBio&rsquo;s board of directors as lead independent director, assisting AntriaBio
in efforts to obtain funding and assisting in business development activities. He also received options to purchase 416,667 shares
on January 30, 2013 and 350,000 shares on March 28, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> On March 26, 2014, Dr. Huh entered into a termination
agreement (the &ldquo;Huh Termination Agreement&rdquo;). Pursuant to the terms of the Huh Termination Agreement, Dr. Huh and the
Company agreed to terminate the Consulting Agreement in accordance with the Huh Termination Agreement. The Huh Termination Agreement
provides for the following: (i) the termination of the consulting agreement; (ii) the waiver of any notice provisions set forth
in the Consulting Agreement; (iii) the release of any obligations owed to or from either Dr. Huh or the Company under the Consulting
Agreement; and (iv) the waiver of any amounts due and owing to Dr. Huh under the Consulting Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (3)&nbsp;&nbsp;&nbsp;&nbsp;On
December 18, 2013, Mr. Howe resigned as the Executive Chairman and remained on as a director of the Board. On March 28, 2014,
he received options to purchase 125,000 shares of common stock. On July 18, 2014, Mr. Howe resigned from the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (4)&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Kukekov was appointed to this position on September 4, 2012. Dr. Kukekov did not receive any compensation for his service as a
Director. Effective September 25, 2013, Dr. Kukekov resigned from the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> (5)&nbsp;&nbsp;&nbsp;&nbsp;Mr.
Bar and Mr. Turnowski were appointed to these positions on July 26, 2010 and resigned on September 15, 2012. For the years ended
June 30, 2014 and 2013 no compensation was paid to either individual. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Nevan Elam</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On June 18, 2012, Antria Delaware entered into an agreement
with Nevan Elam to serve as Chief Executive Officer of Antria Delaware. Under the terms of this agreement, Mr. Elam will be entitled
to receive an annual base of two hundred thirty thousand dollars ($230,000) until the executive commits full time to the business
at which time his salary will increase to three hundred fifty thousand dollars ($350,000). At any time following the date of Mr.
Elam&rsquo;s employment agreement, the Antria Delaware board of directors may request in writing that Mr. Elam commit one hundred
percent (100%) of his time and energy to the business of Antria Delaware and Mr. Elam shall have 60 days to comply with the Antria
Delaware board of directors&rsquo; request or shall tender his resignation as an officer of Antria Delaware. Mr. Elam is entitled
to an annual bonus equal to forty percent (40%) of his base salary based on criteria set by the Antria Delaware board of directors.
Mr. Elam is also eligible for a one-time bonus when the Company raises an aggregate of $5 million dollars in financing. Mr. Elam
is also eligible to receive grants of options to purchase shares of common stock as consideration for services rendered. Mr. Elam
will be eligible to participate in all benefit programs available to our executives and employees, including any employee incentive
option plan, and medical and dental benefit plans. Antria Delaware will also provide life and disability insurance. Also under
the terms of the agreement, Mr. Elam will be entitled to reimbursement for reasonable travel and business expenses and receives
a monthly automobile allowance. Additionally, at age 65, Mr. Elam is entitled to a pension benefit equal to one-month's salary
for each year of employment. The agreement requires Mr. Elam to undertake certain confidentiality, non-competition and non-solicitation
obligations. In the event that Antria Delaware terminates Mr. Elam&rsquo;s employment without cause, Antria Delaware will pay
the base salary severance on a monthly basis to Mr. Elam for a period of six months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On March 26, 2014, we entered into an amended and restated
employment agreement with Mr. Elam, amending his employment agreement. The amended employment agreement provides, among other
things, for: (i) an increase in Mr. Elam&rsquo;s base salary from $230,000 to $390,000; (ii) a termination of the bonus due to
Mr. Elam under the Employment Agreement upon the Company raising at least $5,000,000 in an equity financing; (iii) a termination
of the car allowance granted to Mr. Elam under the Employment Agreement; and (iv) the termination of the pension benefit at the
age of 65 equal to one-month salary for each year of employment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Sankaram Mantripragada</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 1, 2012, Antria Delaware entered into an agreement
with Sankaram Mantripragada to serve as Chief Scientific Officer of Antria Delaware. Dr. Mantripragada will report to the Chief
Executive Officer and under the terms of the employment agreement, Dr. Mantripragada is entitled to receive an annual base salary
of two hundred seventy five thousand ($275,000) which increased to two hundred ninety five thousand ($295,000) on January 1, 2013
that is subject to annual adjustment recommended by the Chief Executive Officer and approved by the Compensation Committee of the
Antria Delaware board of directors. Dr. Mantripragada is eligible for one-time bonuses when certain clinical testing has begun.
Dr. Mantripragada also is entitled to receive an annual cash bonus of up to forty percent (40%) of his base salary, determined
based on specified criteria agreed upon in advance. Dr. Mantripragada is eligible to receive grants of options to purchase shares
of our common stock as consideration for services rendered, at the discretion of our Antria Delaware board of directors. Dr. Mantripragada
is eligible to participate in all benefit programs available to our executives and employees, including medical and dental benefit
plans. Also under the terms of the agreement, Dr. Mantripragada is entitled to reimbursement for reasonable travel and business
expenses and receives a monthly automobile allowance. Additionally, at the age of 65, Dr. Mantripragada is entitled to a pension
benefit equal to one month&rsquo;s salary for each year of his employment. If he is terminated other than for cause or due to or
after a change of control, all of Dr. Mantripragada&rsquo; unvested options will accelerate, and he will continue to receive his
then base salary and health insurance for a period of up to twelve months. The agreement also requires Dr. Mantripragada to undertake
certain confidentiality, non-competition and non-solicitation obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On March 26, 2014, we entered into an amended and restated
employment agreement with Dr. Mantripragada, amending the employment agreement. The amended employment agreement amends the employment
agreement to remove the pension benefit owned to Dr. Mantripragada such that Dr. Mantripragada is no longer entitled to a pension
benefit at the age of 65 equal to one-month&rsquo;s salary for each year of employment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U> Steve Howe </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On April 1, 2012, Antria Delaware entered into an agreement
with Steve Howe to serve as Executive Chairman of Antria Delaware. Under the terms of this agreement, Mr. Howe will be entitled
to receive an annual base of two hundred fifty thousand dollars ($250,000) which is to be raised to three hundred twenty five
thousand dollars ($325,000) when the Company raises an aggregate of five million dollars ($5,000,000) in financing. In addition,
Mr. Howe is entitled to an annual bonus equal to thirty percent (30%) of his base salary based on criteria set by the Antria Delaware
board of directors. Mr. Howe is eligible to receive grants of options to purchase shares of common stock as consideration for
services rendered. Mr. Howe will be eligible to participate in all benefit programs available to our executives and employees,
including any employee incentive option plan, and medical and dental benefit plans. Antria Delaware will also provide life and
disability insurance. Also under the terms of the agreement, Mr. Howe will be entitled to reimbursement for reasonable travel
and business expenses and receives a monthly automobile allowance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On December 13, 2013, Mr. Howe resigned as our Executive
Chairman. Pursuant to his resignation, on March 26, 2014, Mr. Howe and the Company entered into a termination agreement to terminate
Mr. Howe&rsquo;s employment agreement. The termination agreement provides for, among other things: (i) the termination of the
Howe Employment Agreement; (ii) the waiver of any notice provisions set forth in the Howe Employment Agreement; (iii) the release
of any obligations owed to or from either Mr. Howe or the Company under the Howe Employment Agreement; and (iv) the waiver of
any amounts due and owing to Mr. Howe under the Howe Employment Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U> Morgan Fields </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On January 27, 2014, the Company entered into an agreement
with Morgan Fields to serve as the Controller of the Company. Under the terms of the agreement Ms. Fields will be entitled to
receive an annual base of $100,000 an annual bonus of up to 15% of her base salary based on criteria set by the Company. Ms. Fields
is eligible to participate in all benefit programs available to our executives and employees, including medical and dental benefit
plans. The agreement also requires Ms. Fields to undertake certain confidentiality obligations. On July 18, 2014, the board of
directors approved the appointment of Ms. Fields to Chief Accounting Officer. The board approved the change in the annual salary
to $130,000 and the issuance of additional stock options for 25,000 shares of common stock. All other terms of the original employment
agreement remain. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Committee Interlocks and Insider Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We do not have a standing compensation committee or a committee
performing similar functions. Because we assumed the employment agreements of Antria Delaware in connection with the Reverse Merger,
the Board did not have any deliberations concerning the compensation of our executive officers. All amendments to compensation
agreements were approved by the board. With respect to the amendments to Messrs. Elam and Mantripragada&rsquo;s employment agreements,
Dr. Huh and Mr. Howe participated in the deliberation of such amendments. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="CERTAINRELATIONSHIPS"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
AND DIRECTOR INDEPENDENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Relationships and Related Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company entered into an agreement to acquire 100% of
the outstanding stock of Antria Delaware. The Company has issued 5,880,667 shares of common stock in connection with the Reverse
Merger and assumed the options, warrants and convertible securities of Antria Delaware. In connection with the Reverse Merger,
no shares of common stock were issued to Steve Howe, a director of the Company, 666,667 shares of common stock were issued to
Hoyoung Huh and Nevan Elam, directors of the Company, through their control of Konus, 398,667 shares of common stock were issued
to Nickolay Kukekov, a director of the Company, and 1,000,000 shares of common stock were issued to Sankaram Mantripragada, an
officer of the Company. In connection with our assumption of the options, warrants and convertible securities of Antria Delaware,
Messrs. Howe and Elam and Drs. Mantripragada and Huh have the right to purchase shares of common stock pursuant to the terms of
the options between Antria Delaware and the aforementioned officers and directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of our acquisition of Antria Delaware, we assumed all
of the employment agreements between our current executive officers and Antria Delaware. The terms of the employment agreements
are set forth above and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Antria&rsquo;s Relationship with Konus Advisory Group, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Advisory Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 2, 2012, Antria Delaware and Konus Advisory Group, Inc.
(&ldquo;<B>Konus</B>&rdquo;) entered into an advisory agreement (the &ldquo;<B>Advisory Agreement</B>&rdquo;) whereby Konus agreed
to provide Antria Delaware services including, but not limited to, finance and strategy, clinical design, project management and
portfolio assessment. Antria Delaware agreed to pay Konus a monthly retainer in the amount of $9,000 per month to cover general
and administrative matters plus an hour fee ranging from $100 to $700 per hour for additional services provided to Antria Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Consulting Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the Advisory Agreement, on July 1, 2012, Antria
Delaware entered into a consulting agreement (the &ldquo;<B>Consulting Agreement</B>&rdquo;) with Dr. Huh whereby Dr. Huh agreed
to provide Antria Delaware services including, but not limited to, serving on Antria Delaware&rsquo;s board of directors as lead
independent director, assisting Antria Delaware in efforts to obtain funding and assisting in business development activities.
Dr. Huh is a significant shareholder, managing director and member of the board of directors of Konus. Pursuant to a mutual understanding
between Dr. Huh, Konus and AntriaBio, the amounts owed to Dr. Huh pursuant to the terms of the Consulting Agreement will be paid
directly to Konus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 26, 2014, Dr. Huh and the Company entered into the
Huh Termination Agreement. Pursuant to the terms of the Huh Termination Agreement, Dr. Huh and the Company agreed to terminate
the Consulting Agreement in accordance with the termination agreement. The termination agreement provides for the following: (i)
the termination of the Consulting Agreement; (ii) the waiver of any notice provisions set forth in the Consulting Agreement; (iii)
the release of any obligations owed to or from either Dr. Huh or the Company under the Consulting Agreement; and (iv) the waiver
of any amounts due and owing to Dr. Huh under the Consulting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CEO Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On June 18, 2012, Antria Delaware entered into an agreement
with Nevan Elam to serve as Chief Executive Officer of Antria Delaware. Under the terms of this agreement, Mr. Elam will be entitled
to receive an annual base of $230,000 until the executive commits full time to the business at which time his salary will increase
to $350,000. Mr. Elam is a significant shareholder managing director and member of the board of directors of Konus. Pursuant to
a mutual understanding between Mr. Elam, Konus and AntriaBio, the amounts owed to Mr. Elam pursuant to the terms of his employment
agreement will be paid directly to Konus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On March 26, 2014, we entered into an amended and restated
employment agreement with Mr. Elam, amending his employment agreement. The amended employment agreement provides, among other
things, for: (i) an increase in Mr. Elam&rsquo;s base salary from $230,000 to $390,000; (ii) a termination of the bonus due to
Mr. Elam under the Employment Agreement upon the Company raising at least $5,000,000 in an equity financing; (iii) a termination
of the car allowance granted to Mr. Elam under the Employment Agreement; and (iv) the termination of the pension benefit at the
age of 65 equal to one-month&rsquo;s salary for each year of employment. Beginning in April 2014, Mr. Elam was paid directly by
the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Konus Note</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On November 14, 2013, we issued into a 14% promissory note
in the principal amount of $250,000 (Konus Note) to Konus in order to evidence funds Konus loaned to the Company. Pursuant to
the terms of the Konus Note, the principal balance of the Note is due at the earlier of, (i) November 1, 2014 or (ii) ten days
after the closing of an equity financing that raises at least three million dollars. As we completed an initial close of the Unit
Financing for aggregate proceeds of approximately $5 million on March 31, 2014, we paid the outstanding principal and interest
balance on the Konus Note on April 1, 2014. We also issued to Konus a warrant to purchase 39,117 shares of our common stock at
an exercise price of $7.50 per share of common stock for a period of five (5) years from the issuance of the warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Konus Repayment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On March 26, 2014, we entered into a repayment agreement
with Konus. Pursuant to the terms of the Repayment Agreement, we agreed to repay to Konus $1,182,644, representing the total amounts
due and owing to Konus for services rendered by Konus as of January 31, 2014 and its consultants to the Company (Balance) as set
forth in the Konus Agreements (as defined in the Repayment Agreement) through, (i) the issuance of $275,000 worth of shares of
our common stock (Payment Shares) with such Payment Shares to be valued at $1.56 per share and (ii) a cash payment or series of
cash payments totaling $907,644 to be paid at such time as mutually agreed to by Konus and the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Review, Approval or Ratification of Transactions with Related
Persons</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely on our Board to review related party transactions on
an ongoing basis to prevent conflicts of interest. Our Board reviews a transaction in light of the affiliations of the director,
officer or employee and the affiliations of such person&rsquo;s immediate family. Transactions are presented to our Board for approval
before they are entered into or, if this is not possible, for ratification after the transaction has occurred. If our Board finds
that a conflict of interest exists, then it will determine the appropriate remedial action, if any. Our Board approves or ratifies
a transaction if it determines that the transaction is consistent with the best interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Because our common stock is not currently listed on a national
securities exchange, we have used the definition of &ldquo;independence&rdquo; of The NASDAQ Stock Market to determine whether
our current director or our new directors are independent. We have determined that as of the date of this Annual Report Barry
Sherman would qualify as &ldquo;independent&rdquo; in accordance with the published listing requirements of The NASDAQ Stock Market
and for purposes of Section 16 of the Exchange Act. NASDAQ Listing Rule 5605(a)(2) provides that an &ldquo;independent director&rdquo;
is a person other than an officer or employee of the Company or any other individual having a relationship which, in the opinion
of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NASDAQ listing rules provide that a director cannot be considered
independent if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the director
                                         is, or at any time during the past three years was, an employee of the Company; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the director
                                         or a family member of the director accepted any compensation from the Company in excess
                                         of $120,000 during any period of twelve consecutive months within the three years preceding
                                         the independence determination (subject to certain exclusions, including, among other
                                         things, compensation for board or board committee service); </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> a family
                                         member of the director is, or at any time during the past three years was, an executive
                                         officer of the Company; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the director
                                         or a family member of the director is a partner in, controlling stockholder of, or an
                                         executive officer of an entity to which the Company made, or from which the Company received,
                                         payments in the current or any of the past three fiscal years that exceed 5% of the recipient&rsquo;s
                                         consolidated gross revenue for that year or $200,000, whichever is greater (subject to
                                         certain exclusions); </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the director
                                         or a family member of the director is employed as an executive officer of an entity where,
                                         at any time during the past three years, any of the executive officers of the Company
                                         served on the compensation committee of such other entity; or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> the director
                                         or a family member of the director is a current partner of the Company&rsquo;s outside
                                         auditor, or at any time during the past three years was a partner or employee of the
                                         Company&rsquo;s outside auditor, and who worked on the company&rsquo;s audit. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="SECURITYOWNERSHIP"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The following tables set forth information
as of October 23, 2014, regarding the ownership of our common stock by: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt"> &bull; </FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"> each person who is known by
    us to own more than 5% of our shares of common stock; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt"> &bull; </FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"> each named executive officer,
    each director and all of our directors and executive officers as a group. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The number of shares beneficially owned
and the percentage of shares beneficially owned are based on 18,217,793 shares of common stock outstanding as of October 23,
2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Beneficial ownership is determined
in accordance with the rules and regulations of the SEC and generally includes voting or investment power with respect to securities.
Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power
or investment power and includes any shares that an individual or entity has the right to acquire beneficial ownership of within
60 days through the exercise of any warrant, stock option, or other right. Shares subject to options that are exercisable within
60 days following October 23, 2014, are deemed to be outstanding and beneficially owned by the optionee for the purpose of computing
share and percentage ownership of that optionee but are not deemed to be outstanding for the purpose of computing the percentage
ownership of any other person. Except as indicated in the footnotes to this table, and as affected by applicable community property
laws, all persons listed have sole voting and investment power for all shares shown as beneficially owned by them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Information regarding our Equity Compensation Plan is set
forth in Item 5 above and is incorporated herein by Reference. &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"> Shares of Common <BR>
    Stock </TD><TD NOWRAP> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"> Percentage of Class </TD><TD NOWRAP> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"> Name and Address of Benefical Owner </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Beneficially Owned </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Beneficially Owned </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"> EU One Group, LLC (1)<BR> L'Estoril, 31 Avenue Princesse Grace<BR> MC 98000, Monaco </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 3,000,000 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 16.6 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Sankaram Mantripragada<BR> 999 18th Street, Suite 3000<BR> Denver, CO 80202 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 1,204,862 </FONT></TD><TD NOWRAP STYLE="text-align: left"> (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6.6 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Konus Advisory Group, Inc.<BR> 890 Santa Cruz Avenue<BR> Menlo Park, CA 94025 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 842,949 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4.7 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Hoyoung Huh<BR> 890 Santa Cruz Avenue<BR> Menlo Park, CA 94025 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 1,310,657 </FONT></TD><TD NOWRAP STYLE="text-align: left"> (2)(3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7.1 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alpha Ventures Capital Partners, LP<BR> 2026 Crystal Wood Drive<BR> Lakeland, FL 33801 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,307,694 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12.0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Sheldon Miller<BR> 31731 Northwestern Hwy, Suite #280<BR> Farmington Hills, MI 48334 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 969,084 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5.3 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Nevan C. Elam<BR> 890 Santa Cruz Avenue<BR> Menlo Park, CA 94025 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 1,501,629 </FONT></TD><TD NOWRAP STYLE="text-align: left"> (2)(3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8.0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Morgan Fields<BR> 890 Santa Cruz Avenue<BR> Menlo Park, CA 94025 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 21,771 </FONT></TD><TD NOWRAP STYLE="text-align: left"> (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.1 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Barry Sherman<BR> 890 Santa Cruz Avenue<BR> Menlo Park, CA 94025 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 4,688 </FONT></TD><TD NOWRAP STYLE="text-align: left"> (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> All current executive officers and directors as a group (5 persons) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,200,658 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16.5 </TD><TD STYLE="text-align: left"> % </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (1) </TD><TD STYLE="text-align: justify"> EU One Group, LLC is a Nevis limited liability company.
Phillip Feller has sole voting and investment power with respect to these EU One Group, LLC shares. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (2) </TD><TD STYLE="text-align: justify"> Includes the vested portion of the options granted
by Antria Delaware that were assumed by the Company in connection with the Reverse Merger and the options granted under the 2014
Stock and Incentive Plan. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> (3) </TD><TD STYLE="text-align: justify"> Includes shares beneficially owned by Konus Advisory
Group, Inc. Konus Advisory Group, Inc. is a Delaware corporation in which Hoyoung Huh and Nevan Elam, members of our Board, have
shared voting and investment power with respect to these Konus Advisory Group, Inc. shares. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="DESCRIPTIONOFCAPITALSTOCK"></A>DESCRIPTION OF CAPITAL
STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized capital stock consists of 200,000,000 shares
of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock in one or more series, $0.001 par value per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As of October 23, 2014, there were 18,217,793 shares of
our common stock outstanding held of record by 230 stockholders. In addition, there are outstanding options, warrants and rights
to acquire additional shares of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of the common stock are entitled to one vote per share
on all matters submitted to the stockholders for a vote. There are no cumulative voting rights in the election of directors. The
shares of common stock are entitled to receive such dividends as may be declared and paid by the Board of Directors out of funds
legally available therefor and to share, ratably, in the net assets, if any, of AntriaBio upon liquidation. The stockholders have
no preemptive rights to purchase any shares of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transfer agent for the common stock is VStock, Cedarhurst,
New York. Our common stock is traded on the OTCQB and is quoted under the symbol &ldquo;ANTB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation authorizes 20,000,000 shares
of preferred stock. Our Board is authorized, without further stockholder action, to establish various series of preferred stock
from time to time and to determine the rights, preferences and privileges of any unissued series including, among other matters,
any dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund
terms, the number of shares constituting any such series, and the description thereof and to issue any such shares. The Board has
not designated any rights to the preferred stock .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The material terms and provisions of the
Unit Warrants, Bridge Warrants, and Bridge Incentive Warrants (collectively referred to herein as the &ldquo;<B>Offered Warrants</B>&rdquo;)
are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unit Warrants and Bridge Incentive Warrants
entitle the holder to purchase shares of common stock for an exercise price equal to $2.34 per share of our common stock. Bridge
Warrants entitle the holder to purchase shares of common stock for an exercise price of $1.89 per share of our common stock. Subject
to certain limitations as described below, the Offered Warrants are immediately exercisable upon issuance and expire on the third
anniversary of the initial issue date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Warrants entitle the holder
to purchase shares of common stock for an exercise price equal to $1.56 per share of our common stock. Subject to certain limitations
as described below, the Compensation Warrants are immediately exercisable upon issuance and expire on the seventh anniversary of
the initial issue date. The Compensation Warrants contain cashless exercise provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise price and the number of shares
of our common stock issuable upon the exercise of the Offered Warrants and the Compensation Warrants, as applicable, is subject
to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications,
reorganizations or similar events affecting our common stock, and also upon any distributions of assets, including cash, stock
or other property to our stockholders. The warrant holders must pay the exercise price in cash upon exercise of the Offered Warrants.
The Compensation Warrants have cashless exercise features. After the close of business on the expiration date, unexercised Offered
Warrants and Compensation Warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in the event we
consummate a merger or consolidation with or into another person or other reorganization event in which our common shares are
converted or exchange for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or
otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding
common shares, then following such event, the holders of the Offered Warrants will be entitled to receive upon exercise of
the Offered Warrants the same kind and amount of securities, cash or property which the holders would have received had they
exercised the Offered Warrants immediately prior to such fundamental transaction. Any successor to us or surviving entity
shall assume the obligations under the Offered Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon the holder&rsquo;s exercise of an Offered Warrant or a
Compensation Warrant we will issue the shares of common stock issuable upon exercise of the Offered Warrant or a Compensation Warrant
within three (3) business days following our receipt of notice of exercise and payment of the exercise price, subject to surrender
of the Offered Warrant or a Compensation Warrant. Prior to the exercise of any warrants to purchase common stock, holders of the
Offered Warrants, the Compensation Warrants or any other warrant will not have any of the rights of holders of the common stock
purchasable upon exercise, including the right to vote or to receive any payments of dividends on the common stock purchasable
upon exercise.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="SELLINGSTOCKHOLDERS"></A>SELLING STOCKHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus covers an aggregate of 14,958,633 shares of
our common stock, which includes: (i) 2,186,847 shares of common stock issued pursuant to the conversion of the Notes; (ii) 225,259
shares of common stock issuable upon the exercise of the Bridge Warrants; (iii) 5,725,325 shares of common stock issued in connection
with the Unit Financing; (iv) 5,725,325 shares of common stock issuable upon the exercise of the Unit Warrants; (v) 562,346 shares
of common stock issuable upon the exercise of the Bridge Incentive Warrants; (vi) 290,861 shares of common stock issuable upon
the exercise of the Compensation Warrants issued to Paulson as compensation in connection with the Bridge Financing and the Unit
Financing; and (vii) 242,670 shares of common stock issued pursuant to the Note Conversion, that may be sold or otherwise disposed
of the selling stockholders and their transferees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table sets forth certain information regarding
the selling stockholders and the shares that may be sold or otherwise disposed of by them pursuant to this prospectus. Beneficial
ownership and percentage ownership are determined in accordance with the rules and regulations of the SEC and include voting or
investment power with respect to shares of stock. This information does not necessarily indicate beneficial ownership for any
other purpose. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares
of common stock subject to warrants, options and other convertible securities held by that person that are currently convertible
or exercisable, or convertible or exercisable within 60 days of the date of this prospectus are deemed outstanding. Such shares,
however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. The percentage
of beneficial ownership is based on 18,217,793 shares of common stock outstanding on the date of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned Prior </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>to this Offering</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>After this Offering</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding: 0 0 1pt; text-align: left"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> Name of
    Selling Stockholder (1) </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> Number
    of </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> %
    of </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> Number
    of </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares Covered</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Hereby(2)</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> Number
    of </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"><B> %
    of </B></FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares</B></FONT></FONT> </TD>
    <TD NOWRAP STYLE="padding: 0"><FONT STYLE="font-size: 7pt"><B> &nbsp; </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD NOWRAP STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 39%; text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Alpha Venture
    Capital Partners, LP </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 3%; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (3 </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 8%; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 2,307,694 </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 8%; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 11.99 </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 8%; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 2,307,694 </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 8%; text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> - </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 8%; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="width: 1%; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Sheldon L. Miller </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (4 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 969,084 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 5.26 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 969,084 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ACNYC, LLC </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (5 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 641,026 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 3.48 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 641,026 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Gerald Blaine Garst,
    Jr. </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (6 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 623,241 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 3.40 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 623,241 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Christian Kurmann </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (7 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 588,796 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 3.22 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 588,796 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Revocable Deed of Trust
    of Leon C. Sunstein, Jr. DTD 1/1/96 as Amended, Leon C. Sunstein, Jr., Trustee </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (8 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 544,083 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 2.97 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 544,083 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Donald M. Cooper </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (9 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 440,723 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 2.41 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 440,723 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Francis M. Lymburner </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (10 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 339,112 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.86 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 339,112 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Stephen Shumpert </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (11 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 301,826 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.66 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 301,826 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Dale Ragan </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (12 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 256,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.41 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 256,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Thomas Gruber </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (13 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 256,412 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.41 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 256,412 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Mark W. Spates </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (14 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 249,298 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.37 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 249,298 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Joseph O. Manzi </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (15 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 249,545 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.37 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 249,545 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> LRFA, LLC </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (16 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 249,298 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.37 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 249,298 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> KADI Family Trust </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (17 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 233,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 233,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Porter Partners, L.P. </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (18 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 217,950 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 217,950 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Goff VC Fund AB, LLC </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (19 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 186,122 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 186,122 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Millenium Trust Company
    LLC FBO Francis Lymburner IRA </FONT> <FONT STYLE="font-size: 7pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">a/c#xxxx72312</FONT></FONT> </TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (20 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 176,297 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 176,297 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Ashok K. Santhanam and
    Revathi Santhanam, Trustees of the Santhanam Family Trust, dated May 23, 1997 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (21 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 170,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 170,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> J. A. Cardwell </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (22 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 166,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 166,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Nathan Pollack and Sylvia
    Pollack </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (23 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 166,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 166,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Stanton J. Rowe </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (24 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 166,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 166,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Millenium Trust Company
    LLC FBO Jonathan T. Stanney IRA </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (25 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 150,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 150,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Srinivas Akkaraju </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (26 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Adolfo Carmona and Donna
    Carmona </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (27 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Lawrence (Larry) E. Coffman
    Living Trust dtd 1/9/92 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (28 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Howard Hutt </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (29 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> MIS Equity Strategies,
    L.P. </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (30 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Seal Rock 1, LLC </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (31 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 133,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> David A. Ufheil </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (32 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 124,650 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 124,650 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Christopher Hermann </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (33 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Joe N. and Jamie W. Behrendt
    Revocable Trust 10/30/1996 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (34 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Samuel A. Fisher </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (35 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 97,436 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 97,436 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Robert Kantor </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (36 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 96,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 96,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Art Sadin </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (37 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 96,154 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 96,154 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Randall J. Wolfe </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (38 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 96,154 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 96,154 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Mitchell Tracy </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (39 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 93,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 93,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Tom Sego </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (40 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 89,428 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 89,428 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Kenneth Shell </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (41 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Clayton A. Struve </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (42 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Robert Taicher </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (43 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Francis G. Russo </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (44 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 80,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 80,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Jonathan T. Stanney </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (45 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 70,514 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 70,514 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Daniel Gilbert and Cheryl
    Gilbert </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (46 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Christopher T. Hale </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (47 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Richard C. Leto </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (48 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Natan Vishlitzky and
    Miryam Vishlitzky </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (49 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 66,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Michael J. Dugas </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (50 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,118 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,118 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Jorg Brown </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (51 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Steven Collins </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (52 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Raymond Crespo </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (53 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Anthony Farello </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (54 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Harry M. Farnham III </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (55 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Future, LLC </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (56 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Bradford Paskewitz </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (57 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,100 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,100 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Daniel X. Wray </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (58 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 64,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Jason Eisenbeis </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (59 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 62,326 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 62,326 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Rajaee Family Trust dated
    10/10/03 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (60 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 60,098 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 60,098 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Millenium
    Trust Company LLC Custodian FBO John Saefke IRA </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (61 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 51,284 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 51,284 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Philip
    M. Cannella </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (62 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Robert
    Horowitz </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (63 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> James N. Wierzba </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (64 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 44,520 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 44,520 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Dionisios Liberatos </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (65 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 41,668 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 41,668 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 7pt"> Paul Russo </FONT></P>


</TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> (66 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 7pt"> ) </FONT></P>


</TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 7pt"> 41,668 </FONT></P>


</TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font-size: 7pt"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> 41,668 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> EDJ Limited </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (67 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 38,462 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 38,462 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Thomas Eisenberg </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (68 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 38,462 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 38,462 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Barbara Lile-Duzsik </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (69 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 38,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 38,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Joan Rich Baer Pension
    Plan and Trust </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (70 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 35,617 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 35,617 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Heinz Baumann </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (71 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Fred and Betty Bialek
    Revocable Trust Dated 12/20/2004 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (72 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Jack Chitayak </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (73 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Nancy Cowgill </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (74 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Dan DeAutremont </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (75 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Due Mondi Investments
    LTD </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (76 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Keith Fishback and
    Jeanne Fishback </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (77 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Frances Gilbert Family
    LP </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (78 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Robert T. Freres Jr
    Living Trust </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (79 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Noma Hanlon </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (80 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Debra Kanelstein </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (81 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Michael Kennedy </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (82 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Stephen Lesser </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (83 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Clark Schierle </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (84 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Lance Siegall </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (85 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Emerson Thomas Springer,
    Jr. </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (86 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Glen Stein </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (87 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Brenna Tanzosh </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (88 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> The Anthony &amp; Angela Reed Family Trust </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (89 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Mark Thomas </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (90 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Wayne Westerman </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (91 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Wiesenberg Family Revocable Trust </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (92 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 33,334 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Bill Hunt </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (93 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Martin Kupferberg </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (94 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> John Lapinski and Paige Lapinski </FONT> <FONT STYLE="font-size: 7pt"><BR></FONT> </TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (95 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> PENSCO Trust Company Custodian FBO Paul Hamerton-Kelly
    IRA </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (96 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Scott R. Schroeder and Mary K. Schroeder </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (97 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> The Vassily I. Dubenko &amp; Vera Dubenko
    Family Trust </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (98 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 32,052 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> William Sykes </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (99 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 26,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 26,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Austin Mansur </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (100 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 26,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 26,000 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Brian Imwalle </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (101 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 25,578 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 25,578 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Abraham Bakal </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (102 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 22,358 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 22,358 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Gil Bakal </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (103 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 22,358 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 22,358 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Rajaee Trust dated 4/23/1999 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (104 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 22,261 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 22,261 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Parag Doshi </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (105 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> William Esson </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (106 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Allen Gabriel </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (107 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Brian A. Halpern </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (108 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Ed Horton </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (109 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Aman Mongia </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (110 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> David P. Scheid and Carole A. Scheid </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (111 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Patrick Sheehan </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (112 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Richard Vandlen </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (113 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,668 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> William Costigan and Stephanie Costigan </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (114 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,026 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 16,026 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Mitchell Cohen </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (115 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 12,822 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 12,822 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Vincent Gulli </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (116 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 12,822 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 12,822 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Howard Richmond </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (117 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 12,822 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 12,822 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Dale E. Jones </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (118 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 8,905 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 8,905 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Aspire Capital Fund, LLC </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (119 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 242,670 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.34 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 242,670 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> Paulson Investment Company, Inc. </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> (120 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 290,861 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 1.58 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0; text-align: right"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 290,861 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 0 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> TOTAL </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"> 14,958,633 </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 7pt"> &nbsp; </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> Represents
                                         ownership of less than 1%. </TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (1) </TD><TD> This table and the information in the notes below are
                                         based upon information supplied by the selling stockholders, including reports and amendments
                                         thereto filed on Schedule 13D, Schedule 13G, Form 3 and Form 4 with the SEC. </TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"> &nbsp; </P>

<P STYLE="margin: 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (2) </TD><TD> The actual numbers of shares of common stock offered hereby
                                         and included in the registration statement of which this prospectus forms a part includes,
                                         pursuant to Rule 416 under the Securities Act, such additional number of shares of common
                                         stock as may be issuable in connection with the shares registered for sale hereby resulting
                                         from stock splits, stock dividends, recapitalizations or similar transactions. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (3) </TD><TD> Carl C. Dockery is the Manager of the General Partner
                                         of the selling stockholder and has voting and investment power over the shares. The address
                                         of the selling stockholder is PO Box 2477, Lakeland, FL 33806-2477. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (4) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 31731 Northwestern Hwy. Suite
                                         #280, Farmington Hills, MI 48334. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (5) </TD><TD> Andrew Cader is the Managing Member of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 300 Beach Drive NE, Unit 2401, St. Petersburg, FL 33701. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (6) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1062 Eastwood Dr., Los Altos,
                                         CA 94024. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (7) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 280 Diablo Ave., Mountain
                                         View, CA 94043. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (8) </TD><TD> Leon C. Sunstein, Jr is the Trustee of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 1617 JFK Blvd. Suite 1220, Philadelphia, PA 19103. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (9) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 29 Hessian Blvd., Reading,
                                         PA 19607. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (10) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 811 West Ridge Court, Lake
                                         Orion, MI 48359. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (11) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 406 Goodnight Drive, Georgetown,
                                         TX 78628. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (12) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1242 Marion Rd. SE, Rochester,
                                         MN 55904. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (13) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 147 Lakeview Way, Emerald
                                         Hills, CA 94062. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (14) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 328 S. Jackson, Justin, TX
                                         76247. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (15) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 155 Ridge Road, Rumson, NJ
                                         07760. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (16) </TD><TD> David F. Welch is the President of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 217 Camino Al Lago, Atherton, CA 94027. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (17) </TD><TD> William Kadi and Sandra Kadi are the Trustees of the
                                         selling stockholder and have voting and investment power over the shares. The address
                                         of the selling stockholder is P.O. Box 6126, Incline Village, NV 89450. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (18) </TD><TD> Jeffrey H. Porter is the General Partner of the selling
                                         stockholder and has voting and investment power over the shares. The address of the selling
                                         stockholder is 300 Drakes Ldg. Rd., Ste. 175, Greenbrae, CA 94904. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (19) </TD><TD> Caroline Bombardier is the Managing Member of the selling
                                         stockholder and has voting and investment power over the shares. The address of the selling
                                         stockholder is 14023 NW FalconRidge Lane, Portland, OR 97229. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (20) </TD><TD> Francis Lymburner is the individual of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 2001 Spring Road #700, Oak Brook, IL 60523. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (21) </TD><TD> Ashok K. Santhanam and Revathi Santhanam are the Trustees
                                         of the selling stockholder and have voting and investment power over the shares. The
                                         address of the selling stockholder is 1055 Cascade Drive, Menlo Park, CA 94025. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (22) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 6080 Surety Drive, Suite 305,
                                         El Paso, Texas 79905. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (23) </TD><TD> The selling stockholders have voting and investment power
                                         over the shares. The address of the selling stockholder is 2510 Blossom Lane, Beachwood,
                                         OH 44122. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (24) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 3 Shoreridge, Newport Coast,
                                         CA 92657. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (25) </TD><TD> Jonathan T. Stanney is the individual of the selling
                                         stockholder and has voting and investment power over the shares. The address of the selling
                                         stockholder is 2001 Spring Road #700, Oak Brook, IL 60523. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (26) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 251 Churchill Ave., Palo Alto,
                                         CA 94301. </TD></TR></TABLE>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (27) </TD><TD> The selling stockholders have voting and investment power
                                         over the shares. The address of the selling stockholder is 6798 Lake Ave., Greenwich,
                                         CT 06830. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (28) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 501 S Beverly Glen Blvd.,
                                         Los Angeles, CA 90024. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (29) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 912 Bermuda Gardens Road,
                                         Delray Beach, FL 33483 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (30) </TD><TD> Anthony Reed is the Manager of the General Partner of
                                         the selling Stockholder and has voting and investment power over the shares. Anthony
                                         Reed is an affiliate of Cova Capital Partners, a FINRA registered broker-dealer. The
                                         securities registered hereunder for resale by this selling security holder were purchased
                                         in the ordinary course of business and at the time of such purchase this selling security
                                         holder had no agreements or understandings, directly or indirectly, with any person,
                                         to distribute such securities. The address of the selling stockholder is 16217 Kittridge
                                         Street, Van Nuys, CA 91406. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (31) </TD><TD> Brian M. Miller is the Manager of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 60 Summit Avenue, Mill Valley, CA 94941. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (32) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 17863 63rd Ave., N. Maple
                                         Grove, MN 55311. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (33) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 937 NW Glisan St. #1037, Portland,
                                         OR 97209. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (34) </TD><TD> Joe Behrendt is the Trustee of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 12 Skyland Way, Ross, CA 94957 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (35) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 22 Coleman Road, Garrison,
                                         NY 10524. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (36) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The selling stockholder is an affiliate of Time Equities, Inc. a FINRA
                                         registered broker-dealer. The securities registered hereunder for resale by this selling
                                         security holder were purchased in the ordinary course of business and at the time of
                                         such purchase this selling security holder had no agreements or understandings, directly
                                         or indirectly, with any person, to distribute such securities. The address of the selling
                                         stockholder is 7 Heller Drive, Montclair, NJ 07043. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (37) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 2207 Lakeway Drive, Friendswood,
                                         TX 77546. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (38) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 2125 Fairhaven Court, West
                                         Linn, OR 97068. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (39) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 8300 SW 71st Ave., Portland,
                                         OR 97223. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (40) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1045 Hutchinson Ave., Palo
                                         Alto, CA 94301. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (41) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 526 Kingwood Dr 315, Kingward,
                                         TX 77339. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (42) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 175 W. Jackson Blvd. Ste #400,
                                         Chicago, IL 60604. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (43) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 3001 Ponce De Leon Boulevard,
                                         Suite 211, Coral Gables, FL 33134. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (44) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 95 Wall Street, #2318, New
                                         York, NY 10005. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (45) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 2 Firefly Ln., Sandwich, MA
                                         02563. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (46) </TD><TD> The selling stockholders have voting and investment power
                                         over the shares. The address of the selling stockholder is 4820 SW Garden Home Rd., Portland,
                                         OR 97219. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (47) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 12411 N. Golf Dr., Mequon,
                                         WI 53902 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (48) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 7312 49 Ave. East, Bradenton,
                                         FL 34203. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (49) </TD><TD> The selling stockholders have voting and investment power
                                         over the shares. The address of the selling stockholder is 87 Clinton Road, Brookline,
                                         MA 02445. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (50) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 15388 NW Wooded Way, Beaverton,
                                         OR 97006. </TD></TR></TABLE>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (51) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 4032 Jefferson Ave., Emerald
                                         Hills, CA 94062 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (52) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 4299 MacArthur Blvd #107,
                                         Newport Beach, CA 92660. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (53) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 55 Washington Street, Suite
                                         302A, Brooklyn, NY 11201. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (54) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 16 Equestrian Court, West
                                         Hills, NY 11743. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (55) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 7006 McKamy Blvd., Dallas,
                                         TX 75248. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (56) </TD><TD> Jack R. Frank II is the President of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 14470 Eighteenth Fairway, Milton, GA 30004 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (57) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 11 Howell Ct., West Windsor,
                                         NJ 08550. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (58) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is PO Box 2649, Minden, NY 84923. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (59) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1617 Norwood Drive, Eagan,
                                         MN 55122. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (60) </TD><TD> Behrouz Rajaee is the Trustee of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is PO Box 1238, Guasti, CA 91743. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (61) </TD><TD> John Saefke is the individual of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 2001 Spring Road #700, Oak Brook, IL 60523. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (62) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 137 Highbrook Avenue, Pelham,
                                         NY 10803 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (63) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 217 Red Fox Road, Stamford,
                                         CT 06903. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (64) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 2817 W. Country Club Dr.,
                                         Mequon, WI 53092. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (65) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 228 Robby Lane, Manhasset
                                         Hills, NY 11040. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (66) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 13050 La Paloma Rd, Los Altos,
                                         CA 94022. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (67) </TD><TD> Jeffrey H. Porter is the Investment Advisor of the selling
                                         stockholder and has voting and investmetn power over the shares. The address of the selling
                                         stockholder is Loyalist Plaza, Don Mackay Blvd. Marsh Harbour, Abaco, Bahamas AB-20377 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (68) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 22 Melrose Place, Montclair,
                                         NJ 07042. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (69) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 20413 87th Ave., S. Kent,
                                         WA 98031. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (70) </TD><TD> Joan R. Baer and Arthur B. Baer are the trustees of the
                                         selling stockholder and have voting and investment power over the shares. The address
                                         of the selling stockholder is 199 Concord Dr., Madison, CT 06443. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (71) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 17 Skylark Drive #4, Larkspur,
                                         CA 94939. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (72) </TD><TD> Fred Bialek is the Trustee of the selling stockholder
                                         and has voting and investment power over the selling stockholder. The address of the
                                         selling stockholder is 200 Winding Way, Woodside, CA 94062 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (73) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1836 El Camino Del Teatro,
                                         La Jolla, CA 92037. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (74) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 27080 SW Xanthus Ct., Sherwood,
                                         OR 97140. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (75) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 4910 SW Taylors Ferry Rd.,
                                         Portland, OR 97219. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (76) </TD><TD> Robert S. Beadle is the General Partner of the selling
                                         stockholder and has voting and investment power over the shares. The address of the selling
                                         stockholder is 8620 Willow Wind, Boerne, TX 78015 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (77) </TD><TD> The selling stockholders have shared voting and investment
                                         power over the shares. The address of the selling stockholder is 11375 NW Roy Rd., Banks,
                                         OR 97106. </TD></TR></TABLE>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (78) </TD><TD> Daniel L. Gilbert is the Manager and General Partner
                                         of the selling stockholder and has voting and investment power over the shares. The address
                                         of the selling stockholder is 4820 SW Garden Home Rd., Portland, OR 97219. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (79) </TD><TD> Robert T. Freres, Jr. is the Trustee of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is 141 14th Street Lyons, OR 97358. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (80) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1110 SW Myrtle Drive, Portland,
                                         OR 97201. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (81) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 135 High Street, Closter,
                                         NJ 07624. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (82) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 5445 SW Burton Dr., Portland,
                                         OR 97221. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (83) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 11342 178th Place NE, Redmond,
                                         WA 98252. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (84) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 4512 Grand Ave., Western Springs,
                                         IL 60558. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (85) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 717 Dartmouth Avenue, Silver
                                         Spring, MD 20910. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (86) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 4916 SE Antelope Hills Dr.,
                                         Gresham, OR 97080. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (87) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 2063 NW 19th Way, Boca Raton,
                                         FL 33431. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (88) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 3203 SW Newby Terrace, Portland,
                                         OR 97239. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (89) </TD><TD> Anthony Reed is the Trustee of the selling stockholder
                                         and has voting and investment power over the shares. Anthony Reed is a registered representative
                                         of Cova Capital Partners, a FINRA registered broker-dealer. The securities registered
                                         hereunder for resale by this selling security holder were purchased in the ordinary course
                                         of business and at the time of such purchase this selling security holder had no agreements
                                         or understandings, directly or indirectly, with any person, to distribute such securities.
                                         The address of the selling stockholder is 16217 Kittridge Street, Van Nuys, CA 91406. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (90) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 3 Monroe Parkway #P 350, Lake
                                         Oswego, OR 97035. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (91) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 2628 Summit Drive, Burlingame,
                                         CA 94010. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (92) </TD><TD> James H. and Susan Wiesenberg are the Trustees of the
                                         selling stockholder and has voting and investment power over the shares. The address
                                         of the selling stockholder is 10040 E. Happy Valley Rd #454, Scottsdale, AZ 85255. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (93) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 9122 SW Trail Ct., Portland,
                                         OR 97219. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (94) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 150 East 69th Street, New
                                         York, NY 10021 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (95) </TD><TD> The selling stockholders have voting and investment power
                                         over the shares. The address of the selling stockholder is 245 South Clark Drive, Beverly
                                         Hills, CA 90211. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (96) </TD><TD> Paul Hamerton-Kelly is the individual of the selling
                                         stockholder and has voting and investment power over the shares. The address of the selling
                                         stockholder is PO Box 173859, Denver, CO 80217. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (97) </TD><TD> The selling stockholders have voting and investment power
                                         over the shares. The address of the selling stockholder is 2265 Dawnwood, Philomath,
                                         OR 97370. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (98) </TD><TD> Sonia Beecher and Vassily I. Dubenko are the Co-Trustee
                                         of the selling stockholder and have voting and investment power over the shares. The
                                         address of the selling stockholder is 1108 SE Dogwood Ln., Oak Grove, OR 97267. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (99) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 130 N. Country Road 1675 East,
                                         Hindsboro, IL 61930. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (100) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 875 N. Michigan Avenue, #3620,
                                         Chicago, IL 60611. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (101) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 10956 E. Cosmos Circle., Scottsdale,
                                         AZ 85255. </TD></TR></TABLE>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (102) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 24 Spielman Rd., Fairfield,
                                         NJ 07004. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (103) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 24 Spielman Rd., Fairfield,
                                         NJ 07004. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (104) </TD><TD> Behrouz Rajaee is the Trustee of the selling stockholder
                                         and has voting and investment power over the shares. The address of the selling stockholder
                                         is PO Box 1238, Guasti, CA 91743. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (105) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 852 Saints Drive, Marietta,
                                         GA 30068. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (106) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 16656 S. 14th St., Phoenix,
                                         AZ 85048. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (107) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 785 NW Valley Street, Camas,
                                         WA 98607. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (108) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 552 N. Greencraig Rd., Los
                                         Angeles, CA 90049. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (109) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 3971 Catamarca Dr., San Diego,
                                         CA 92124. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (110) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 860 Saints Drive, Marietta,
                                         GA 30068. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (111) </TD><TD> The selling stockholders have voting and investment
                                         power over the shares. The address of the selling stockholder is 1536 McCoy Avenue, San
                                         Jose, CA 95130. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (112) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1270 Ridgeline Ct., San Jose
                                         CA 95127. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (113) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 1015 Hayne Rd., Hillsborough,
                                         CA 94010. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (114) </TD><TD> The selling stockholders have voting and investment
                                         power over the shares. The address of the selling stockholder is 8815 NW Lakecrest Ave.,
                                         Vancouver, WA 98665 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (115) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 3967 Vierra Street, Pleasanton,
                                         CA 94566 </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (116) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 133-16C 87th Street, Ozone
                                         Park, NY 11417. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (117) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 31913 SE 28th Street, Fall
                                         City, WA 98024. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (118) </TD><TD> The selling stockholder has voting and investment power
                                         over the shares. The address of the selling stockholder is 7490 Bush Lake Rd., Edina,
                                         MN 55439. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (119) </TD><TD> Aspire Capital Partners, LLC is the managing member
                                         of Aspire Capital Fund, LLC. SGM Holdings Corp. is the managing member of Aspire Capital
                                         Partners, LLC. Steven G. Martin is the president and sole shareholder of SGM Holdings
                                         Corp. Erik J. Brown is a principal of Aspire Capital Partners, LLC. Christos Komissopoulos
                                         is a principal of Aspire Capital Partners, LLC. Each may be deemed to have shared voting
                                         and investment power over shares owned by Aspire Capital Fund, LLC. Each of Aspire Capital
                                         Partners, LLC, SGM Holdings Corp., Mr. Martin, Mr. Brown and Mr. Komissopoulos disclaim
                                         beneficial ownership of the shares of common stock held by Aspire Capital Fund, LLC.
                                         Aspire Capital is not a licensed broker dealer or an affiliate of a licensed broker dealer.
                                         The address of the selling stockholder is 155 North Wacker Drive, Suite 1600, Chicago,
                                         IL 60606. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (120) </TD><TD> Represents shares underlying the Compensation warrants
                                         issued to Paulson as compensation for services rendered as the exclusive placement agent
                                         for the Unit and Bridge Financing. Trent Davis, as the Chief Executive Officer of Paulson
                                         Investment Company, Inc., a broker-dealer registered with the SEC and member of FINRA,
                                         has voting and investment power over the shares. The address for Paulson is 1331 NW Lovejoy
                                         St., Suite 720, Portland, OR 97209. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="PLANOFDISTRIBUTION"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders, which as used herein includes donees,
pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received
after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may,
from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of
common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These
dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market
price, at varying prices determined at the time of sale, or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may use any one or more of the following
methods when disposing of shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> ordinary
                                         brokerage transactions and transactions in which the broker-dealer solicits purchasers; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> block trades
                                         in which the broker-dealer will attempt to sell the shares as agent, but may position
                                         and resell a portion of the block as principal to facilitate the transaction; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> purchases
                                         by a broker-dealer as principal and resale by the broker-dealer for its account; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> an exchange
                                         distribution in accordance with the rules of the applicable exchange; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> privately
                                         negotiated transactions; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> short sales
                                         effected after the date the registration statement of which this prospectus is a part
                                         is declared effective by the SEC; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> through
                                         the writing or settlement of options or other hedging transactions, whether through an
                                         options exchange or otherwise; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> broker-dealers
                                         may agree with the selling stockholders to sell a specified number of such shares at
                                         a stipulated price per share; </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> a combination
                                         of any such methods of sale; and </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> any other
                                         method permitted by applicable law. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may, from time to time, pledge or grant
a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their
secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this
prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending
the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under
this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the
transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of our common stock or interests
therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders
may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge
the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares
such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate proceeds to the selling stockholders from the
sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any.
Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in
whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds
from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders also may resell all or a portion of
the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria
and conform to the requirements of that rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any underwriters, broker-dealers
or agents that participate in the sale of the common stock or interests therein may be &ldquo;underwriters&rdquo; within the meaning
of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares
may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &ldquo;underwriters&rdquo;
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required, the shares of our common stock to be
sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents,
dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying
prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to comply with the securities laws of some states,
if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition,
in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration
or qualification requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have advised the selling stockholders that the anti-manipulation
rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders
and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or
amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements
of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the
sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have agreed to indemnify the selling stockholders against
certain liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of
the shares offered by this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed with the selling stockholders to keep the registration
statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered
by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (2) the date on which
all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="LEGALMATTERS"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the shares of our common stock offered hereby
and certain other legal matters will be passed upon for us by the law firm of Dorsey &amp; Whitney LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="EXPERTS"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> EKS&amp;H LLLP, our independent registered public accounting
firm, has audited our financial statements included in our Annual Report on Form 10-K, for the years ended June 30, 2014 and 2013,
which is included in this Amendment No. 1 to our Registration Statement on Form S-1. Our financial statements are included in
reliance on their reports given upon their authority as experts in accounting and auditing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="ADDITIONALINFORMATION"></A>ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file annual reports, quarterly reports, current reports,
and proxy and information statements and other information with the SEC. You may read and copy materials that we have filed with
the SEC at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the public reference room. Copies of reports and other information from us are available on the SEC&rsquo;s
website at http://www.sec.gov. Such filings are also available at our website at http://www.antriabio.com. Website materials are
not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANTRIABIO, INC. AND SUBSIDIARIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#f_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-2</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#f_002">Consolidated Balance Sheets as of June 30, 2014 and 2013</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-3</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#f_003">Consolidated Statements of Operations for the years ended June 30, 2014 and 2013</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-4</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#f_004">Consolidated Statements
    of Stockholders&rsquo; Equity (Deficit) for the years ended June 30, 2014 and 2013</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-5</FONT></TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"> &nbsp; </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#f_005">Consolidated Statements of Cash Flows for the years ended June 30, 2014 and 2013</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-6</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#f_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-7</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders of AntriaBio, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Menlo Park, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets
of AntriaBio, Inc. and subsidiary (the &ldquo;Company&rdquo;) as of June 30, 2014 and 2013, and the related statements of operations,
stockholders&rsquo; deficit, and cash flows for each of the periods then ended. The Company&rsquo;s management is responsible
for these consolidated financial statements. Our responsibility is to express an opinion on these financial statements based on
our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of
the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration
of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the financial statements referred to above
present fairly, in all material respects, the financial position of AntriaBio, Inc. and subsidiary as of June 30, 2014 and 2013,
and the results of their operations and their cash flows for the periods then ended in conformity with accounting principles generally
accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered
recurring losses from operations and has a net capital deficiency that raises substantial doubt about the Company&rsquo;s ability
to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note 3. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Denver, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> September 29, 2014 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_002"></A>AntriaBio, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Consolidated Balance Sheets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,934,534</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Note receivable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,829</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest receivable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,341</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Due from related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,346</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred financing, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,037</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">95,469</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,307,559</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">815,549</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Fixed assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Deposit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">750,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total non-current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,097,093</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">288,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,404,652</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,103,971</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Liabilities and Stockholders' Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">460,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">188,346</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">397,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">807,001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,732,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380,575</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Warrant derivative liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">157,761</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">964,040</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,266,183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Non-current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred lease liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,881</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,881</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">997,921</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,266,183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and Contingencies (Note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Preferred stock, $0.001 par value; 20,000,000 shares
    authorized; none issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.7pt">Common stock, $0.001 par value, 200,000,000 shares
    authorized; 18,091,792 and 6,666,667 shares issued and outstanding, June 30, 2014 and 2013, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,135,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,847,591</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 18.7pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,746,924</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,016,470</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders' equity (deficit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,406,731</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(4,162,212</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders' Equity (Deficit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,404,652</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,103,971</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B><A NAME="f_003"></A>AntriaBio, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B><U>Consolidated Statements
of Operations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Years&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Consulting fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">579,817</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">647,925</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Compensation and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,260,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,485,064</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,494</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Meals and entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,670</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">724,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">620,162</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,952</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Travel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,048</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Amortization and depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">295</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Investor relations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">661,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,031</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">475,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,660</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,176,033</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,106,881</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,176,033</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,106,881</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,044</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,230,112</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(568,859</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Derivative expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(336,489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(157,761</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in">Total other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,554,421</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(620,576</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,730,454</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,727,457</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per common share - basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per common share - diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9.35pt; padding-left: 9.35pt; padding-bottom: 2.5pt">Weighted average number of
    common shares outstanding - basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">9,384,662</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">6,204,568</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9.35pt; padding-left: 9.35pt; padding-bottom: 2.5pt">Weighted average number of
    common shares outstanding - diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">9,384,662</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">6,204,568</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B><A NAME="f_004"></A>AntriaBio, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B><U>Consolidated Statements
of Stockholders' Equity (Deficit)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Total</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Additional</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Stockholders'</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Common&nbsp;Stock,&nbsp;$0.001&nbsp;Par&nbsp;Value</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Paid-in</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accumulated</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Subscribed</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Deficit</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">(Deficit)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold"><FONT STYLE="font-size: 10pt">Balance at June 30, 2012</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">5,880,667</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">5,881</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(5,881</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(1,289,013</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(1,288,913</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Stock-based compensation</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,687,502</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,687,502</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Warrant expense</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">191,126</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">191,126</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Conversion of equity in reverse merger acquisition</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">786,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">786</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,881</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(31,137</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(24,470</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Net loss for the year ended June 30, 2013</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,727,457</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,727,457</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">Balance at June 30, 2013</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">6,666,667</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">6,667</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">3,847,591</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">(8,016,470</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">(4,162,212</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Stock-based compensation</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,081,792</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,081,792</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Beneficial conversion feature</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,922,938</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,922,938</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Fair value of warrants for financing and conversion</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,476,606</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,476,606</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Fair value of warrants to be issued</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">690,187</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">690,187</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Issuance of common stock, net of issuance
    costs of $2,263,804</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,725,327</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,725</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,477,683</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,483,408</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Issuance of common stock for note conversions</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,297,964</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,298</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,959,581</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,964,879</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Issuance of common stock as repayment
    of related party balance</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">176,283</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">176</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">274,824</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">275,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Cashless exercise of warrants</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100,550</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Issuance of common stock for services</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">125,001</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">404,462</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">404,587</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net loss for the year ended June 30, 2014</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(9,730,454</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(9,730,454</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Balance at June 30, 2014</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">18,091,792</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">18,092</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">24,135,563</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">(17,746,924</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt">6,406,731</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B><A NAME="f_005"></A>AntriaBio, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B><U>Consolidated Statements
of Cash Flows</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Year&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(9,730,454</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(6,727,457</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of notes payable discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,356,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,312</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416,337</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">279,096</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of intangible asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,544</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">295</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,759</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,081,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,687,502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">404,587</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Derivative expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">336,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,761</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Bad debt expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Decrease in other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,706</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">(Increase) in inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66,600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">(Increase) decrease in due from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206,609</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Increase in accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">(Decrease) increase in accounts payable and accrued expenses - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(134,946</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">804,861</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Increase in interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,451</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred lease liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,881</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,167,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,627,965</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchase of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,974</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,717</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Payment of deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(750,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Acquisition of assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(500,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">(Increase) decrease in interest receivable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,211</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,206</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Issuance of note receivable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(305,603</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Payments on note receivable - related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">974,228</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash (Used In) Provided By
    Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(830,185</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">185,114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Payments of financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(270,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(157,500</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from issuance of convertible notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,703,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,575,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Repayments of convertible notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from issuance of notes payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Repayments of notes payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(234,700</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from issuance of equity financing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,931,434</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Payment of placement agent compensation and issuance
    costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,365,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash Provided By Financing
    Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,931,549</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,417,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase (decrease) in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,934,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,351</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash - Beginning of Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">527</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">25,878</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash - End of Year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,934,534</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">527</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: none; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">SUPPLEMENTARY CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash Paid During the Period for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 9pt">Interest</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,726</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Non-Cash Transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Assumption of accrued expenses in reverse merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Assumption of due to/from related party in reverse merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,263</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Conversion of convertible notes payable to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,308,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Conversion of interest payable to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">722,587</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Conversion of accounts payable and accrued expense
    - related party to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">275,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Beneficial conversion feature recorded as a debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,922,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Warrant value recorded as a debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">433,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Reclassification of warrant liability to equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,407,739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Warrant value recorded as issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">898,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Assets acquired in asset acquisition:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">223,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Fixed Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for asset acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_006"></A>AntriaBio, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B><BR>
<B>June 30, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 1 Nature of Operations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements represent the
consolidated financial statements of AntriaBio, Inc. (&ldquo;AntriaBio&rdquo;), formerly known as Fits My Style, Inc., and its
wholly owned operating subsidiary, AntriaBio Delaware, Inc. (&ldquo;Antria Delaware&rdquo;). AntriaBio and Antria Delaware are
collectively referred to herein as the &ldquo;Company&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2013, Antria Delaware merged
with AntriaBio, a public company pursuant to a share exchange agreement in which the existing shareholders of Antria Delaware
exchanged all of their issued and outstanding shares of common stock of Antria Delaware for 5,880,667 shares of common stock of
AntriaBio (the &ldquo;Reverse Merger&rdquo;). After the consummation of the Reverse Merger, stockholders of Antria Delaware own
88.2% of AntriaBio&rsquo;s outstanding common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Reverse Merger, Antria
Delaware became a wholly owned subsidiary of AntriaBio. For accounting purposes, the Reverse Merger was treated as a reverse acquisition
with Antria Delaware as the acquirer and AntriaBio as the acquired party. As a result, the business and financial information
included in this Annual Report on Form 10-K is the business and financial information of Antria Delaware. The accumulated deficit
of AntriaBio has been included in additional paid-in-capital. Pro-forma information has not been presented as the financial information
of AntriaBio was insignificant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective May 1, 2014, the Company effected
a 6 to 1 reverse split of the Company&rsquo;s common stock, in which for every six (6) shares of common stock combined into one
(1) share of common stock. All share and per share amounts have been retroactively restated to reflect the forward split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 2 Summary of Significant Accounting
Policies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal accounting policies applied
in the preparation of these financial statements are set out below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basis of Presentation</I> - </B>The
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principals of Consolidation</I>
&ndash; </B>These consolidated financial statements include the accounts of AntriaBio, Inc. and its wholly owned subsidiary. All
material intercompany transactions and balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounting Estimates </I></B>- The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others,
the following: estimated useful lives and potential impairment of intangible assets, the fair value of share-based payments and
warrants, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred
tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks and Uncertainties</I> </B>-
The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and
other risks associated with a development stage company, including the potential risk of business failure. See Note 3 regarding
going concern matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash </I></B>- In the statement
of cash flows, cash includes cash in hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Note Receivable &ndash; Related
Party &ndash; </I></B>Notes receivable represent amounts due to the Company, and are recorded at cost less an allowance for note
losses, if necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Inventory </I></B>&ndash; Inventory is stated at the
lower of cost or market. Inventory consists of materials of AB101 acquired from PR Pharmaceuticals, Inc., as well as inventory
purchased to make new material. All inventory is recorded at its acquisition cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Deferred Finance Costs</I> - </B>Direct,
incremental finance costs related to the convertible notes payables that are recorded in liabilities are amortized over the term
of the respective instrument through charges to interest expense using the effective interest method. Total deferred financing
cost included in deferred financing amount to $146,037 as of June 30, 2013, which is net of accumulated amortization of $362,088.
As of June 30, 2014, the Company amortized $416,337 of deferred financing costs into interest expense as all of the associated
notes were converted into equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fixed Assets </I></B>&ndash; Fixed assets are carried
at cost less accumulated depreciation and amortization. The fixed assets primarily consist of lab and manufacturing equipment.
Depreciation is computed using the straight-line method over the estimated useful lives. The fixed assets have not been placed
into service as of June 30, 2013 and had not begun depreciating as they were being stored until a lab facility has been established
at which time the assets can be installed and placed into service. The Company placed the assets into service in June 2014 and
began depreciating the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intangible Assets</I> &ndash; </B>Costs
of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The value of the
current intangible asset is based on the asset values assigned in the asset acquisition discussed in Note 5. The intangible assets
are being amortized over 11 years which is the remaining life of the patents acquired. The amortization expense is expected to
be $1,181 for each of the next five fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Deposits </I></B>&ndash; Deposits
represent amounts paid as a security deposit on the lease of the facilities and is recorded at cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Due to Related Parties</I></B> -
Due to related parties represent obligations to pay for goods or services that have been acquired in the ordinary course of business
from suppliers, have been paid for by a related party, and are classified as current liabilities if payment is due within one
year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Convertible Notes Payable - </I></B>Borrowings
are recognized initially at the principal amount received. Borrowings are subsequently carried at amortized cost; any difference
between the proceeds (net of transaction costs) and the redemption value is recognized as interest expense in the statements of
operation over the period of the borrowings using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Beneficial
Conversion Feature of Convertible Notes Payable</I></B> - The Company accounts for convertible notes payable in accordance with
the guidelines established by the Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards Codification
(&ldquo;ASC&rdquo;) Topic 470-20, <I>Debt with Conversion and Other Options</I>, Emerging Issues Task Force (&quot;EITF&quot;)
98-5,&nbsp;<I>Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion
Ratios</I>, and EITF 00-27, <I>Application of Issue No 98-5&nbsp;To Certain Convertible Instruments</I>. The Beneficial Conversion
Feature (&quot;BCF&quot;) of a convertible note is normally characterized as the convertible portion or feature of certain notes
payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related
to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those
convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when
the contingency is resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCF of a convertible note is measured
by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the
convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital.
The Company calculates the fair value of warrants issued with the convertible note using the Black Scholes valuation model and
uses the same assumptions for valuing any employee options in accordance with ASC Topic 718 <I>Compensation &ndash; Stock Compensation</I>.
The only difference is that the contractual life of the warrants is used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of the proceeds received from
a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated
fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount
is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged
to interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue </I></B>&ndash; The Company
recognizes revenue when it is realized or realizable and earned. We consider revenue realized or realizable and earned when all
of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the
services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collection is reasonably
assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses - </I></B>Expenses
necessary to generate revenue are expensed in the period incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes </I></B>&ndash; The
Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent
differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for
income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company&rsquo;s
balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income
taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to
the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the
Company&rsquo;s valuation allowance in a period are recorded through the income tax provision on the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 740 (formerly
known as FIN No. 48, <I>Accounting for Uncertainty in Income Taxes</I>). ASC 740 clarifies the accounting for uncertainty in income
taxes recognized in an entity&rsquo;s financial statements and prescribes a recognition threshold and measurement attributes for
financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an
uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to
be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less
than a 50% likelihood of being sustained. Additionally, ASC 740 provides guidance on derecognition, classification, interest and
penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740, the Company
recognized no material adjustment in the liability for unrecognized income tax benefits. The Company reports tax related interest
and penalties as a component of interest expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Segment Reporting &ndash; </I></B>Operating
segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief
operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has
been identified as the Chief Executive Officer and the board of directors that makes strategic decisions. The Company operates
one segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Comprehensive Income (Loss) &ndash;
</I></B>Comprehensive income (loss) is defined as all changes in stockholder&rsquo;s equity from transactions and other events
and circumstances. Therefore, comprehensive income (loss) includes our net loss and all charges and credits made directly to stockholder&rsquo;s
equity other than stockholders contributions and distributions. As of June 30, 2014 and 2013, the Company has no items other than
net loss affecting comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income (Loss) Per Common Share &ndash;
</I></B>Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders
by the weighted average number of common shares outstanding during that period. Diluted earnings per share is calculated on the
treasury stock method, by dividing income available to common shareholders, adjusted for the effects of dilutive convertible securities,
by the weighted average number of shares of common shares outstanding during the period and all additional common shares that
would have been outstanding had all potential dilutive common shares been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although there were common stock equivalents
of 12,420,943 and 10,172,431 shares outstanding at June 30, 2014 and 2013, respectively, consisting of stock options and warrants;
they were not included in the calculation of earnings per share because they would have been anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments
</I>- </B>From inception, the Company adopted ASC 820, <I>Fair Value Measurements and Disclosures</I>, which provides a framework
for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair
value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the
use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure
fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                         1: Quoted prices for identical assets and liabilities in active markets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                         2: Quoted prices for similar assets and liabilities in active markets; quoted prices
                                         for identical or similar assets and liabilities in markets that are not active; and model-derived
                                         valuations in which all significant inputs and significant value drivers are observable
                                         in active markets; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                         3: Valuations derived from valuation techniques in which one or more significant inputs
                                         or significant value drivers are unobservable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of financial instruments
including cash and cash equivalents, notes receivable &ndash; related party, due to related parties, and notes payable approximated
fair value as of June 30, 2014 and 2013 due to the relatively short maturity of the respective instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrant derivative liability recorded as of June 30, 2014
and 2013 is recorded at an estimated fair value based on a Black-Scholes pricing model. On April 16, 2014, the Company recorded
a warrant derivative liability at and estimated fair value using an income approach based on a Lattice Model due to down round
provisions and reclassified to equity on May 16, 2014 when the down round provisions were removed at an estimated fair value based
on a Black-Scholes pricing model. The warrant derivative liability is considered a level 3 fair value measurement with the entire
change in the balance recorded through earnings. See significant assumptions in Note 10. The following table sets forth a reconciliation
of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Balance as of June 30, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(157,761</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total unrealized gains (losses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Included in earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(336,489</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant reclassified to equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,407,739</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Warrant recorded as derivative liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(949,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(35,595</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recently Issued Accounting Pronouncements</I></B><I>
-</I>In June 2014, the FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2014-10, <I>Development Stage Entities (Topic
915)</I>. The objective of the amendments in this update is to improve financial reporting by reducing the cost and complexity
associated with the incremental reporting requirements for development stage entities. The amendments in this update remove all
incremental financial reporting requirements from US GAAP for development stage entities, thereby improving financial reporting
by eliminating the cost and complexity associated with providing that information. The amendments are effective for annual reporting
periods beginning after December 15, 2014, and interim reporting periods beginning after December 15, 2015. Early adoption is
permitted. The Company has elected to early adopt this guidance, and therefore is no longer presenting the financial statements
in accordance with ASU 915, with inception to date disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reclassifications</I></B><I> &ndash; </I>Certain amounts
reported in prior years in the Consolidated Financial Statements have been reclassified to conform to the current year&rsquo;s
presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Subsequent Events </I></B>&ndash; The Company has considered
subsequent events through the date of issuance of this Report on Form 10-K, and has determined no additional disclosure is necessary,
other than those disclosed in the footnotes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 3 Going Concern</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying financial
statements, the Company has a net loss of $9,730,454 and net cash used in operations of $3,167,357 for the year ended June 30,
2014, and stockholders&rsquo; equity of $6,406,731 and a deficit accumulated during the development stage of $17,746,924 at June
30, 2014.&nbsp;&nbsp;In addition, the Company is a preclinical stage company and has not yet generated any revenues. These factors
raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects that its current cash
resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than
one year. The ability of the Company to continue its operations is dependent on Management's plans, which include continuing to
raise equity based financing. There is no assurance that the Company will be successful in accomplishing this objective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded
assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 4 Critical Accounting Estimates
and Judgments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estimates and judgements are continually
evaluated and are based on historical experience and other factors, including expectations of future events that are believed
to be reasonable under the circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting
estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant
risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Share-based Payments and Warrants
&ndash; </I></B>The Company is required to exercise judgment in calculating the fair value of the share-based payments and warrants.
The fair value calculation includes several inputs that are subject to management&rsquo;s judgement. Management reviews these
inputs on a regular basis to determine that the values used in the calculation are consistent with current economic events and
historical events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Derivative Liability &ndash;
</I></B>The Company is required to exercise judgment in calculating the fair value of the warrant derivative liability. The fair
value calculation includes several inputs that are subject to management&rsquo;s judgement. Management reviews these inputs on
a regular basis to determine that the values used in the calculation are consistent with current economic events and historical
events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Contingent Liabilities -</I></B>
The Company is required to make judgments about contingent liabilities including the probability of pending and potential future
litigation outcomes that, by their nature, are dependent on future events that are inherently uncertain. In making its determination
of possible scenarios, management&nbsp;considers the evaluation of outside counsel knowledgeable about each matter, as well as
known outcomes in case law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes - </I></B>Significant
judgement is involved in determining the Company&rsquo;s provision for income taxes, including any valuation allowance on deferred
income tax assets. There are certain transactions and computations for which the ultimate tax determination is uncertain during
the normal course of business. The Company recognizes liabilities for expected tax issues based upon estimates of whether additional
taxes will be due. Where the final outcome of these matters is different from the amounts that were initially recognized, such
difference will impact the income tax and deferred tax positions in the year in which such determination is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 5 Acquisition of Assets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 30, 2013, the Company closed
on an asset purchase agreement with the Chapter 7 Estate of PR Pharmaceuticals, Inc. (PRP). Pursuant to the agreement, the Company
has acquired certain tangible and intangible assets in exchange for $400,000 in cash plus an initial deposit of $100,000 paid
to the Chapter 11 Trustee of PRP which is included in the purchase price, plus contingent consideration up to a maximum amount
of $44,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the purchase was treated as an asset
acquisition, the value assigned for the assets acquired for the price paid in cash is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">Material inventory</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">223,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contingent consideration is payable
in the following amounts, upon the occurrence of the following events:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Two
                                         million dollars ($2,000,000) related to the initiation of Phase 2b clinical studies for
                                         a multi-day injectable insulin, payable 30 days after the first dosing of a patient in
                                         a formal Phase 2b clinical study;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Two
                                         million dollars ($2,000,000) to be paid within 30 days after the exclusive license of
                                         the multi-day injectable insulin in the United States to a commercial pharmaceutical
                                         company.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Five
                                         million dollars ($5,000,000) after the initiation of Phase 3 clinical studies for the
                                         multi-day injectable insulin by the Company or a licensee of the Company, payable 30
                                         days after the first dosing of a patient in a formal Phase 3 clinical study.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Ten
                                         million dollars ($10,000,000) upon the approval by the FDA or EMEA to allow the marketing
                                         and sales of the multi-day injectable insulin by the Company or a licensee of the Company,
                                         payable 30 days after the receipt of the approval letter or notice from the FDA or EMEA.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Twenty
                                         five million dollars ($25,000,000) if the twelve month cumulative sales of the multi-day
                                         injectable insulin by the Company or a licensee of the Company reaches five hundred million
                                         dollars ($500,000,000) in any one given twelve consecutive month period, so long as such
                                         period occurs during the life of the patents included in the purchased assets, payable
                                         90 days after the twelfth month in which sales equaled or exceeded five hundred million
                                         dollars.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All contingent consideration events must
occur within five years of the closing of the asset purchase agreement. If an event is not reached within five years, no remaining
contingent consideration would be required to be paid. No contingent events have occurred through the report date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 6 Fixed Assets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of fixed assets
and accumulated depreciation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Useful</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Furniture and fixtures</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">5 - 7 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,728</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lab equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3 - 15 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Construction in process</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">-</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,012</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,691</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,759</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">337,932</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">275,717</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $7,759 and none
for the years ended June 30, 2014 and 2013, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 7 Related Party Transactions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective September 1, 2011, the Company issued a $1,000,000
line of credit to a related party, which has common ownership with the Company. The line of credit was issued in order for the
Company to obtain a higher interest rate on excess cash. The balance due on the line of credit as of June 30, 2014 and 2013 was
zero and $163,829, respectively, plus accrued interest of zero and $3,341, respectively. The Company was obligated to fund the
unused amount under the line of credit through maturity of the line of credit. The line of credit bears interest equal to the
lower of 10%, or the Wall Street Journal Prime Rate (3.25% at June 30, 2013) plus 5%. The interest rate at June 30, 2013 was 8.25%.
The line of credit was for a period of one year and matured on August 31, 2012. A late charge of 5% of the outstanding balance
was charged on the line of credit on December 31, 2012. The line of credit is secured by one million shares of the related party&rsquo;s
common stock. As of June 30, 2014, the Company wrote off the entire balance due from the related party of $177,382.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2014, the
Company incurred consulting expenses of $321,205 and professional expenses of $57,345, for services performed by related parties
of the Company and included in the statements of operations. As of June 30, 2014, $397,055 of related party expenses are recorded
in accounts payable and accrued expenses &ndash; related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2013, the
Company incurred consulting expenses of $598,995 and professional expenses of $135,000, for services performed by related parties
of the Company and included in the statements of operations. As of June 30, 2013, $807,001 of related party expenses are recorded
in accounts payable and accrued expenses &ndash; related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2014 and 2013, the due from related party was
zero and $183,346 respectively, for expenses paid on behalf of related parties. The Company wrote off the entire balance due from
the related party during fiscal 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 8 Convertible Notes Payable</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2010 Notes (See (A) below.) - </I>During 2010 and 2011,
the Company issued 8% convertible notes payable for which principal and interest is due two years after date of issuance. The
Company is required to pay a loan fee equal to 100% of the notes principal balance, which is recorded as a loan discount and being
amortized on the effective yield method over the term of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon the close of a &ldquo;Financing&rdquo;, which means any
third party capital investment in the Company, in cash, that is $2,500,000 or greater, the outstanding principal balance and at
the option of the Lender, the unpaid accrued interest on these convertible notes shall convert in whole into the number of whole
shares of common stock obtained by dividing the outstanding principal balance and unpaid accrued interest on these convertible
notes at the time of such Financing, by the Conversion Price. The &ldquo;Conversion Price&rdquo; under these notes shall initially
be 65% of the common share price of the Financing, subject to adjustment as provided herein. If the Company elects to pay the
accrued interest on these convertible notes in cash, the accrued interest payment shall be due on the date the principal amount
is converted to common stock. These terms were modified as disclosed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2011 Notes (See (B) below.) &ndash; </I>During June 2011,
the Company issued 8% convertible notes payable via Private Placement Memorandum (&ldquo;PPM&rdquo;). The PPM authorizes the issuance
of up to $2,000,000 of convertible notes payable for which principal and interest is due one year after date of issuance. Pursuant
to the terms of the PPM, upon an offering by the Company of common stock totaling at least $5,000,000 (a &ldquo;Qualified Offering&rdquo;)
the notes will automatically and on a mandatory basis convert (the &ldquo;Mandatory Conversion&rdquo;) into common shares of the
Company and the right to receive warrants. On the date of closing of a Qualified Financing of common shares, the Notes will convert
into common shares of the Company at a price equal to 65% of the price per common share of the Qualified Financing (the &ldquo;Mandatory
Conversion Price&rdquo;), subject to a maximum conversion pre-money valuation of $20,000,000, and the right to receive Warrants.
The conversion will include the face amount of the Notes and include any accrued and unpaid interest. For each common share received
as a result of the Mandatory Conversion, the Investor will receive one (1) warrant to purchase one (1) common share of the Company
at an exercise price equal to 135% of the price per common share at which the Notes are converted pursuant to the Mandatory Conversion.
The warrants will be exercisable at any time for a period of five years from the date of the Qualified Offering. These terms were
modified as disclosed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2011 Notes (See (C) below) </I>&ndash; In September 2011,
the Company amended its 2011 PPM (above) to remove the mandatory conversion feature and to permit conversion of the notes payable
at the option of the lender. The remaining terms remain essentially the same as the 2011 Notes described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 1, 2012, the Company amended its June 15, 2011 PPM
on its twelve month, 8% convertible notes payable to issue up to an additional $2,000,000 in convertible notes and to extend it
offering termination date to October 1, 2012. In addition, the amended PPM changes the definition of a &ldquo;Qualified Financing&rdquo;
from $5,000,000 to $2,500,000. On the maturity date of the convertible notes, or the closing of a Sale of the Company, whichever
occurs first, the lenders are permitted an elective conversion option to convert the outstanding principal and interest on the
convertible notes at the lower of 65% of the price per share of common stock in the Qualified Financing or 65% of the common stock
price using a pre-money valuation of the Company of $20 million. With each share of common stock received, the investor will also
receive a warrant to purchase two shares of common stock at 135% of the price per common stock at the time the note was converted.
The Company reserved the right to withdraw the offering at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2012 Notes (See (D) below) - </I>In December 2012, the Company
amended its PPM on its twelve month, 8% convertible notes payable to issue up to an additional $1,000,000 in convertible notes
and to extend the offering termination to December 31, 2012. On the date of a Qualified Financing, the lenders are permitted an
elective conversion option to convert the outstanding principal and interest at the lower of 50% of the price per share of common
stock in the Qualified Financing or $4.50 per share. With each share of common stock received, the investor will also receive
a warrant to purchase one share of common stock at 150% of the price per common stock at the time the note was converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the second fiscal quarter of 2014, the Company sent letters
to the holders of the 2010, 2011 and 2012 notes requesting amendment of their convertible notes payable. The convertible notes
payable were amended to: (i) fix the conversion price of the notes into common stock at $1.50 per share, (ii) require mandatory
conversion of principal and interest, and (iii) change the definition of a qualified financing to an equity financing of at least
$3,000,000. Note holders of $3,032,500 of the convertible notes payable balances outstanding have signed and returned the amendment
letter. Based on the fixed conversion price, the intrinsic value of the beneficial conversion feature of $653,000 was calculated
and recorded as a discount to the notes payable. As of June 30, 2014, $653,000 of the debt discount has been amortized into interest
expense as these all amortized as part of the conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2013 Notes </I>&ndash; In December 2013 and January 2014,
the Company issued $2,703,000 of 8% convertible promissory notes payable for which principal and interest is due six months after
the date of issuance. Pursuant to the note agreements, if the Company issues equity securities in a transaction resulting in gross
proceeds of at least $3,000,000, the promissory note and accrued interest will automatically convert to common stock at a conversion
price of $1.26 per share. The notes also allow the investor to convert at any time prior to maturity at $1.26 per share at their
option. With the promissory note, the investor will also receive a warrant to purchase common stock equal to one-half of the principal
amount of the promissory note. The warrant will have an exercise price of $1.89 per share and will be exercisable for three years
from date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The value of the proceeds of the notes was allocated to the
warrants as discussed in Note 9 and the remaining balance was allocated to the beneficial conversion feature as the intrinsic
value of the beneficial conversion feature was greater than the remaining proceeds of the notes. The discount on the notes is
being amortized into interest expense over the remaining life of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2014, the Company closed on an equity transaction
which qualified as a &ldquo;qualified financing.&rdquo; As such the $2,703,000 in 2013 Notes and the accrued interest was converted
into 2,186,838 shares of our common stock. The Company has also converted $4,275,172 of the 2010, 2011 and 2012 Notes and accrued
interest into 3,111,126 shares of our common stock as of June 30, 2014. The remaining balance of any debt discounts on the notes
converted was recorded into interest expense at the time of the conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The convertible notes outstanding as of
June 30, 2014 and 2013 include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">2010 Notes (A)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">60,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">562,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2011 Notes (B)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">645,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2011 Notes (C)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">2012 Notes (D)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">825,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">60,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,732,500</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The notes originated at various dates
from April 2010 through January 2013 and matured at various dates from February 2012 to January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2014, all of the outstanding convertible notes
have matured and payments were due on demand and remaining convertible at the holders option. The convertible notes which have
not been repaid or converted continue to accrue interest at a rate of 8%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Note Payable &ndash; Related Party </I>&ndash; On November
14, 2013, the Company issued a 14% promissory note with a related party. The note allows funds to be borrowed until March 1, 2014
for up to $250,000. The note matures on the earlier of November 1, 2014 or when the Company closes on an equity financing of at
least $3,000,000. The Company also issued a warrant for one share of common stock for each dollar of principal loaned. The warrant
was issued on March 1, 2014 for option to purchase up to 39,117 shares of common stock. The warrant exercise price will be $7.50
per share and will be exercisable for five years. As of June 30, 2014, the outstanding balance on the note is zero and the accrued
interest is zero as the principal balance of $234,700 and interest of $12,895 was paid in full on April 1, 2014. The warrants
were issued on March 26, 2014 for a fair value of $76,062.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 9 Shareholders&rsquo; Equity
(Deficit)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Stock - </I>The Company is authorized
to issue 200,000,000 shares of $0.001 par-value common stock. All shares of the Company&rsquo;s common stock have equal rights
and privileges with respect to voting, liquidation and dividend rights. Each share of common stock entitles the holder thereof
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>One non-cumulative vote for each share held of record
                                         on all matters submitted to a vote of the stockholders;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>To participate equally and to receive any and all such
                                         dividends as may be declared by the Board of Directors out of funds legally available
                                         therefore; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>To participate pro rata in any distribution of assets
                                         available for distribution upon liquidation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders have no pre-emptive rights
to acquire additional shares of common stock or any other securities. Common shares are not subject to redemption and carry no
subscription or conversion rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preferred Stock</I><B> &ndash; </B>The
Company is authorized to issue 20,000,000 shares of Preferred Stock with each share having a par value of $0.001. No preferred
shares are designated and there are no preferred shares issued and outstanding as of June 30, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2014, the Company completed a private placement transaction
in which the Company issued 5,725,327 units to accredited investors. Each unit consists of one share of our common stock and one
common share purchase warrant. Each warrant entitles the holder to purchase one share of common stock at a price of $2.34 per
share and the warrant will expire 36 months following the issuance. The Company received net proceeds of $7.6 million after the
placement agent compensation and issuance costs paid of $1,365,085 and $898,719 of warrant expense recorded as issuance costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the units issued, the Company also issued 562,352
additional warrants to investors who invested in the 2013 Notes and also in the private placement. For each dollar that was invested
in the 2013 Notes, the Company would issue one-half of one common share purchase warrant for their investment in the private placement
transaction for up to 150% of their investment in the 2013 Notes. The warrants will be exercisable at $2.34 per share and will
expire 36 months after they were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2014, the Company entered
into a services agreement whereby the Company receives assistance with investor relations relating to digital strategy, website
and investor materials, market awareness and other services. The compensation for these services will be 500,000 shares of common
stock to be issued over a twelve-month period. As of June 30, 2014, 125,001 shares of common stock have been issued under the
agreement and recorded advertising expense of $404,587 during the year ended June 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company issued no
shares of common or preferred stock during the year ended June 30, 2013 other than those shares issued as part of the Reverse
Merger. The Company has not declared or paid any dividends or returned any capital to shareholders as of June 30, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Note 10 Stock-Based
Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Options - </I>AntriaBio adopted individual stock option
plans in January 2013 for four officers and/or directors of the Company. The stock option plans granted 1,500,000 option shares
with an exercise price of $4.50 per share. Options to purchase 819,445 shares vested immediately, options to purchase 541,667
shares vest monthly over 3 years and 138,888 shares vested on May 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, AntriaBio adopted individual stock option plans
for two consultants of the Company. The stock option plans granted 8,334 shares with an exercise price of $4.50 per share. Option
to purchase 2,084 shares vested immediately with the remaining shares vesting at various dates through October 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 26, 2014, the Company adopted the AntriaBio, Inc.
2014 Stock and Incentive Plan which allows the Company to issue up to 3,750,000 of common stock in the form of stock options,
incentive options or common stock. As of June 30, 2014, the Company granted 2,835,000 of these shares to current employees and
directors of the Company. The options have an exercise price from $3.12 to $3.44 per share. The options vest monthly over 4 years,
with some options subject to a one year cliff before the options begin to vest monthly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AntriaBio has computed the fair value of all options granted
using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made
regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate,
volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to
valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of a peer company. Due to the small
number of option holders and all options being to officers, directors, or high level employees AntriaBio has estimated a forfeiture
rate of zero. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options.
The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of
similar maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AntriaBio has computed the fair value of all options granted
during the year ended June 30, 2014 using the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">94%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.16% - 2.26%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock option activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number&nbsp;of</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, June 30, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; padding-bottom: 1pt; text-indent: 11pt">Granted</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">1,508,334</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 12%; padding-bottom: 1pt; text-align: right">4.50</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, June 30, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,508,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 11pt">Granted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,835,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">3.14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding, June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,343,334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">3.61</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">5.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,387,871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">4.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">4.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Stock-based compensation expense related to the fair value
of stock options was included in the statement of operations as payroll expense of $1,081,792 and $3,687,502 for the years ended
June 30, 2014 and 2013, respectively. The unrecognized stock-based compensation expense at June 30, 2014 is $7,756,739. AntriaBio
determined the fair value as of the date of grant using the Black-Scholes option pricing method and expenses the fair value ratably
over the vesting period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Warrants<B>- </B></I>AntriaBio issued warrants to agents
in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted Average</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number of</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, June 30, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: 0in; padding-left: 0.125in">Warrants issued to placement agents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">41,424</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued to placement agent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">233,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.03</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0.125in">Warrants issued to placement agent</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">4.95</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, June 30, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">293,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued to note holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued to note holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,039,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued in private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,287,679</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued to placement agent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">290,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants issued for investor relations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.125in">Warrants exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100,550</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0.125in">Warrants forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1.17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding, June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,099,739</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">2.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">3.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company issued warrants to purchase 41,424 shares of common
stock at a price of $2.03 per share, exercisable from August 2012 through August 2017 to a placement agent in connection with
the closing of convertible notes payable on specific PPMs. The Company issued a warrant to purchase 233,334 shares of common stock
at a price of $2.03 per share, exercisable from August 2012 through August 2017 to a placement agent in connection with the closing
of over $1,000,000 in convertible notes payable. The Company issued warrants to purchase 18,334 shares of common stock at a price
of $4.95 per share, exercisable from February 2013 through February 2018 in connection with the closing of convertible notes payable
on specific PPMs. The Company issued warrants to various note holders to purchase 225,259 shares of common stock at a price of
$1.89 per share, exercisable from December 2013 through January 2017 in connection with the issuance of convertible notes. The
Company issued warrants to a related party as part of a settlement of debt to purchase 39,117 shares of common stock at a price
of $7.50 per share, exercisable from March 2014 through March 2019. The Company issued warrants to various note holders to purchase
4,039,184 shares of common stock at an average price of $1.98 per share of common stock, exercisable through April 2019 in connection
with the conversion of convertible notes payable into equity. The Company issued warrants to purchase 6,287,679 shares of common
stock at a price of $2.34 per share, exercisable through April 2017 in connection with the issuance of units in the private placement
that was closed in April. The Company issued warrants to a placement agent to purchase 290,861 shares of common stock at a price
of $1.56 per share, exercisable through April 2021 in connection with the private placement that closed in April. The Company
issued warrants to purchase 66,667 shares of common stock at a price of $3.44 per share, exercisable through May 2017 and 2019
in connection with investor relations activities that were performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants exercisable for the 41,424 shares of common stock
were accounted for under liability accounting and were fair valued at each reporting period until April 1, 2014 when the warrants
were reclassified to equity as the exercise price became fixed. The value of the warrants to purchase 41,424 shares as of April
1, 2014 was $102,917, which was the fair value of the warrants on the date it was reclassified to additional paid-in capital,
and was $157,761 as of June 30, 2013, which was recorded as a liability on the consolidated balance sheets with the fair value
adjustment recorded as derivative expense on the consolidated statements of operations. The warrants exercisable for the 233,334
shares of common stock were accounted for under liability accounting and were fair valued at each reporting period until March
31, 2014 when the warrants were reclassified to equity as the exercise price became fixed. The value of the warrants to purchase
233,334 shares as of March 31, 2014 was $614,635, which was recorded as additional paid-in capital, and was not valued as of June
30, 2013 as the value could not be determined as an exercise price had not yet been fixed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants exercisable for the 18,334 shares of common stock
are accounted for under equity treatment and fair valued as of the date of issuance. The fair value of the warrants was valued
at $191,126 and recorded as additional paid-in-capital and deferred financing fees. The deferred financing fees were being amortized
over the term of the notes associated with the warrants and were fully amortized as of June 30, 2014. The warrants for the 225,259
shares of common stock are accounted for under equity treatment and were recorded at the allocated fair value as of the date of
issuance. The fair value of the warrants was $524,594 and the allocated fair value of $433,062 was recorded into additional paid-in
capital and as a discount to the note payable balance. The unamortized discount was fully expensed into interest upon the conversion
of the bridge notes in fiscal 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants exercisable for the 6,287,679 shares of common
stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The
fair value of the warrants was $14,432,123 and the allocated fair value of $3,184,222 was recorded into additional paid-in capital.
The warrants for the 4,039,184 shares of common stock were accounted for under the equity treatment and were recorded at the allocated
fair value as of the date of issuance. The fair value of the warrants was $11,111,739 and the allocated fair value of $2,065,708
was recorded into additional paid-in capital. The warrants for the 39,117 was accounted for under the equity treatment and fair
valued as of the date of issuance. The fair value of the warrants was valued at $76,062 and recorded as additional paid-in capital
and interest expense. The warrants exercisable for the 290,861 shares were accounted for under liability accounting on the date
they were recorded. The warrants to purchase 290,861 shares value was $898,719 when recorded using a Lattice pricing model. On
May 16, 2014, the warrants to purchase 290,861 shares terms were fixed and the warrants were fair valued at $690,187 using a Black-Scholes
pricing model and reclassified into equity with the fair value adjustment recorded as a derivative expense on the consolidated
statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants exercisable for the 66,667 shares of common stock
are accounted for under liability accounting for the shares that have vested and were recorded at their fair value on the date
of issuance of $50,365 as a liability and as professional fees and investor relations expense. The fair value as of June 30, 2014
was $35,595, which is reflected as a liability with the fair value adjustment recorded as a derivative expense on the consolidated
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 2, 2014, an investor elected to exercise their warrant
under a net issue exercise in which 100,550 shares of common stock were issued and 41,570 warrant shares were forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These warrants were valued using the Black-Scholes option pricing
model on the date of issuance, except for the warrants to purchase 290,861 shares which were valued using a Lattice pricing model.
In order to calculate the fair value of the warrants in both models, certain assumptions were made regarding components of the
model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield,
and warrant term. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility
factor utilizing a comparable published volatility of a peer company. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Black-Scholes valuation methodology was used because that
model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions
were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">92% - 97%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.78% - 2.21%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contractual term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;3 - 7 </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 77%; text-align: left">Dividend yield</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">0%</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We utilize a lattice model to determine
the fair market value of the warrants to purchase 290,861 shares on the day they were issued. The warrants issued resulted in
a warrant derivative liability of $898,719. The lattice model accommodates the probability of exercise price adjustment features
as outlined in the warrant agreement. Under the terms of the warrant agreement, at any time while the warrant is outstanding,
the exercise price per share can be reduced in proportion to the exercise price per share of future warrants issued that is lower
than the exercise price per share as stated in the warrant agreement. The estimated fair value was derived using the lattice model
with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 77%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">92</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contractual term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 11 Income Taxes</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taxing jurisdictions related to income
taxes are the Unites States Federal Government and the State of Colorado. The</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provision for income taxes is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Year Ended June 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 0.125in">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-indent: 0in; padding-left: 0.125in">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,006,831</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,052,267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,548</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,451</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 0.125in">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,086,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,236,718</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 0in; padding-left: 0.125in">Total tax expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred taxes are a result of differences
between income tax accounting and GAAP with respect to income and expenses. The following is a summary of the components of deferred
taxes recognized in the financial statements as of June 30, 2014 and 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: yellow">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: yellow">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">As of June 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: 0.125in">Net operating loss carryforward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,267,379</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">562,335</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in">Start-up and organizational expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580,219</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.125in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,683,247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in">Derivative expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,943</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0.125in">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,093</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25in">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,555,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,468,821</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0.125in">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,555,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,468,821</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 0.25in">Net deferred taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation allowance was established
because the Company had not reported earnings in order to support the recognition of the deferred tax asset. The Company has net
operating loss carryforwards of approximately $5,869,000 for federal and state income tax purposes. Federal and state net operating
loss carryforwards, to the extent not used, will expire starting in 2031. Under provisions of the Internal Revenue Code, substantial
changes to the Company&rsquo;s ownership may result in limitations on the amount of net operating loss carryforwards that can
be utilized in future years. The Company is no longer subject to income tax examinations for federal income taxes before 2010
and for Colorado before 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision differs from
the amount of income tax determined by applying the U.S. federal income tax rate of 34% to pretax income for the following periods,
due to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Year Ended June 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Computed "expected" tax expense (benefit)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,308,354</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2,293,815</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in income taxes from:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">State taxes net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,549</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184,451</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,301,524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,548</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0.125in; padding-left: 0in">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,086,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,236,718</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Note 12 Commitments and Contingencies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Employment Agreements</I> - The Company
entered into employment agreements with the officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 1, 2012, the Company entered into an employment agreement
with its Chief Scientific Officer. This agreement provides for an initial salary of $275,000 through December 31, 2012 and a base
salary $295,000 thereafter. The Chief Scientific Officer is also entitled to one-time bonuses totaling $275,000 upon achieving
certain clinical testing milestones. Furthermore, the Chief Scientific Officer is entitled to an annual performance bonus equal
to 40% of his base salary beginning in calendar 2013 based on criteria set by the Board of Directors in its sole discretion. Termination
benefits for base salary and certain other benefits are provided for a period of twelve months. On March 26, 2014, we entered
into an amended and restated employment agreement which removed the pension benefit owed to the Chief Scientific Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 18, 2012, the Company entered into an employment agreement
with its Chief Executive Officer. This agreement provides for an initial salary of $230,000 from the effective date of the agreement
until the executive commits full time to the Company&rsquo;s business and his base salary increases to $350,000. The Chief Executive
Officer is entitled to one- time bonus of $40,000 upon the close of a Company financing of at least $5,000,000. Furthermore, the
Chief Executive Officer is entitled to an annual performance bonus equal to 40% of his base salary beginning in calendar 2013
based on criteria set by the Board of Directors in its sole discretion. The agreement also provides for stock options to purchase
3,500,000 shares of common stock of the Company at an exercise price equal to the fair value of these shares on the date of grant.
These options will vest 50% on December 31, 2012 and the remaining shares vest equally over the following thirty-six months of
service. Termination benefits for base salary and certain other benefits are provided for a period of six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 26, 2014, we entered into an amended and restated
employment agreement with our Chief Executive Officer. The Amended and Restated Employment Agreement provides, among other things,
for: (i) an increase in Mr. Elam&rsquo;s base salary from $230,000 to $390,000; (ii) a termination of the bonus due to Mr. Elam
under the Employment Agreement upon the Company raising at least $5,000,000 in an equity financing; and (iii) a termination of
the car allowance granted to Mr. Elam under the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Advisory Agreement</I> - On July 2, 2012, the Company entered
into an advisory agreement whereby the Company receives services including, but not limited to finance and strategy, clinical
design, project management and portfolio assessment. The Company agreed to pay a monthly retainer in the amount of $9,000 per
month to cover general and administrative matters plus an hour fee ranging from $100 to $700 per hour for additional services
provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Consulting Agreements </I>&ndash; On March 31, 2014, the
Company entered into a services agreement whereby the Company receives assistance with investor relations relating to digital
strategy, website and investor materials, market awareness and other services. The compensation for these services will be 500,000
shares of common stock to be issued over a twelve-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 1, 2014, the Company entered into a services agreement
whereby the Company receives assistance with strategic media placement, third &ndash;party research, e-mail blasts and media buys
to generate awareness of the Company. The Company agreed to pay $20,000 per month plus expenses for these services through March
31, 2015, and can be renewed on a monthly basis at that point in time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I> Lease Commitments &ndash; </I> In
May 2014, the Company entered into a lease of approximately 27,000 square feet of office, laboratory and clean room space to be
leased for seventy two months. The lease requires monthly payments of $28,939 adjusted annually by approximately 3% plus triple
net expenses monthly of $36,427 adjusted annually. The Company also made a security deposit of $750,000 which is held by the landlord
and will be returned gradually over the next several years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2014, minimum rental commitment
under the operating lease is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Year Ending June 30,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; text-indent: 0.125in">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">262,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">359,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,252</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">381,360</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392,855</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 0.125in">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">335,747</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,101,865</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Legal Matters</I> - From time to time,
the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of
June 30, 2014, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the
results of our operations. There are no proceedings in which any of our directors, officers or affiliates, or any registered or
beneficial shareholders, is an adverse party or has a material interest adverse to our interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 107px; width: 325px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANTRIABIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>14,958,633 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 23, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Options: NewSection Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.P"Q`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`WZ;G^I_VY]^Z]UZY_J?]N??NO=8IZF&E@FJJJHBI:6FB
M>>IJ:F9(*>GAC4O)-//*R10Q(H)+,0`/=))(X8VFF94B4$EB0``,DDG``'$G
MK1(4%F("CSZ*7O7YX?$[8=748[,=S[>R.0I9&BGH]IP97>#1R*2KHU3MRAR-
M`'5A8CS7!]PQO_WB/9GER=K6_P!^M)+I#0I;B2Y-1Q%8$D2ORU=$EQS)LELQ
M5YU+CR4%OYJ"/Y],FV_YB'Q`W-5)1P=PT>&GE=8XSNC`[FVY3.S$`:J_)XF&
MAA7GEI)$4?U]EVT_><]D=WE$,>^102L:#ZB*>`?F\D2H!\RPZ;BYIV.5M(G"
MG^DK*/VD4Z-]@\_A-SXNESFV\WB]P86M771Y;"9&DRN-JD_U4%;0S3TTMOS9
MB1^?<WV&X[?NMHE_M<\-S8R"JR1.LB,/Z+H2I_(]'L<L4R"2%E>,\"""/VCI
MVN?ZG_;GVLZOUZY_J?\`;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_;GW
M[KW7KG^I_P!N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_
M`&Y]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`;GW[KW7K
MG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW77OW7N@\[6[2V9TQL+</8^_LH
M,7MO;M)YZAD"R5M?5RL(J#$8FE+(U;ELI5,L4$0(U,UV*H&8!GG'F_8N1.7+
MGFGF.80[5:IJ8\6=CA(XU_')(U%11Q)R0*D);V]M]OMFN[DTB4?F3Y`#S)\N
MM7_Y/_-#MCY,YBL@RF0JMJ=:QU+-@^M\16R)C$IXR5IZG<]1#XFW-F'3U.TW
M^31,2(8T')Y&^[GOUSG[L7TD5U*]ERF&_2L8W(32/A:X84\>0C)U?IJ<(@XF
M(-WWZ]W>0^(2EI7$8./]M_$?MQZ`=%!``````'``%@!_@![@\``4'#HEZ[][
MZ]T-W1OR'[7^.^Y8MQ=9[EJ,="\T;YG:]8TE7M/<D"L#)39K"LZT[O(EU6IB
M\=7"3=)`1S('MY[G\Y^U^ZKN?*=VT418&6W>K6TX\UEBK2I%0)$TR+Q5NE^W
M[G>;7-XUFY'JIRK?:/\`+Q'D>MG_`.+OR9V;\H.NHMX[=5<3G\9)#C=[;0FJ
M4J*[;.;:,NJB0+&U9A\BB-+156E1-&"K!9(Y$7KE[0^[&Q>[G*R[[M8\'<8B
M([JV+`O;RTK2N-4;BK124`=:B@9642]LV[P;Q:^/%VRKAU\U/^4'R/G]H/1D
M_<J]&W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW78!/`!)_H.??NO==>_=>
MZ][]U[I$;K[+Z[V+48^CWIOC:NU:S+34]/BJ//9N@QE7DZBJG^VIH,?2U,R3
MULU14>A$C5F9N`/9#O'-/+?+\D4.^W]G9S3LJQK-*D;2,QTJJ*S`LS'`"@DG
MATFGO+2U(6XD1&;@"0"?L'GTMSQP?J/9]TIZ]8CZCZ\C_'W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=:\/\V'NZNW7VWAND\;5NNV.LL=1YC-TT<EXJ_?&XJ,52R5"
MH=+_`,#V]40QQ`W*254W]??,?[YGN!<;QSG;^W]HY&T[5$LLR@X>ZG74"U./
MA0%0M>#2R=1?SGN#3WRV"']&$`GYNPK_`"6E/M/545//)2SPU,)034\L<\1D
MBBGC$L3K(GD@G22">/4HU(ZLCCA@02/>&D4KP2K-'3Q$8,*@,*@U%58%6&,@
M@@C!!'0,R#4<>K&]D_%+9ORZZTJ]_P#QWR&,V9V_M=(:;LKI#,5K)MRKR$B/
MX-P[!RU0TM7@L/N3Q%X*6J,])3U'DI_+"L:%LI=A]F]@][>5'YF]L)(MOYWM
M`%OMJD8^`TA!I-9R&K0Q3T+(CZXT?5%JC"`D46^S0[W:FYVLA+Y/[2$GM)_B
M0^0;T-0#45%.B$;TV/O#KG<5=M+?FV<SM+<N.8K5X?.44M%5HMR$GAUCQ5E'
M-:\<\+20R#E6(]XW;_R]OO*NZ2;)S):3V6ZQ?%'*I5J>3+Y.A\G0LC>1/0<G
M@GMI3!<(R3#B"*'_`&1\QCI+>R?IKHX7P7[RK.B_D3LS*2UCP[2WK74>PM[T
MK2%::7$9^LCI<?DYE)">7;^:EAJE?ZK$)5'#M><ON[^X4_M[[H6-R[E=EW&1
M;.Z6O:4F8+'(?*L,I5Z\0FL?B/1WR]N+;=ND<E?T)"$?[&-`?]J<_MZVOR+$
M@_@D?[;WV5ZFCI.[GW=M/9.-&9WEN?;VTL0U3%1KE-RYG'X2@>LG#&"CCJLE
M44T,M7/H.B)27>QL#[V`3@<>O=2:;<.`K1AS19S#U@W#13Y+`-29*CJESF.I
M8Z>:IK\0T$TBY*BIXJN)GEA+QH)4N1J6^J'K=.D]B^S^M,Y69C'83L78>9R&
MWJ"3*Y^AQ6\-O9&LP>+A;1-DLS34>1FFQ>/A?AYIUCC4_4^]E6'$'K74S!;^
MV)NG;]1NS;&]MH;DVK1O5QU>Y\#N7"YC;U+)0`&O2IS>/K:C&P/1`WF#R@QC
M]5O?B"#0@UZ]T63J[Y:];]S]U]B[;V+V)M&LZ[ZJH,5M"IS`S>'AIM^=K;BJ
MCD<C1;7GJ:A9\SC-AX+'PP/44I,%17925`9/MPWN[1LJ@D9/^#_9Z\,\.C!0
M]Q=15%+N&NI^U>MJBBVC20U^[*R#?6UYJ7:]#42-#3UNXJB+*/%A:2HF4I')
M4F)'<$`D\>ZZ6X4.>O=`A\B(NO\`OKK>BZNV]\JJ?I?.[[RFS<OM/>/6?8>U
MJ3>.;IX\M193'X[;8_C$-1F:#=<2K$@I68SAUTZUNC62J-J*U`]>O=&4S&>V
M_LG`'+;MW-C,'A<5!24]=N/=66QV)I-=HZ6*;(9*MDHJ%*NMGMQZ=<K65;D#
MW0`DX&>O=<L?NO:^6HL)D<5N3`Y/'[EFDI]N5U!EZ"LI,]40T]95S4^'J*>>
M2+)3PTN/J)'2$NR)!(6`"-;U".O4Z(I\FJB@[`^4_P`6.ILA44=/MCKV;<?R
M/[#JZ^>G@QN/Q^U$&'V:V2J*AT@I8*G<#NEY&53J'/O&?W7D@YE]W^3^3;AD
M7:ML:??+QG*A$2V'A6I<MA09V(S0<.@MO!6ZWFSL6($,6J=R:4`7"U].[H\=
M%OC9>3P;;JQV[]K9#;*RO$^XZ//XFIP*3QRB&6&3+PU;4$<T<S!&1I`RL;$`
M^\@K??MCN[#]ZVEY:2[6"1XR2QM%4&A'B!BE0<$5J#CCT(UN;=XO'21#!_$&
M&G]M:=!KTYM*DQ.5[1WGB>Y<[VWA.R=Z29[%TE9GL;N#;>PA2PM2U&U]IU&+
MGJ:>&BA=PKQADT+%&I0.&=PKR1L\-G>;OOMIOEQO-ANE\9HU>9)H+32-+06Q
M0D*@."M132H(U!F9'80*CS7"7#3QS2:@-094_HK3R_V.A(@WQLNIR[8"FW;M
MNHSB5DF.?$P9K'RURY*%&EFQAITJ&?\`B<42,[4W^?5%+%0`3[%,>_;)+=FP
MBO+9KT2%"@D0MX@!)CH#76`"2GQ`"I%,]*Q=6S2>$)$,M:4J*U]/M^7'I4^S
M;I_KWOW7NNQR0/ZD>_=>ZU`_EM7562^4/?\`55C.T_\`I7W?2^LDE8,?DI,?
M21B_T2.DI8U4?A0/?$?WKN9KKW>YEFGKK_?%PN>(5'T(/L"J*?*G4'[TQ;=[
MDMQ\=_Y&@_D.B]>XPZ+.AZ^,O:79747=.RMS=4T59G-TUN4I=N_W/I1+)'OC
M'9BIA@J]JU<$5]25UE>.4@_:SQI/QXS[DCVDYOYKY*Y^L-UY-C>YW>698/IE
MJ1=I*P#6[`?Q8*O_`*&ZK)P4]&.U7EW8W\<UD"TQ8+I_C!.5_/R]#0^76TYW
M#T?U7WULW^#=P[/QM;3P8]JN/(3U$%+G=G5#4WEJI\3NJE*38]J%K^1TD-+*
M$O(CIQ[[!<[^W_)WN-L7T'/%C#)"(]0=B%EMFTU9HIUHR%?,AM#4[@RXZF&_
MVZRW*WT7\8(`K7@R>M&\J?L/GUJO_(OKOJ[K#LK*;6ZD[6INV]KTNL_QNGH3
M"<55B5DDPD^6I[X;<DU(`+UM!:G?Z%58$>^/?NEROR?RAS7-L_)6\IO6TI7]
M0+3PFK0Q-*OZ4Y7_`'[#13P(#5'4.[I;6=I=M#93">$>=.!]*\&IZC'0%I-)
M3NE1"Q2:G=*B%Q]4F@82Q./\5D0$>XZ$CPL)HS21"&!]"#4?S'1?4C(XCK=D
MVS53Y';FW*ZI)-378+"U=06^IGJL=2S3%O\`$R.;^^^^US27.V6UQ+_:R01L
MWVL@)_F>I^A8M"C-\14'^759?Q6SS_*KY>?*3O;=JKE=J?'+?4WQN^/F!J[5
M.'VQ4X>*2;L_?U'13+X(]V;MKOMX?OM/W$6/_P`F5@FH,;R#PXU4<6%3_DZ<
M\^L'P52M[.^3'S2[HBS-5E.LMB]GYWX]]%XQ&B.W-OXVDRR;S[=J=M10*L"0
M;CWY64\TDJ@LZQJFKQQQHOI>V-4_$14_Y.O#-3T&GQEP^V>[ODI\]/EIOFFQ
M,71VV=\475>&\E/3KA-V8;X\8:23+Y',QK&(LEM;"Y7R9)H)=<%97M"T@(HU
M4[<E42-?CI7]O6QZ]._P,W%%UG\/?E#\T=V8JEV]@.ZNP^[/DQA=I>"*BQ6+
MV3CJ6HH=I446/1(Z:&?/+@M?H11,LT1%^#[]*-4JQ#B`!UH<*]#_`/RP^J9^
MO_AUUAF-V44)WUV]49WO3>E76T\+5<N=[2R4VY*9F>53(K4^WI*-+<:0AX'/
MND[5D('`8_9UL<.BQ?##J3:WRR[`^;_R,[!V_19;JCN7MO/]:;%P1B2EH=R[
M6ZWV_5=:T^ZYA2>(R2X['5-3'C9P2T-=4U-2A$\4$D;DK&,(B_$!7]O6AY_;
MU,W9T_L*7YQ?`_XB]7X"/']8_#?KG<OR$S5.9Y\O78R?R?W7ZVH<EEJ^2>OF
MJY,]JJSY)"7^X+6L`!H,?">1OB8T_P`_7O,#H3]@YJH^4?\`,5[K7<H&2ZG^
M#F&VKM386U*L>7#57>._Z.HK\_V-D,;*)*6OSFVL115&.QLDBL:$,98=$CLQ
MJ1X<(I\3?X!Y=>\^HO0!K.UOYD/ROW+CLK/5]3?'"APVR-I;>@\46`QW=O9N
MW\`W;6?HX*=%2;-+1;2-)52.6:.2JFMH::77M^V%1^)O\`X=;XGH1>@-LTG<
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MC4CX3W"A4'K3_4[7RY:V-N2EY=.JZAQ4R$LQ'S`-/E^70L?.+"8'I7X?8+8_
M7-",1DL9V!U+@NLDH;C+?WRH]U464ILO#41`5=5GZW^'U$]34$F:HDED+LQ<
MW&/W@+';^0_9*WV'E>/P+R+<=NAL`E1)]4MS'(L@8=S3-H=Y'RSEG+$EC5;S
M%%%M^Q);6HTNLL8CIQU!@:^NHT))XG/KU8U3_<&GIS5A15FG@-6$_0*HQ(:@
M)^-`FU6_P]Y0Q>)X2^-3Q=(U4X5IFGRKT+%K0:OBIGK-[OUOKWOW7NM6?^8W
MUK5]=?*W?U6U/)'B>QEH.Q,+4,I$=0,S3K2YM(V_2STNX:"I#`<@.I/ZA[X_
M_>EY4FY8]Y-QG*D66ZJE[$WDWB#1,!\UF1Z^@93Y]0[S1:-:[U*?P2T<?GQ_
MXT#T18D`$DV`!))X``Y))_``]X\$@"IX=!XFG'JV/XPGICX3;8A[X[XF;+]Y
M;LPQEZOZ@Q,4%5N[:^U\G3EX]P9N"=A!M7(;II733/6&)Z?'OIC22265%S0]
MI!R)[`;./<7W&8S>X5]!6PVV,!KFWMY%J)95.+=[A2.^4J4A.E0S.Z@9;0;#
M8(OWEN/=N+K^G$,LJD?$W\);U/!>%22.BS?)/YQ]T_)&:JQ64R1V5UT\C?;=
M>[6JZF''5,(;]MMSY,B&NW/4D`$K*(Z16Y2!3S[B7W5^\+S[[IN]G<R_N_E<
MG%G;L0K#R^HDPTY]0=,0.1&#GHIW;F"_W8E)#X=K_`IQ_MCQ8_;CT'1-0```
M!8#@`?0#^@]P3PP.'1'T)O3'7F2[9[9Z[ZXQ4#SU.[MVX;%S:$+BGQ?W25.:
MKI0/I!C\-3SS.?\`4QGV+>0>6+KG3G7:^5K12TE[>Q(U!73&&#3.?DD2NQ^0
MZ56-L][>16D?Q2.!^5<G\A4];F,,45-'#!3HL<%-'%#!&!94A@18XD`_HJ(!
M[[L(B1H(XQ1%```\@,`=3P`%%!P'1#^H_B7OCI7<OR`P6Q^P<#CNGN_NULWV
M]7/%BLI#VELS);OI:2GWCM7;616K;;[4.1DI+T.5E45>.25@L$LJQS(H:0.`
M2.X"GRZV*#I/?%+X:=C_`!LZERW6I[0VQDWP%=VQD^J)\#MS.8FBIMQ=B5&3
MEQV]^R/N\W65.YL]M^CKDHJ>GIQ!304RR,6FF>.6'TD@=M5/2OY=>&!U-VS\
M'JW:O\OO.?"[$=AQ4.Z-R[`W?@<YVG1X>>*+);OWKE:[.9[<%3B36FM:BR55
M7-32QF<S?:FP8L![\9:S>*1BO#KU,4ZXYWX5[FWU\.MW_&[>?8^&Q^Z=S=0[
M2ZEQ&=V9MVOH-B[)P>Q8L6^#HL-MK(9>HR60CS%?C#-F:J>H6HK?.418HH88
MU\)0)1(!BM>O'(IT(6`Z0[UGZCRF"WMV9L$=JT/467ZMZUR6QMIY["]?;"GR
M.WDP!WI)BLAG*[.9S=%0E-`[2"6DIZ6&+P4T,8DGDEKJ354`Z:U/7NA,^+O1
MF/\`C5\?NJNC<=D(\PO7FUJ?$Y#-Q4K429W.U%149/<.<%+)+/+!_%LW73SA
M'D=E#@%C;WJ1];E_4]>X=`%2?$/?%+\M^\^^%[,PR]?=\;:ZQP.Y-NI@<HG8
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M64B"&>0O5@2T;-\5`,-ZK4BGG4=)3L?X=8C+_&(_'?K?/+MRVXL%NVNW!N:G
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M<>=H(%\>.A6EI:6@NTEII6U*HO\`D.7F?FRPYGYNEBDM-H9I+*RB#&%+EA0W
M<\CA6FE1:K`NA$AJS4=V#*X^WO=WD=W?%2D)JD:UTAOXV)H6(_"*`#CD]&']
MR7T:]>]^Z]U[W[KW1(?G1\44^3O64(VZ*2F[2V*U9E=C5E2R00Y:.HCC_BVT
M*^K:PIZ3-K3QM#*WH@K(HV:R&2^/_P!X;V;7W;Y2"[;H3F[;RTEH[4`DU`>)
M;.WDDH`TL<)(J,:+JJ'N8]E_>]H/"H+R.I0^OJI/H?(^1`\J]:N^4Q6X-F[A
MK</F\=D-N[GVWDVI<AB\G2M29/$96@F!,-52SIJBGIYD#"X*L+,+J03R(N[/
M<]AW22QW"*6UWBTFTO'(NF2*1#6C*>!!%1Q!P14$'J'W22*0QR`K*IH010@C
MY=-]=75V4K:O)9.LJ\CD:^>2JKLA7U,U96UM5*=4M15U=0\D]1/(W)9V+'VE
MN;FXO;F2\O)'ENY6+.[L7=V/%F9B68GU))ZTQ+,78DL>).2?M/47VSUKKP!)
M50"S,RHJJ"S.[L%1$506=W8@``$DFP]^%20!DDT`\R3@`#S)/`>?7NMA;^6M
M\.,IU3CYN\^T,4^.W]NC$F@V;MNNAT5VT-KUX62KR>2B<>2DW!N.-47PD"2D
MHQH>SS2(G3?[J?L9><F6K>X/-T)BYDO(=%M`XH]M;M0L[@Y6:>@JN#'&-+=S
MNHDWE/8I+-?WE>+2X=:(IXJIXD^C-Z>0P<D]6U>\T.AMU[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=%4^1?PWZ4^2\!J]Z8:?#;S@IA38[L':[08_<T$<
M:,*>FR+20S46?Q\+$6AK(Y"B@B-X[W]P][G^QO(/NM%XN_V[0[XJ:4O("$N%
M`':K$@K*@_@E5J#X"M:]$NZ[#M^[#5.I6XIAUPWV'R8?(_E3JJ'>G\H#MS'U
M<[=?]G["W1C0Y^V3<M-FMJ9;QW](G6CI=Q8]G`^K+(H)_LCWAGOWW(><[:9F
MY;WC;KNTKVBX26WD^5=`G0GYU'V#H&3\CWR,?IIHG3^E53_(,/Y],>V_Y1/?
MV0JD7<^^^K]LT(D42ST57N#<E9XR1J:"CCP^(@D<#Z!YXP?Z^R_:?N3>XUU*
M/WQN6TVEO7)0S3O3U"^'$I_-QTW%R1N;G]62%%^19C^0H/\`#U9=\<OY>'2'
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0Z][]U[KWOW7NO>_=>Z__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!K`44#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBBD`44
M44`%%1SW$5M$TL\BQQKU9C@5S5_XWMXB4L86G(_C?Y5_Q-1.K"'Q,F4E'<ZF
MBO/)_&&JS$[)(XAZ(@_KFJ__``DNKY_X_G_[Y7_"N=XVGV9G[>)Z717GL'C'
M582-[Q3#T=,?J*W+#QM:SD)>Q-;L?XA\R_XBKABJ<M+V*56+.FHID4L<\:R1
M.KHW(93D&GUT&@4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%9VL:S!H]MYDOS2-Q'&#R
MQ_P]ZM7MY%86<MS.<)&,GW]J\QU'4)M3O7N9S\S=%[*.P%<V(K^S5EN95*G*
MM-QVI:K=:K/YET^0#\J#[J_0?UJG14A@D$`FV$Q9V[QT!]#Z5Y;;D[LY'=ZD
M=%%%(04444`7]*UFZTB;=;OF,GYXF/RM_@?>O0]+U6WU:T$]N>G#H>J'T->6
MU=TG5)=)OEN(LE>DB?WEKIH8ATW9[&M.HXZ/8]2HJ*WGCNK>.>%MT<BAE/M4
MM>KN=@4444`%%%%`!1110`4444`%%%("",@Y%`"T444`%%(2%4EB`!R2>U4-
M,UW3]7DE2QN5E:+[P`(X]1GJ*`-"BBB@`HHI&!*D*<-C@D9Q0`M%<G=ZKJL7
MB.+3([F)@S+N98@"`>3Z]JZRHA44[VZ$QE<***I1ZQ93:@UE'.IN%SE,'MU&
M:IM+<J]B[1113`****`"BBB@`HHHH`XSQQJ!::&P0_*H\R3W/85R=7M:N#=:
MU=RDY!D*CZ#@?RJC7BUI\\VSAG+FDV%7](U-M,NMS*)+>0;9HB,AU^GJ*H45
M$6XNZ)3L[HZ^_P#"4%[`MWHLBA9!N$9/RGZ'M]*Y6XMIK28Q7$31R#JK#%;G
MA77O[/G%I<M_HTI^4G_EFW^!KM+[3;74H/+NHED'8]U^A[5V*C"O'FAHS?DC
M45X[GE5%=#J_A"YLMTMGFY@'.`/G7\._X5SW?!ZBN2<)0=I(QE%QT84445))
MV?@?4"\4U@Y_U?[R/Z'J/S_G765YKX:N#;^(+4@\.QC/XC_'%>E5ZN$GS4[/
MH=E&5XA117-:SX@N'U:/1=%V&]?_`%LS#*PCJ>.YQ72:G2T5A7-K<Z-9->IJ
M%U<M"-\R3,"LB_Q8&/E..1CTJ+3-;.N^(YA9NW]GV<>"PZ2NQZ_0`'%`SHJ*
MR/$*R0:9=7D=_<6QAB+`1[=N1TR".YXK$\,:MJ=UI`#2FYOKF1C&TOW8HQ@;
MCCMG.!W/XT`=E17":UJ&J^'?$%@O]IRW:W!!DB=%`^\!@`=.O'TKMYXFFA*+
M*\1/\:8R/S!H$9/B35OL-HEK;L/MUXPA@4=1G@M]!6K;P):VT4$?W(U"#Z`8
MKSK0+(ZSXTNIA<W#1VI9DF9@S]=J\D8]>U=ZFGR(K@W]VVY<`DK\ON/EZT#+
MM%<'<ZI>V7C068U.XDLH`))@VTG`7)7@<]A^-/\`$<OB:-[2ZM6G4S$_Z/`F
M5BZ;0Q[D]^U`6.W=%D1D<95A@CU%9&B>%[#09II;/S"\HVY=L[5]!6=XLGO-
M,T3[='J%Q#<,R*(EVE-QZ@<9]>]:?A66ZG\.VDU[*TLTH+EFZX)./TQ0!KT5
MS>M^(9QJD6C:,$:_E^_(PRL(ZYQW..:GN+.[TBQ>]34;JYE@&^5)F!211]X`
M8^7C.,4`;M(2`"2<`5SNG:Y_;OB5TL9#]@LXB68=)7;@?@!G\:T/$5W]BT.Y
MD!PS+L7ZGBE*7*FV)NRN8'AH'4_$U[J+#*IDK^)P/T%=E7)^%+:9]*VV[F!'
M<M+,!EF/0*N?0=3[T7&HW>A>(XK:6ZDN+2?:<2D%ER<=?8URTI^SIIR6_P"I
MC"7+%-G65EP>'K*WU=M00/YS$MM+?*">I`I^LAXK">Y6[F@\J,D;-N,]NHJA
MX0NKR]T^:>\F:7,FU"V.`!S6TI1<U!KS+;7,DT=!16)K>NM93QV-B@FOIL!5
M/1,]S5F'2Y?LY^TWUS)<,.9%<J%/LHXQ]:KGNVHZV'S7=D:5%8?AO6)-1CGM
M[H@W-LVUF`QO&<9Q^%;E.$U./,AIIJZ"BBBJ&%%%%`'D<Q)GD)ZEV_G3*M:G
M";?5+J(_P2L/PS56O":L['GO<****0@[<UZ-X6>\DT6(WH]HB?O%.V?\]*Y;
MPQH1U2Z\^=?]$B/.?XV]/IZUW=S=V]A;F6XD2*->YX_`5WX2FU^\>B.FC%KW
MF3URWBN#1@C/<-Y=Z1E?)`W-_O#T]S5'5_&<T^Z+3088^GFM]X_0=JYAF9W+
M.Q9F.22<DT5\3%KEBKA4JIJR$HHHK@.8M:82-5M".HF3^8KU6O,-`A,^O6:`
M9Q(&/T'/]*]/KT<$O=;.JALRMJ%T+'3KBZ;I#&S_`%P*XWX<P-<W&HZE.=TS
ML$W'U/S-_2NKUZV>\T&^@B&9)(6"CU..E<]\-Y8QH=TI8!TG+.#Q@;1C/Y&N
MTZ.AK^+KM;/PQ>LQ&9$\I1ZEN*H_#^P^R^'1.PP]S(7_`.`C@?R_6L+Q]J,E
M_%:^2<6)D98W_P">K`<L/]D9P#WYKJ[*Y4-::;ICH\=LB_:)5^954#A<_P!X
M_H/PH`R_B+?_`&?18K1"=]S)R!_=7D_KBM;PQI1TK1H4D'^D.@,A]..%^@_G
MFN8U<_V[\1;6S'S0VI`8=N/F;^@KKM?NWL-!O;F+[\<3%?8],T`<?;_\5+\1
M'F^];61R/3"\#\VYKL-?OO[-T*\N<X9(SM_WCP/U-<EX)N+?3-"GG!$M]<S>
M7'"#\[D#@>PY))]*N>/VN8O"UM'*X=WE43.HP"<$_EF@"3X=6'V?1)+IA\US
M)P?]E>!^N:ZN218HGD<X1`6)]`*PM,U?3[#PY8K!*DLGDJL<$;`N[XZ8]<_E
M5?Q3>3Z;X.D6YEW75Q^[)'0%CD@>P&10!A^#;9M;\1WNJSC,2OOP>[$Y4?@.
M?RKT2N?\$V'V#PS;[AAY\S-^/3],5T%`,X+Q],]_J^G:1"<LQ#,!ZL<#],UV
M4K1Z5I3LHQ';0D@>RC_ZU<-93Q7/Q*N[F^E2-+8OM,C``;1M'7\ZZB<W&M:)
MJ+("L,\3+:H5PS#!^8_[QZ#TQZT`<]\.XFO+_4=4N#NF8A=Q]6^8_P!*Z;Q5
M=K9>&KZ1CRT9C7W+<#^=87PVD0:7>H2%D2;+`\$#:/\``U0\?:E)?6UN+<_Z
M")2JOVE<#DC_`&1TSW.?2@.IL?#RQ^S:`UPPPUS(6'^Z.!_6CQM,TILK",_-
M*^XC]!_,U?TZX18['3-,='6"-#<2+AE1<=/]YC^0R:S_`!4A@UW2[R0?N%95
M9NP(;/\`GZ5AB?X;,ZOPG36=LEE:16\0PD:A17'>)P;OQ9:VZ<L!&OYMG^5=
MA=WD-C:O<7#A(D&2?7Z5SWA_3IKW4YM;O4*&0DPHW4`\9_+@4JRYK4U_2%-7
MM%$GC:\\C24MU/S3O@C_`&1R?UQ6GH]J--T."-A@I'O?ZGDUSOB%ENO%]E;3
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MH.U5Z*NI6E/1[%2FY!11169`445+;6TMY<QP0+NDD.%%"U&=)X'L2]W->L/E
MC7RT/N>OZ?SKMJJ:7I\>F:?%:Q\[!\S?WCW-6Z]FC3]G!1.V$>6-@K,E\-Z3
M-=-<O8Q&5CEB,@-]1T/XUIT5J64[[2;+4[=(+RVCEB0Y53QM^F.E2V=E;Z?;
MK!:0I#$O14&!4]%`%*#2+&UO9+R"UC2YDSND`^8YZU;DC2:-HY%#HPPRL,@C
MTIU%`&?I^@Z;I<K265G%#(PP6`R<>F3T%6KJT@O;=H+J))8G^\CC(-344`9V
MGZ!IFERF2RLXHI",%P,M^9J:_P!+L]41$OK>.=4.5#C.#5NB@!J(L<:HBA54
M``#H!3J**`,V?P]I5S??;)[&%[C()=AU([D=#6C2T4`9DWAS2KB[:YDLHC,W
MWB,@-]0.#^-3WNE66HVJV]W;1R0H054C&W'ICI5RB@"O96-MIUN(+.!(8AR%
M08_&I)[>*ZA:*>-9(VZJPR#4E%&X%"/0]/C=&%N&V?<#L6"_0$X%7Z**2BEL
MA));%.\TFQU"17N[9)648!/7'I5J.-(HU2-55%&`JC``IU%"BD[I!9%:?3[>
MXF$LD?[U1@2*Q5L>F1VHMK"VM&9H(55W^\_5F^I/)JS11RJ][!9!1113&%%%
M%`!1110`5S_B3PX-47[3:@+=J.1T$@]#[^]=!14S@IKED*45)69Y%)&\,K1R
MHR2*<,K#!!IM>G:KH=GJR?Z0F)`,+*G##_&N1O\`P=J%J2UMMN8^VWAOR->9
M4PLX;:HY)4I+8Y^BIIK2XMVVSP2QD?WD(J'-<S5MS,**G@LKFY;$%O-(?]E"
M:V[#P9?7)#7;+;1^GWF_+H*N%.<_A0U!RV1@P02W,RPP1M)(QP%4<FO0/#OA
MY-(B\V;#W;CYF'1!Z#_&KNF:/::3%MMH\,?O2-RS?C5ZO1H894_>EN=-.ERZ
MO<****ZC8****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!",C!YIOE)_<7\J?10`G0
M<4M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
:4444`%%%%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
